A Report 201213

2012-13
Annual Report
2012-13
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
Annual Report | 2012-13
Contents
1. INTRODUCTION
2. AN OVERVIEW OF PHARMACEUTICALS INDUSTRY
3. PHARMACEUTICALS INDUSTRY
4. NATIONAL PHARMACEUTICALS PRICING AUTHORITY
5. PUBLIC SECTOR UNDERTAKINGS
6. NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (NIPER)
7. NEW INITIATIVES
8. IMPLEMENTATION OF RAJBHASHA
9. GENERAL ADMINISTRATION
10. PERFORMANCE EVALUATION AND MANAGEMENT SYSTEM
11. CITIZEN CENTRIC GOVERNANCE
12. INFORMATION AND TECHNOLOGY
13. ANNEXURE
Brief Contents
1. INTRODUCTION 7
1.1 Mandate of Department of Pharmaceuticals 7
1.2 Vision and Mission of the Department 8
2. AN OVERVIEW OF PHARMACEUTICALS INDUSTRY 9
2.1 Financial Performance of the Drugs and Pharmaceuticals Industry 11
2.2 Imports 12
2.3 Exports 12
2.4 Share in National Trade 13
2.5 Pharma Export Promotion Council (Pharmexcil) 13
2.6 International Cooperation/Export Promotion of Pharmaceuticals 14
2.7 Proposed Major areas of International Conference 14
2.8 India Pharma Summit - 2012 14
3. PHARMACEUTICALS INDUSTRY 15
3.1 Pharmaceuticals Industry 17
3.2 Creation of IPR Facilitation Centers in Phamexcil 17
3.3 Pharmaceuticals Policy 17
3.4 Foreign Direct Investment in Pharmaceutical Sector 18
4. NATIONAL PHARMACEUTICALS PRICING AUTHORITY 21
4.1 NPPA 23
4.2 Drug Price Equalization Account (DPEA) 26
5. PUBLIC SECTOR UNDERTAKINGS 29
5.1 Central Public Sector Undertakings 31
5.2 Joint Sector Undertakings 39
5.3 Wholly Owned Subsidiaries 40
5.4 Status of Annual Accounts 41
5.5 Generic Drugs Campaign The Jan Aushadhi Campaign 41
6. NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (NIPER) 43
7. NEW INITIATIVES 71
8. IMPLEMENTATION OF RAJBHASHA 75
9. GENERAL ADMINISTRATION 79
9.1 Organisation Set Up 81
9.2 Record Management 83
9.3 Grievance Cell 83
10. PERFORMANCE EVALUATION AND MANAGEMENT SYSTEM 85
10.1 Our Vision 87
10.2 Our Mission 87
10.3 Our Objective 87
10.4 Functions 87
11. CITIZEN CENTRIC GOVERNANCE 89
11.1 Our Vision 91
11.2 Our Mission 91
11.3 Our Clients 91
11.4 Our Commitment 91
11.5 Our Services 91
11.6 Our Activities 91
11.7 RTI-2005 91
11.8 CPGRAMS 92
12. INFORMATION AND TECHNOLOGY 93
12.1 Local Area Network (LAN) 95
12.2 IT Infrastructure 95
12.3 Website 95
12.4 Video Conferencing 95
12.5 File Tracking System 95
12.6 Voice Mail Facility 96
12.7 E. Governance 96
13. ANNEXURE 97
Annexure I 99
Annexure II 103
Annexure III 105
Annexure IV 111
Annexure V 113
Chapter
1
INTRODUCTION
1.1 Mandate of Department of Pharmaceuticals
1.2 Vision and Mission of the Department
7
CHAPTER 1
INTRODUCTION
1.1 MANDATE OF DEPARTMENT OF
PHARMACEUTICALS
The Department of Pharmaceuticals in the Ministry of
Chemicals & Fertilizers was created on 01.07.2008
to provide greater focus for the growth of the
Pharmaceuticals industry.
Following work has been allocated to the Department
of Pharmaceuticals:
1) Drugs and Pharmaceuticals, excluding those
specifcally allotted to other departments.
2) Promotion and co-ordination of basic, applied
and other research in areas related to the
Pharmaceuticals sector.
3) Development of infrastructure, manpower
and skills for the Pharmaceuticals sector and
management of related information.
4) Education and training including high end
research and grant of fellowships in India and
abroad, exchange of information and technical
guidance on all matters relating to pharmaceutical
sector.
5) Promotion of public private partnership in
pharmaceutical related areas.
6) International cooperation in pharmaceutical
research, including work related to international
conferences in related areas in India and
abroad.
7) Inter-sectoral coordination including coordination
between organizations and institutes under the
Central and State Governments in areas related
to the subjects entrusted to the Department.
8) Technical support for dealing with national
hazards in pharmaceutical sector.
9) All matters relating to National Pharmaceuticals
Pricing Authority including related functions of
price control/monitoring.
10) All matters relating to National Institutes for
Pharmaceuticals Education and Research
(NIPERs).
11) Planning, development and control of; and
assistance to, all industries dealt with by the
Department.
12) Bengal Chemicals and Pharmaceuticals Limited.
13) Hindustan Antibiotics Limited & its subsidiaries
as & JVs.
14) Indian Drugs and Pharmaceuticals Limited & its
subsidiaries.
15) Karnataka Antibiotics and Pharmaceuticals
Limited.
16) Rajasthan Drugs and Pharmaceuticals Limited.
17) Bengal Immunity Limited.
18) Smith Stanistreet Pharmaceuticals Limited.
A draft proposal to modify the 2
nd
Schedule to the
Government of India (ALLOCATION OF BUSINESS)
RULES 1961 was forwarded to the Cabinet Secretariat
on 11.01.2013.
The work of the Department has been organized into
three Divisions viz. Pharmaceuticals Industry Division,
Public Sector Undertakings Division and R&D Division
comprising National Institute of Pharmaceutical
Education & Research, (NIPER) and Research
& Development. The National Pharmaceuticals
Pricing Authority (NPPA), an attached offce of this
Department, is entrusted with fxation and revision of
prices of Pharmaceuticals products under Drug Price
Control Order, 1995 (DPCO, 1995).
There are fve Central Public Sector Undertakings
(CPSUs) viz Indian Drugs and Pharmaceuticals
Limited (IDPL), Hindustan Antibiotics Limited (HAL),
Bengal Chemicals and Pharmaceuticals Limited
(BCPL), Bengal Immunity Limited (BIL) and Smith
Stanistreet Pharmaceuticals Limited(SSPL). Earlier
Karnataka Antibiotics & Pharmaceuticals Limited.
(KAPL) was a joint venture between Hindustan
Antibiotics Limited (HAL) and State Government of
Karnataka and Rajasthan Drugs and Pharmaceuticals
Limited (RDPL) was a joint venture of Indian Drugs
and Pharmaceuticals Limited (IDPL) and the State
Government of Rajasthan. But in order to sustain
the growth & development of KAPL & RDPL,
Government has approved de-linking of both these
companies from HAL & IDPL respectively. The shares
of KAPL held by HAL have now been transferred to
the President of India w.e.f. 1
st
October, 2009 and
8
similarly shares of RDPL held by IDPL have been
transferred to the President of India w.e.f. 17
th
August,
2010. The shareholding of respective States in these
joint ventures would continue to remain unaffected.
National Institutes of Pharmaceuticals Education
& Research (NIPERs) are autonomous institutions
under this Department.
Shri M.K. Alagiri is the Minister of Chemicals and
Fertilizers and Shri Shrikant Kumar Jena is the
Minister of State, Independent Charge in the Ministry
of Statistics and Programme implementation and
Minister of State in the Ministry of Chemicals and
Fertilizers. Shri Dilsher Singh Kalha, is Secretary in the
Department of Pharmaceuticals w.e.f 25.01.2012.
1.2 VISION AND MISSION OF THE
DEPARTMENT
Vision:
Based on the mandate given to the Department of
Pharmaceuticals through the allocated functions a
vision has been fxed in concurrence with the Cabinet
Secretariat, which is as follows:
India : The largest global provider of quality medicines
at reasonable prices.
Mission:
Ensure availability of drugs at reasonable prices
as per provisions of the Drug Prices Control
Order, 1995
Develop Human Resources for Pharmaceutical
Industry and Drug Research and Development
Formulate Scheme/ Project for promoting
Public-Private Partnership for development of
pharmaceuticals Industry
Formulate Scheme/ Project for promoting Pharma
Brand India through International Cooperation
environmentally sustainable development of
Pharmaceutical Industry
Chapter
2
AN OVERVIEW OF PHARMACEUTICALS INDUSTRY
2.1 Financial Performance of the Drugs and Pharmaceutcals Industry
2.2 Imports
2.3 Export of Drugs and Pharmaceutcals Industry
2.4 Share in Natonal Trade
2.5 Pharma Export Promoton Council (Pharmexcil)
2.6 Internatonal Cooperaton/Export Promoton of Pharmaceutcals
2.7 Proposed Major areas of Internatonal Conference
2.8 India Pharma Summit - 2012
11
CHAPTER 2
AN OVERVIEW OF PHARMACEUTICALS INDUSTRY
2.1 FINANCIAL PERFORMANCE OF THE DRUGS AND PHARMACEUTICAL INDUSTRY
The fnancial performance of the Drugs and Pharmaceutical industry for the year 2010-11, 2011-12 & 2012-13
(Forecast) and the quarterly performances during the Year 2012-13, all compared as a percentage change over the
year ago are given in Table below:-
Drugs and Pharmaceuticals : Growth and Proftability in the Year 2012-13
(%age change over year ago)
Sl. No. Particulars Quarterly Annual
June12 Sept.12 Dec.12 March13 2010-11 2011-12 2012-13
Forecast Forecast Forecast
1 Income 14.0 17.4 15.3 11.4 10.9 16.0 14.5
2 Net sales 14.7 13.2 15.2 14.3 12.4 16.5 14.4
3 Total expenses 23.2 9.1 -1.9 12.0 19.2 18.4 9.6
4 Raw Materials 8.1 11.10 16.6 11.0 14.8 11.3 11.8
5 Salaries & Wages 15.4 19.6 15.6 13.0 21.1 15.7 15.9
6 Power & fuel 45.6 50.7 17.6 16.0 20.1 9.4 28.9
7 Selling & Marketing 41.0 34..1 14.0 12.2 11.9 10.2 23.8
8 Other expenses 60.4 -4.0 -10.0 14.1 15.9 40.6 9.8
9 Depreciation 14.3 13.8 10.0 20.0 12.4 15.3 14.5
10 Interest expenses 48.7 12.6 13.0 -15.0 6.6 46.5 10.9
11 Tax provision 11.0 37.4 94.3 28.6 73.6 -48.4 39.2
12 PBDIT -31.6 45.4 60.3 20.7 -1.1 0.8 20.2
13 PAT -63.5 116.6 - 3.4 -31.6 -9.8 58.9
14 PBDIT/Net Sales (%) 12.3 19.4 18.6 19.2 19.0 16.7 17.5
Source: Center for Monitoring Indian Economy (CMIE) Report December 2012.
Net sales of the industry grew by a healthy 14.7
percent in the quarter ending June 2012 as compared
to the year ago quarter. The depreciation in the value
of rupee against the USD, though favorable for the
export-oriented drug companies had an adverse
impact on the profts of companies. The industry
imports around 38 percent of its raw material
requirements which exerted pressure on the proft
margins. Huge forex losses brought down the proft
of the drugs & pharmaceuticals industry in the June
2012 quarter. The industrys PAT slumped during the
quarter.
The drugs & pharmaceuticals industry performed well
in the second quarter ending September 2012. Rising
sale from the US generic market, strong growth in
domestic market, robust growth in other income and
slower growth in expenses boosted the fnancial
performance of the drugs & pharmaceuticals industry.
Net sales of the industry grew by a healthy 13.2
percent in the September 2012 quarter as compared
to the year ago quarter. Other income increased
during the quarter due to forex gains made by some
companies. Raw materials expense, the largest cost
component of the industry, rose by a slower percent
as compared to the growth in sales. In the absence
of forex losses, other expenses also fell. Resultantly,
the industrys operating expenses corresponding to
goods sold rose by a slower percent. This improved
the core operating performance of the industry. A
healthy operating performance and a robust growth
12
in other income boosted the fnancial performance of
the drugs & pharmaceuticals industry.
The sales growth of the pharma industry is likely to
remain healthy in the second half of the year 2012-13.
The Pro Generic policy of developed markets and
strong demand scenario in the developing market.
Export volumes are likely to remain healthy due to
strong demand for generic drugs. On a y-o-y basis,
the rupee continues to remain weak. Hence, export
realizations are also likely to remain strong.
2.2 IMPORTS
As per the Directorate General of Commercial
Intelligence and Statistics (D.G.C.I.S.) Kolkata, value of
imports of Medicinal and Pharmaceuticals Products
for the period 2003-04 to 2011-12 is as under:
(Rs. in crore)
Year Value of Import
of Medicinal and
Pharmaceuticals
Products
Growth (%)
2003-04 2,956 3.18
2004-05 3,139 6.19
2005-06 4,515 43.84
2006-07 5,866 29.92
2007-08 6,734 14.79
2008-09 8,649 28.43
2009-10 9,959 15.15
2010-11 11,114 11.60
2011-12(P) 14385 29.43
(Source: Directorate General of Commercial Intelligence
and Statistics (DGCIS), Kolkata)
It may be observed that the imports have shown a
growth of 29.43% in the year 2011-12 compared to
previous year. The country is almost self-suffcient in
production of most of formulations/ pharmaceuticals
products. As such imports are being resorted to on
quality & economic considerations and not necessarily
due to non-availability from domestic sources.
Manufacturers of Drugs & Pharmaceuticals are free
to produce any drugs approved by the Drug control
authorities.
Import of Drugs & Pharmaceuticals is regulated as
per the Foreign Trade Policy of Government of India.
Import of some drugs and drug intermediates are
restricted under current Foreign Trade Policy. These
restrictions are basically due to common HS codes
assigned to some narcotic substances or similarity
to some Ozone Depleting Substances (ODS) with
pharmaceutical products.
2.3 EXPORTS
As per DGCIS, Kolkata Exports of Drugs and
Pharmaceuticals and Fine Chemicals for the period
2003-04 to 2010-11 are below:-
(Rupees in crore)
Year Value of Exports
of Drugs and
Pharmaceuticals and
Fine Chemicals
Growth
(%)
2003-04 15,213 18.61
2004-05 17,228 13.25
2005-06 21,230 23.23
2006-07 25,666 20.89
2007-08 29,354 14.37
2008-09- 39,821 35.66
2009-10 42,456 6.62
2010-11 48,810 14.97
2011-12(P) 63,347 29.78
Source: DGCIS, Kolkata
It may be observed that the exports have shown a
growth of 29.78% in the year 2011-12 compared to
previous year.
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
2003-04 2004-05 2005-06 2006-07 2007-08 2008-09 2009-10 2010-11 2011-12
2,956 3,139
4,515
5,866
6,734
8,649
9,959
11,114
14385
R
s
.
i
n
C
r
o
r
e
s
Years
VALUE OF IMPORT OF "MEDICINAL &
PHARMACEUTICALS PRODUCTS"
13
2.4 SHARE IN NATIONAL TRADE
(Value in Rs. Crore)
Items/Years
2007-08 2008-09 2009-10 2010-11 2011-12
A: Total National Exports 655864 840755 845534 1142922 1459281
(a) Drugs Pharmaceuticals and Fine
chemicals
29354 39821 42456 48810 63347
Share in Total Export % 4.5 4.7 5.0 4.3 4.3
B: Total National Imports 101232 1374436 1363736 1683467 2344772
(b) Medicinal and Pharmaceuticals
Products
6734 8649 9959 11114 14385
Share in Total Import % 0.7 0.6 0.7 0.7 0.6
(c) Trade Balance (a)-(b) 22620 31172 32497 37696 48962
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
2003-04 2004-05 2005-06 2006-07 2007-08 2008-09- 2009-10 2010-11 2011-12
15,213
17,228
21,230
25,666
29,354
39,821
42,456
48,810
63,347
R
s
.
i
n
C
r
o
r
e
s
Years
Value of Export of "Drugs Pharmaceuticals
and Fine chemicals"

2003-04 2004-05 2005-06 2006-07 2007-08 2008-09- 2009-10 2010-11 2011-12
Exports 19 13 23 21 14 36 7 15 30
Imports 3 6 44 30 15 28 15 12 29
19
13
23
21
14
36
7
15
30
3
6
44
30
15
28
15
12
29
-
5
10
15
20
25
30
35
40
45
50
I
n
d
i
c
e
s
Growth of Import "Medicinal and
Pharmaceucals Products" & "Export Drugs
Pharmaceucals and Fine chemicals"

1459281
63347
Total National Exports
Drugs Pharmaceuticals and
Fine chemicals
2344772
14385
Total National Imports
Medicinal and
Pharmaceuticals Products
The share of Exports of the Drugs Pharmaceuticals
and Fine Chemicals in the total National Exports
declined from 4.50% to 4.30% during the period 2007-
08 to 2011-12, However in the absolute terms there
is growth in Exports. The share of Imports is declined
0.7% to 0.6% in the corresponding period.
2.5 PHARMA EXPORT PROMOTION
COUNCIL (PHARMEXCIL)
The Department had played a pivotal role in the
formation of Pharmexcil consequent to the
recommendation from 9
th
Five Year Plan Working
Group Report on Drugs and Pharmaceuticals. In the
light of this, the Department constantly interacts with
Pharmexcil in their work areas. The role of Pharmexcil
is for facilitation of exports of Drugs, Pharmaceuticals,
Biotechnology products, Herbal medicines and
Diagnostics, to name a few. It is authorised to issue
Registration-cum-Membership Certifcate (RCMC)
which is one of the requirements for the importers
14
and exporters of commodities. In addition to this,
Pharmexcil is concerned with giving export thrust
to the various products through visits of delegations
to various markets abroad, organizing of seminars,
workshops and exhibitions. As a major area of work,
Pharmexcil also holds Buyers/Sellers meets and
compiles detailed data base on pharma exports and
problems in exporting pharma products.
2.6 INTERNATIONAL COOPERATION/
EXPORT PROMOTION OF
PHARMACEUTICALS
An important focus area for the Department
of Pharmaceuticals is promotion of Indian
Pharmaceutical Products in global market. The
Department participated in the following International
Cooperation events during 2012-2013:-
1. Participation in US-India Bio-Pharma and
Healthcare Summit organized by USA-India
chamber of Commerce (USAIC) held on 11
th
May,
2012 at Massachusetts in USA.
2. Participation in the Fourth Session of the Indo-
Ukrainian Inter-Governmental Commission on
Trade, Economic, Scientifc, Technological,
Industrial and Cultural cooperation (IUIGC) held
on 31 May-June 1, 2012 at Kyiv, Ukraine.
3. Participation in the meeting of India-EU Sub
Commission on Trade held on 30
th
October, 2012
in New Delhi.
4. Participation in the 18
th
Session of India-
Russia Working Group on Trade and Economic
Cooperation (IRWGTEC) held on 11
th
-12
th

October, 2012 in New Delhi.
5. Participation in the VI Session of India-Russia
Forum on Trade and Investment held on 15
th

October, 2012 in New Delhi.
6. The Department of Pharmaceuticals has signed
a Memorandum of Understanding with Belarus
on 14
th
November, 2012 for Cooperation in the
Field of Production and Trade of Pharmaceutical
Products.
The Department of Pharmaceuticals also provided
fnancial assistance for the following activities/events
for promotion and development of the Pharma sector:
1. For organizing a Workshop on Promoting/ use of
Quality Generic Medicines.
2. For organizing Bio Asia: Global Bio-business
forum in January, 2013.
3. For preparation of 1
st
draft & 2
nd
Interim draft of
DPR 2020 for developing India as drug discovery
&Pharma Innovation Hub 2020.
4. For submitting a DPR on Establishment of an
Indian Pharma Innovation Venture Fund for Drug
Design, Discovery & Development.
2.7 PROPOSED MAJOR AREAS OF
INTERNATIONAL COOPERATION
The Department proposes to leverage Inter-Country
partnership through MoUs for formulating greater
market access to Indian Pharma in key markets like
Russia, Ukraine, Kazakhstan etc amongst the CIS,
Mexico, Brazil, Venezuela, etc in LAC region, Japan,
ASEAN, etc in the East Asia, South Africa, Nigeria,
Kenya, etc in Africa and some key Gulf Countries like
Saudi Arabia, UAE, etc. It is also targeting focus on
European countries like Spain, Greece, Germany,
France and Italy for APIs and niche formulations.
2.8 INDIA PHARMA SUMMIT-2012
The Department of Pharmaceuticals in collaboration
with Federation of Indian Chamber of Commerce and
Industry (FICCI) and WHO India organized India
Pharma Summit 2012, on 4
th
December, 2012 in
New Delhi.The theme of India Pharma Summit 2012
was INDIAN PHARMA - ACCESS TO MEDICINES
& GLOBAL OUTREACH. The India Pharma Summit
was a one day event to showcase Indias capability
in the Pharma Sector before all the stakeholders as
well as to provide the networking opportunities to
the Indian Pharma Industry for having a meaningful
interaction with various stakeholders. It provided
a platform that brought all the stakeholders such
as policy makers from Government of India, State
Governments, Indian Pharma Industry, Regulatory
Authorities from focus countries, Academia, Global
Pharma Leaders/ Experts on one platform and
facilitated a meaningful interaction. It generated
a healthy debate as well to come up with the
solutions to issues of the problems being faced by
Pharma Sector. India Pharma Summit 2012 was the
4
th
event in successful series after the Department of
Pharmaceuticals was carved out of Department of
Chemicals & Petrochemicals in July 2008.
Chapter
3
PHARMACEUTICALS INDUSTRY
3.1 Pharmaceutical Industry
3.2 Creation of IPr Facilitation Centres in Pharmexcil
3.3 Pharmaceutical Policy
3.4 Foreign Direct Investment in Pharmaseutical Sector
17
CHAPTER 3
PHARMACEUTICAL INDUSTRY
3.1 PHARMACEUTICAL INDUSTRY
The annual turnover of the Indian Pharmaceutical
Industry is estimated to be about Rs. 119075.6
1
Crores
during the year 2010-11. The share of export of Drugs,
Pharmaceuticals and Fine Chemicals is more than
Rs. 47363.3
2
Crores. This segment of Industry has
shown tremendous progress in terms of infrastructure
development, technology base and wide range of
products. The industry has developed excellent
GMP (Good Manufacturing Practices) compliant
facilities for the production of different dosage forms.
The strength of the industry is in developing cost
effective technologies in the shortest possible time
for drug intermediates and bulk activities without
compromising on quality. This is realized through the
countrys strengths in organic chemicals synthesis
and process engineering.
The domestic Pharma Industry has recently achieved
some historic milestones through a leadership position
and global presence as a world class cost effective
generic drugs manufacturer of AIDS medicines. Many
Indian companies are part of an agreement where
major AIDS drugs based on Lamivudine, Stavudine,
Zidovudine, Nevirapine are supplied to Mozambique,
Rwanda, South Africa and Tanzania which have
about 33% of all people living with AIDS in Africa.
Many US Schemes are sourcing Anti Retrovirals from
Indian companies whose products are already US
FDA approved.
The Indian Pharmaceutical companies maintain
highest standards in Purity, Stability and International
Safety, Health and Environmental (SHE) protection
in production and supply of bulk drugs. This speaks
of the high quality standards maintained by a large
number of Indian Pharma companies as these bulk
actives ingredients are used by the buyer companies
in manufacture of dosage forms which are again
subjected to stringent assessment by various
regulatory authorities in the importing countries. More
of Indian companies are now seeking regulatory
approvals in USA in specialized segments like Anti-
1 Source CMIE(July, 2012)
2 Source CMIE(Mar, 2011)
infectives, Cardiovasculars, CNS group. Along with
Brazil & PR China, India has carved a niche for itself
by being a top generic Pharma player.
Many Indian companies have got various international
regulatory approvals for their plants, from agencies
like USFDA, MHRA-UK, TGA-Australia, MCC-South
Africa etc. Outside USA India is the only country
having the highest number of USFDA approved
plants for generic drugs manufacture outside USA.
Major share of Indian Pharma exports is going to
developed western countries and it speaks not only
about excellent quality of Indian pharmaceuticals but
also about the reasonableness of the prices. Some of
the leading Indian Pharma companies derive 50% of
their turnover from International business.
3.2 CREATION OF IPR FACILITATION
CENTRES IN PHARMEXCIL
The Working Group on Drugs and Pharmaceuticals
for the 11
th
Five Year Plan (2007-2012) recommended
setting up of 3 IPR Facilitation Centres at 3 offces
of Pharmexcil in order to disseminate information on
IPRs and related issues to the Pharma Industry in an
effective manner. For this purpose, a fund Rs. 5 crores
was proposed by the Working Group for the 11
th
Five
Year Plan. The frst centre was opened at Hyderabad
on 11
th
July, 2008. Subsequently, centre at Mohali was
opened. These centres are offering various services
to the members like General Information on Patents,
Patent status of pharmaceutical products in India and
other countries, Interpretation of search information
etc. Keeping in view the importance of this scheme,
it has been recommended to Planning Commission
to continue and further strengthen this scheme in the
12
th
Five Year Plan.
3.3 PHARMACEUTICAL POLICY
This Department has been exercising Drug Price
Control on the basis of criteria mentioned in
Modifcations in Drug Policy, 1986 announced in
September, 1994, which is based on production data
of 1990.
Further the Department of Pharmaceuticals prepared
a draft National Pharmaceutical Pricing Policy, 2011
18
(NPPP-2011) based on the criteria of essentiality and
requirements as stipulated by Ministry of Health &
Family Welfare. The draft National Pharmaceutical
Pricing Policy, 2011(NPPP-2011) was circulated
among the concerned Ministries/Stakeholders. The
draft Policy was/is also available on the Departments
website www.pharmaceuticals.gov.in for comments
by 30.11.2011 of any other interested person. In the
draft policy it was proposed to bring the NLEM-2011 &
associated medicines under price control.
The Department of Pharmaceuticals has notifed
the National Pharmaceutical Pricing Policy-2012
(NPPP-2012). The objective is to put in place a
regulatory framework for pricing of drugs so as to
ensure availability of required medicines essential
medicines at reasonable prices even while providing
suffcient opportunity for innovation and competition
to support the growth of industry, thereby meeting
the goals of employment and shared economic well
being for all.
The salient features of this policy are as under:
All the medicines, as under National List of
Essential Medicines (NLEM) -2011, that takes
care of the healthcare needs of the majority of
the population of the country, will come under
Price Control.
Nearly 614 formulations, spread over 27
therapeutic categories including HIV, diabetes,
heart diseases, cancer etc will be under price
control.
The Prices of nearly 63% of medicines under
NLEM-2011 will decrease by more than 20%. In
some cases this reduction is even up to 80%of
the present market price. For example Diclofenac
50mg tablet, priced at Rs. 4.65 per tablet will be
capped at Rs. 1.97 per tablet.
The total domestic pharma market is around
Rs. 60,000 Crores and with the implementation
of NPPP-2012, nearly Rs 15,000 Crores market
will come under price control which is 25% of the
domestic market.
3.4 FOREIGN DIRECT INVESTMENT IN
PHARMASEUTICAL SECTOR
Foreign Direct Investment (FDI) up to 100% has
been in operation in Pharmaceutical Sector since
2001. However, during the period of August 2006 to
December 2010, acquisitions of some of the major
Indian Pharma Companies like Ranbaxy and Piramal,
led to a strong apprehension that these takeovers
could affect the domestic Pharma Industry especially
the Generic Medicines.
The Department of Pharmaceuticals requested the
Department of Commerce to conduct a study on
the takeovers of Indian companies by the MNCs.
The Department of Commerce entrusted the work to
Ernst & Young. Department of Commerce informed
that the report recommended continuation of the
existing FDI policy (100% through automatic route) in
pharmaceutical sector.
However, with a view to examine the issued involved in
FDI in a broader perspectives, Planning Commission
had, with the approval of the Honble Prime Minister,
constituted a High Level Committee (HLC) under
the Chairpersonship of Shri Arun Maira, Member
(Industry), Planning Commission to consider all the
relevant aspects. The majority of the members of
the Committee were of the view that the acquisitions
in Pharmaceutical Sector should be monitored and
controlled through Competition Commission of
India (CCI).
The Honble Prime Minister chaired a meeting to discuss
the FDI policy in drugs and pharmaceutical sector on
10
th
October, 2011. The meeting deliberated upon the
report of Shri Arun Maira, Member (industry) Planning
Commission, which followed a CCEA decision to get
greater clarity on the issue of FDI policy governing
mergers and acquisitions in the pharmaceutical sector,
while striking a balance between larger public health
concerns and strengthening domestic manufacturing
capacities. The following considered decisions were
taken in the meeting:
(a) India will continue to allow FDI without any limits
(100%) under the automatic route for Greenfeld
19
investments in the pharma sector. This will
facilitate addition of manufacturing capacities,
technology acquisition and development;
(b) In case of brownfeld investments in the
pharma sector, FDI will be allowed through the
FIPB approval route for a period of upto six
months. During this period, necessary enabling
regulations will be put in place by the CCI for
effective oversight on mergers and acquisitions
to ensure that there is a balance between public
health concerns and attracting FDI in the pharma
sector. Thereafter, the requisite oversight will be
done by the CCI entirely in accordance with the
competition laws of the country.
Subsequently, Department of Industrial Policy &
Promotion issued Press Note No. 3 (2011 Series)
dated 8.11.2011 amending the existing FDI policy
under which 100% FDI was permitted through
automatic route. As per Press Note 3(2011 Series)
issued by Department of Industrial Policy and
Promotion on 08.11.2011:-
(i) FDI, upto 100%, under the automatic route,
would continue to be permitted for greenfeld
investments in the Pharmaceuticals sector.
(ii) FDI upto 100%, would be permitted for brownfeld
investment (i.e. investments in existing
companies), in the pharmaceuticals sector, under
the Government approval route.
On 03.12.2012, a meeting was held under the
Chairmanship of Honble Prime Minister and it
was decided that FIPB shall continue to scrutinize
proposals for FDI in brownfeld Pharma till the CCI
is equipped with the power to impose conditionalities
on Mergers and Acquisitions with Public Health
concerns
Chapter
4
NATIONAL PHARMACEUTICALS PRICING AUTHORITY
4.1 NPPA
4.2 Drug Price Equalization Account (DPEA)
23
CHAPTER 4
NATIONAL PHARMACEUTICAL PRICING AUTHORITY (NPPA)
4.1 NPPA
The National Pharmaceutical Pricing Authority (NPPA)
was established as an independent body of experts
under the Ministry of Chemicals and Fertilizers by
Gazette notifcation dated 29.08.1997. The Authority
is entrusted with the task of price fxation / revision
of the 74 scheduled bulk drugs and formulation
containing any of the scheduled drugs under the Drugs
(Prices Control) Order, 1995 as well as monitoring and
enforcement of prices. NPPA also provides inputs to
the Government for policy formulation and on other
specifc issues concerning affordable medicines to
the consumer.
The functions of the National Pharmaceutical Pricing
Authority (NPPA) are:
(1) To implement and enforce the provisions of the
Drugs (Price Control) Order (DPCO), 1995 in
accordance with the power delegated to it.
(2) To undertake and/or sponsor relevant studies in
respect of pricing of drugs/formulations.
(3) To monitor the availability of drugs, identify
shortages, if any, and to take remedial steps.
(4) To collect/maintain data on production, exports
and imports, market share of individual
companies, proftability of companies etc. for
bulk drugs and formulations.
(5) To deal with all legal matters arising out of the
decisions of the Authority.
(6) To render advice to the Central Government of
changes/revisions in the drug policy.
(7) To render assistance to the Central Government
in parliamentary matters relating to drug pricing.
The organizational structure of NPPA is given in the
chart below:-
The performance of NPPA since its inception (up to
31.01.2013) is as under:
The National Pharmaceutical Pricing Authority (NPPA)
since its inception has fxed / revised the prices of
scheduled bulk drugs in 532 cases, which includes
342 bulk drugs and 190 derivatives of scheduled bulk
drugs.
Of these, the prices of 7 scheduled bulk drugs and 3
derivative and 510 formulations were fxed / revised
during the period from 01.04.2012 to 31.01.2013.
The NPPA compiles the annual data on production
of selected monitored bulk drugs. The data on
production for the years 2009-10, 2010-2011, 2011-
2012 and 2012-13 (upto November, 2012) is given in
the Annexure - I.
The price of scheduled bulk drugs fxed during
the last four years & since inception are given in
Annexure - II and summarized below:
BULK DRUGS PRICES
Particulars 2009-10 2010-11 2011-12 2012-13
(upto 31
st

Jan., 13
Since
inception
of NPPA
No. of Bulk Drugs Where Price Increased 15 10 19 06 158
No. of Bulk Drugs Where Price Decreased 10 07 01 04 347
No. of Bulk Drugs Where price fxed For First Time 02 01 0 0 17
No change In Price 01 03 01 0 10
Total 28 21 21 10 532
24
MONITORING OF PRICES
The NPPA monitors and analyses month-wise price
movements of non-scheduled formulations based
on the reports of IMS Health. The prices of these
formulations are fxed / determined by manufacturers
themselves depending on various factors like the
cost of production, market competition, companys
proftability status etc. NPPA monitors the prices
of non-scheduled formulations through various
methods like (a) scrutiny of price lists submitted by
manufacturers (b) analysis of monthly Stockiest
Secondary Audit Reports published by IMS Health,
and (c) complaints / references received from offcial
and non-offcial sources. Wherever price increase
beyond 10% is noticed, manufacturers of such
formulations are asked to clarify the reasons for such
price increases.
The manufacturers are impressed upon to bring
down the prices voluntarily and to maintain the price
FORMULATION PACKS
Particulars 2009-10 2010-11 2011-12 2012-13
(upto 31
st

Jan., 13)
Since
Inception of
NPPA
Price Increased 184 223 257 81 1870
Price Decreased 450 60 50 104 3513
Price fxed for frst time 1155 371 239 253 6315
No change in prices 35 59 61 72 472
Total 1824 713 607 510 12170
level. So far 33 companies have reduced prices of
65 non-scheduled formulation packs voluntarily after
intervention of NPPA. This is an on-going process.
Further, NPPA has fxed the price of 30 non-scheduled
formulations under para 10(b) of DPCO, 1995. Thus
prices of 95 non-scheduled formulation packs have
been reduced through the intervention of NPPA till
31
st
January, 2013.
CREATION OF ENFORCEMENT DIVISION &
ITS PERFORMANCE
A separate Enforcement Division was created in
NPPA in June, 2007 to facilitate suo-moto detection
of violation of DPCO 1995. Since inception 4032
samples were analysed leading to prima facie
detection of 1308 cases of overcharging and 549
cases of selling of scheduled medicines without price
approval.
25
RECOVERY OF OVERCHARGED AMOUNT
There are a total no. of 919 cases wherein demand
notices have been issued involving total overcharged
amount of Rs. 2596.69 crores including interest since
inception of NPPA till January, 2013. An amount of
Rs. 234.31 crores has been recovered till 31.01.2013
which also includes recovery through Court orders.
During the year 2012-13 (upto 31.01.13) Demand
Notice have been issued for Rs. 134.44 crore and
Rs. 14.49 crore has been recovered. As on 31.01.13,
116 cases involving total demand of Rs. 2448.36
crore are under litigation in various High Courts and
also in the Supreme Court, out of which Rs. 180.62
crore has already been deposited by the companies
in pursuance of the court order and the balance
Performance of Enforcement Division
Year No. of Samples
Collected
Prima Facie
Violations detected
Referred for
Overcharging
Identifed for
Price fxation
2007-08 1450 840 456 384
2008-09 520 284 172 112
2009-10 464 246 208 38
2010-11 533 225 216 9
2011-12 559 156 152 4
2012-13 (upto Jan. 2013 * 486 106 104 2
* 70 cases are under process
amount is still pending. 50 cases amounting to
Rs. 16.63 crore are pending with the Collectors of
various States for recovery arrears of Land Revenue.
The recovery of the overcharged amount is affected
due to various Court orders passed by various High
Court and also Supreme Court in cases fled by the
Pharmaceuticals Companies challenging the price
fxation / notifcation issued by NPPA / Government.
Inclusion of some bulk drugs under price control
(scheduled-I of DPCO95) has also been challenged
by the Pharma companies in different courts of India.
NPPA / Government is defending such cases through
SG, ASGs and Senior Government Counsels.
Whenever necessary NPPA fles urgent application
in the Courts for vacation of interim orders and also
for early hearing / disposal of the case.
The Status of cases of overcharging since inception till 30th January, 2013
SI
No.
Particulars Aug,
1997 to
March
2006
2006-07 2007-08 2008-09 2009-10 2010-11 2011-12 2012-13
(upto
Jan.,
2013)
Cummulative
(Aug, 97 to
Jan., 2013)
1 No. of Cases 335 67 118 135 89 42* 46 93 919
2. Overcharged
amount
demanded
alongwith interest
700.22 38.01 820.31 435.62 156.22 146.93 164.94 134.44 2596.69
3. Amount Realized 99.16 0.96 4.51 51.41 35.41 17.26 10.69 14.91 234.31
26
SI
No.
Particulars Aug,
1997 to
March
2006
2006-07 2007-08 2008-09 2009-10 2010-11 2011-12 2012-13
(upto
Jan.,
2013)
Cummulative
(Aug, 97 to
Jan., 2013)
4. Amount
Outstanding
601.06 37.05 815.80 384.21 120.81 129.67 154.25 119.53 2362.38
5. Amount still
under litigation
including cases
referred to
collector and
contested by the
companies in the
court of law
-- -- -- -- -- -- -- -- 2267.74
6. Cases referred
to collector &
amount still to be
recovered
-- -- -- -- -- -- -- -- 16.63
7. Amount pending
relating to the
overcharging
cases under
process
-- -- -- -- -- -- -- -- 78.01
4.2 DRUG PRICES EQUALISATION
ACCOUNT (DPEA)
Drug Prices Equalisation Account (DPEA) has been
maintained by Government under the provisions
of Drugs (Prices Control) Order, 1979. Under the
DPCO, 1979 there were 345 bulk drugs under
price control. The Department computed tentative
liabilities in respect of 47 bulk drugs only on suo-motu
basis covering 172 cases till the Interim stay dated
30.6.1997 was granted by the Honble Bombay High
court in the Writ petition No. 2368/1996 fled by the
Indian Drugs Manufacturers Association (IDMA) and
Organisation of pharmaceutical producers of India
(OPPI) restraining the Department and its committees
etc., from issuing fresh notices to the drug companies
calling for information required for determining
liabilities. Out of these 172 cases where the liabilities
have already been determined tentatively and
communicated to the companies, only 72 such cases
during the period 1994-97 could be referred to the
Drugs Prices Liabilities Review Committee (DPLRC)
constituted on 21.3.1994 under the Chairmanship
of a judge of Honble Delhi High Court retired in
October, 1994) alongwith two members to review/
determine the liability in such cases. Out of these 72
cases, the Committee after deliberation in each case
and giving adequate opportunity of hearing to the
drug companies to present their point of view gave
reports in 47 cases. In view of the stay granted by the
Honble Bombay High Court the Committee had not
taken up the other 25 cases and also any fresh case.
On the basis of the recommendations of the DPLRC,
Department issued demand notices in 45 cases (no
liability in one case and one case inked with another
case). Most of these companies fled Writ petition
in the different High Courts against the demand
notices. The total amount of liability on the basis of
the recommendations of the DPLRC is to the tune of
Rs. 228.47 crore (appx). During the current year till
November, 2012 DPEA Cell has recovered about Rs.
137.00 crores of the liabilities. Till November 2012
total amount collected and deposited in DPEA is Rs.
299.65 crores.
27
Since, no new cases could be taken up by DPLRC for
determination of the DPEA liability because of the stay
granted by the Honble Bombay High Court, there was
no work with the DPLRC. Hence a conscious decision
wastaken by the Government to keep the DPLRC
under suspended animation w.e.f. 31 December,
2005 vide Resolution dated 16
th
December, 2005.
At that time 25 cases were pending with the DPLRC
because of stay, where no quantifcation could be
done. In addition to these 25 cases, there may be a
large number of DPEA liability cases in respect of 298
bulk drugs where information from the companies
concerned is to be gathered for determination of the
DPEA liability. The aforesaid W. P. No. 2368/1996 has
since been dismissed by Honble High Court vide its
judgement dated 22.12.2011.
Chapter
5
PUBLIC SECTOR UNDERTAKINGS
5.1 Central Public Sector Undertakings
5.2 Joint Sector Undertakings
5.3 Wholly Owned Subsidiaries
5.4 Status of Annual Accounts
5.5 Generic Drugs Campaign The Jan Aushadhi Campaign
31
CHAPTER 5
5.1 CENTRAL PUBLIC SECTOR UNDERTAKINGS
The total production and sales of fve Pharma Central
Public Sector Undertakings (CPSUs) under the control
of this Department for the last four years are as under:-
(Rs. in crore)
2009-10* 2010-11* 2011-12*
2012-13*(up to
November 2012)
Production 616.22 545.01 496.08 300.26
Sales Turnover 590.87 522.3 501.91 269.57
0
100
200
300
400
500
600
700
* Provisional
I) KARNATAKA ANTIBIOTICS &
PHARMACEUTICALS LIMITED (KAPL),
BANGALORE
Karnataka Antibiotics & Pharmaceuticals Limited
(KAPL) is a proft making Mini Ratna Central PSU
having 59% of the equity shares of GoI and 41%
of equity shares of Karnataka State Industrial and
Investment Development Corporation (KSIIDC). The
paid up share capital of the company as on date is
Rs.13.49 crores. The Company was incorporated
on 13th March, 1981 and the commercial production
started from August, 1984. The manufacturing units
and the registered offce of the company is located
at Bangalore (Karnataka). The main products are
Pharmaceuticals formulations like tablets, capsules,
injectables, etc. It is a Memorandum of Understanding
(MOU) signing company.
Earlier it was a Joint Sector Undertaking of Hindustan
Antibiotics Limited (HAL) in collaboration with KSIIDC.
But in the interest of continued growth and development
of the company, Government has implemented the
delinking of KAPL from HAL and transferred the
shareholding of HAL in KAPL to Government of India.
Government of India had also invested Rs. 7.10 crore
in KAPL for upgrading its manufacturing facilities
conforming to WHO-GMP standards and setting up
a new WHO-GMP compliant Cephalosporin plant.
Other joint venture partner, viz. Karnataka State
Industrial and Investment Development Corporation
(KSIIDC) would bring in additional investment of
Rs. 4.90 crore in KAPL. The company has also ISO-
9001 and ISO 14001 accreditation.
It has been continuously generating profts for the last
12 years and the performance of the company has
further improved.
Production & Sales
(Rs. in crore)
2009-10 2010-11 2011-12
2012-13*(up to
November 2012)
Production 218.75 240.31 251 165.92
Sales Turnover 212.82 210.04 230.89 137.43
0
50
100
150
200
250
300
* Provisional
Product range of the company includes Antibiotics,
Anti-diabetic, cardiovasculars, pain management,
general medicines and animal health products.
Presently the Company is undertaking creation of
separate manufacturing facilities for Cephalosporin
product at an estimated cost of Rs.22.23 crores. The
Project is likely to be completed by end of the fnancial
year 2012-13. When the project is completed, it will
be possible for the Company to increase its exports,
as new range of products can be added to export.
II) RAJASTHAN DRUGS &
PHARMACEUTICALS LIMITED (RDPL),
JAIPUR
Rajasthan Drugs and Pharmaceuticals Limited
(RDPL) is a consistently proft making Central Public KAPL - Small Volume Parenterals Plant
32
Sector Unit in Joint Sector with a total paid-up equity
capital of Rs. 4.98 crores where Government of India
(GoI) and Rajasthan State Industrial Development &
Investment Corporation Limited (RIICO) hold 51%
and 49% respectively. It was incorporated in 1978
and commercial production started in 1981. The
Company has its manufacturing facilities & registered
offce at Road no. 12, VKI Industrial Area, Jaipur
(Rajasthan).
The company has carved for itself a name in the
institutional market in India as a reputed manufacturer
of high quality life saving drugs and other specialized
medicines, with its marketing activities spread
throughout the country.
The company is engaged in manufacture and selling
of medicines of high quality at reasonable rates to the
Govt. of Rajasthan, Central Government Institutions,
viz ESIC, Defence, Railways, other PSUs and also
to other State Govt. Institutions, and proud to be a
prime partner in the novel and noble endeavour of
Government of India in the implementation of Jan
Aushadhi Scheme where quality generic (unbranded)
medicines are made available to the public at large in
the country at affordable prices.
The product range of the Company includes anti-
infectives, anti-malarial, NSAIDS, antacids, analgesic,
anti-pyretics & anti-infammatory, anti-emetics, anti-
spasmodics, anti-diarrhoeal / anti-amoebic, cough
expectorants, cardio-diabetics, anti-allergic, anti-
bacterials, anti-fungal, vitamins & mineral, ophthalmic
preparations & Oral Rehydration Salt (ORS).
The company is further diversifying its marketing
activities into Pharma Prescription Markets (Open
Trade Sales), Veterinary Markets, Marketing of
Ayurvedic and other Indian system of medicines
This is a formulation unit engaged in production of
Tablets, Capsules, Liquid Orals, ORS Powder &
Opthalmic medicines in a Schedule M compliant
facility.
The company, under the quality management, has a
existence of a well-equipped laboratory with modern
equipments like High Performance/Pressure Liquid
Chromatography (HPLC), Fourier Transform Infrared
Spectroscopy (FTIR) etc., for ensuring high quality
parameters.
In the interest of continued growth and development
of the company, Government has delinked RDPL
from Indian Drugs & Pharmaceuticals Ltd. (IDPL) (the
original promoter representing GOI) and transferred
the shareholding of IDPL in RDPL to Government of
India in August 2010.
The Company has since then enhanced its
manufacturing capacities by installing new machines
and at the same time the workers have also acquired
skills and expertise for attaining high productivity. The
Company has changed its outlook and entered in the
RDPL Blister Packing Machine
arena of select Public Sector Companies showing
consistent profts amidst stiff competition. It is now
fairly on the path of growth.
33
in order to enhance its market share and also in
its endeavour to improve the proftability of the
organization.
Production & Sales
(Rs. In crore)
2009-10 2010-11 2011-12*
2012-13*(up to
November 2012)
Production 82.88 83.8 82.26 44.11
Sales Turnover 85.35 80.67 82.72 42.91
0
10
20
30
40
50
60
70
80
90
*Provisional
PROJECTS UNDERTAKEN & FUTURE
PROJECTS
The Company has almost completed the Phase-I
(Schedule M) of the expansion and modernization
plan and has embarked upon Phase-II programme
to qualify for WHO (GMP) requirements to become
eligible for exploring International Markets as well
as for participating in the Internationally Funded
Projects of GOI and other Governments.
was incorporated on 30th March, 1954. This
was the frst Public Sector Company in drugs and
Pharmaceuticals. HAL has its plant located at
Pimpri. The company produces a wide range of
Pharmaceutical formulations including agro-vet
products. There are two joint sector units promoted
by HAL in collaboration with the respective State
Governments. These are Maharashtra Antibiotics
& Pharmaceuticals Ltd. (MAPL) at Nagpur,
Maharashtra (since closed) and Manipur State
Drugs & Pharmaceuticals Ltd. (MSDPL) at Imphal,
Manipur (since closed). Karnataka Antibiotics &
Pharmaceuticals Limited (KAPL), Bangalore, which
was earlier a Joint Sector Undertaking of HAL in
collaboration with Karnataka Government, has
since been de-linked from HAL after approval of the
Government.
RDPL- Liquid Filling And Sealing Machine
Hindustan Antibiotics Limited, Pimpri, Pune-411018
Company's Main Entrance
After establishment, the company made profts for
several years. However, as the company started
incurring continuous losses since 1993-94, it was
referred to the Board for Industrial & Financial
Reconstruction (BIFR) in January, 1997. BIFR
declared the company formally sick on 31.3.1997
and appointed Industrial Development Bank of India
(IDBI), Mumbai as the Operating Agency (OA) for
a Techno-Economic Viability Study and Report.
Accordingly, a Rehabilitation Scheme was prepared
by HAL which was later revised on the directions of
the BIFR and the Government.
III) HINDUSTAN ANTIBIOTICS LIMITED
(HAL), PIMPRI, PUNE
Hindustan Antibiotics Ltd. (HAL), Pimpri, Pune
34
Based on the Scheme, the Government approved
the Rehabilitation of the company on 9
th
March
2006 followed by BIFR approval on 5
th
June 2007.
The Rehabilitation Scheme inter alia involved the
following:-
(Rs. in crores)
Sl.
No.
Particulars Amount
1. Cash infusion 137.59*
2. Write off/exemptions from
Government of India
267.57
3. Sacrifces by Banks, fnancial
institutions and PSUs
103.34
Total 508.50
(* This includes interest free loan of Rs. 56.96 crores to be
repaid by HAL by sale of land within a period of two years.)
The entire cash infusion of Rs. 137.59 crores has been
released to the company. Parliament has approved
writing off of loan and waiver of interest to the extent
of Rs. 259.43 crores. As regards generation of
Rs. 56.96 crore as part of Cash Infusion, BIFR issued
guidelines for sale of land as per the Rehabilitation
Scheme through an Assets Sale Committee. Action is
under progress by HAL in this regard.
Further, Government has additionally approved
proposals of Rs. 30.17 crore received from HAL
for setting up new powder injectable facilities for
Cephalosporin and upgradation of existing vialling
facilities for Betalactum (Penicilllin) Antibiotics
complying to WHO-GMP standards at an estimated
cost of Rs. 20.17 crores and for upgradation of
manufacturing facilities of Tablet, Capsule and Liquid
Sections complying to WHO-GMP standards at an
estimated cost of Rs. 10.00 crore in order to make
the company further viable.
HAL has completed the work on Cephalosporin
in record time of 9 months. It has commissioned
commercial production in February, 2009 and also
obtained WHO-Certifcation for the same. Work
relating to upgradation of existing vialling facilities for
Betalactum Antibiotics has also been completed and
production has been started.
New Cephalosporin Plant Building of Hindustan
Antibiotic Ltd., Pimpri,, Pune
HAL-Dry Powder Injectable Packing Line for
Cephalosporin Plant
Production & Sales:
Details of Production & Sales of HAL from 2009-10
onwards are as under:
(Rs. in crore)
2009-10 2010-11 2011-12*
2012-13*(up to
November 2012)
Production 123.15 85.54 53.85 31.91
Sales Turnover 117.87 95.39 72.39 32.1
0
20
40
60
80
100
120
140
* Provisional
FUTURE PROJECTS
Sl.
No.
Project Estimated Cost
(Rs. in crore)
1. Upgradation of Large Volume
Parenteral with facilities
complying to WHO-GMP
45.00
35
IV) BENGAL CHEMICALS &
PHARMACEUTICALS LIMITED (BCPL),
KOLKATA
BCPL was a chemicals manufacturing company
set up in the private sector in 1901 by Dr. Acharya
P.C. Roy, the great visionary and scientist. Later on
being sick, it was taken over by the Government and
nationalized on 15th December, 1980. A new public
sector company in the name and style of Bengal
Chemicals & Pharmaceuticals Limited (BCPL) was
incorporated in March, 1981.
The company has four manufacturing units one each
at Maniktala (Kolkata), Panihati at North 24 Parganas
(West Bengal), one at Mumbai (Maharashtra) and
one at Kanpur (UP). Besides, the company is having
nine sales outlets and three C&F agencies spread
all over India. The company manufactures and
markets a wide range of industrial chemicals, drugs
and Pharmaceuticals besides cosmetics and home
products. In the home products, the well known
products include Cantharidine Hair Oil and Lamp
Brand Phenol are quite popular.
Post 1980, company continued its operations.
However, due to continued losses, the company
was declared sick by the Board for Industrial and
Financial Reconstruction (BIFR) on 14
th
January,
1993. A Revival Package was accordingly prepared &
approved by the BIFR on 4
th
April, 1995. The package
was reviewed by BIFR from time to time, based on
which a Modifed Revised Rehabilitation Scheme was
then prepared. BIFR approved this Modifed Scheme
on 14.1.2004.
Finally, based on the requirements for modernization
of plants & machinery and taking into account the
earlier Schemes, the Board for Reconstruction of
Public Sector Enterprises (BRPSE) at its meeting
held on 25.8.2006 recommended a modifed revival
plan for revival of BCPL.
The recommendations of BRPSE were confrmed by
the Cabinet Committee on Economic Affairs (CCEA)
which approved the BRPSE Scheme in its meeting
held on 21
st
December 2006. The Revival Scheme
which include interalia:
(i) Cash infusion by GOI Rs. 207.19 crores
(ii) Write off / Waiver of Rs. 233.41 crores
Loans/Interest
Parliament has approved writing off of GOI loans
& interest of Rs. 233.41 crore and cash infusion
component of Rs. 207.19 crore. The component as
approved by the Government has been released. The
company has appointed Consultants for undertaking
the work of upgradation & modernization of plant &
machinery including compliance with Schedule M/
WHO- GMP standard.
Production & Sales:
Details of Production & Sales of BCPL from 2009-10
onwards are as under:
(Rs. in crore)
2009-10* 2010-11* 2011-12*
2012-13*(up to
November 2012)
Production 83.24 80.12 59.22 24.89
Sales Turnover 78.24 76.20 63.44 22.71
0
10
20
30
40
50
60
70
80
90
* Provisional
STEPS TAKEN FOR UPGRADATION &
MODERNIZATION
Upgradation& Modernization Projects including
capacity augmentation for Chemical Plants at
Panihati (West Bengal) and in Pharmaceutical
Plants at Maniktala (Kolkata) and Kanpur have been
BCPL- Mumbai Building
36
undertaken. In addition, Greenfeld Projects for
Cephalosporin and Betalactum range of products are
under commissioning at Maniktala. Upgradation of
Ointment, Stores Building, Batalactum, Cepahlosporin
Blocks, ETP, Roads, drains etc. are also completed at
Maniktala. Upgraded Phenol Manufacturing and flling,
Composite Production Block, renovated Alum Plant,
QC Block, Finished Goods Stores, Administrative
Block and other allied services are in operation at
Panihati after renovation.
The Upgradation & Modernization of Tablet, ORS
Powder, Liquid and Home Product Sections at Kanpur
is in progress. Modernization of QA Block, Utilities,
Amenities, ETP completed at Kanpur.
V) INDIAN DRUGS & PHARMACEUTICALS
LIMITED (IDPL), GURGAON
Indian Drugs and Pharmaceuticals Ltd (IDPL) was
incorporated on 5
th
April, 1961 for achieving Indias
march towards self-suffciency and self-reliance in
the feld of drugs and pharmaceuticals, particularly
with the primary objective of creating self suffciency
in essential life saving drugs and medicines.
IDPL is the largest Central Pharma Public Sector
Undertaking in India with plants at Rishikesh
(Uttarakhand), Hyderabad (Andhra Pradesh) and
Gurgaon (Haryana) and wholly owned subsidiaries,
namely, IDPL (Tamil Nadu) Ltd., Chennai (Tamil
Nadu) and Bihar Drugs & Organic Chemicals Ltd.
(BDOCL) at Muzaffarpur (Bihar). In addition, IDPL
has one joint sector undertaking, promoted in
collaboration with the Orissa State Government,
namely, Orissa Drugs & Chemicals Ltd. (ODCL)
Bhubaneswar.
UNITS, PRODUCT PROFILE & MANPOWER
Unit Maniktala Panihati Mumbai Kanpur
Products Tablets, Capsules, Ointment,
Spirituous preparations, Non-spirituous
preparations, Antiseptic preparations,
Injectables, Anti snake venom serum
(ASVS), Syrup, Hair oil etc.
Alumina ferric, Phenol,
Naphthalene balls,
Bleaching powder, Floor
Cleanser, Liquid soap.
Hair oil Tablet, Non-
spirituous
preparations,
Hair oil
Manpower as
on 01.11.2012
269 140 15 23
Total Manpower as on 01.11.2012: 656, Offcers: 119 Non-Offcers: 537
BCPL- Panihati Administrative Building
FUTURE PROJECTS
A project for manufacture of Anti-Rabies and other
vaccines at Panihati under Joint Venture/PPP mode
have been considered. Front View of IDPL- Tamilnadu Ltd., Chennai Plant
37
IDPL played a major role in the strategic National
Health Programmes like Family Welfare Programme
& Populations Control (Mala-D & MalaN) anti-
malarial (Chloroquine) and prevention of dehydration
(ORS) by providing quality medicines.
IDPL was formally declared sick by the Board for
Industrial & Financial Reconstruction (BIFR) on 12
th

August, 1992. A revival package for the company was
formulated and approved by BIFR on 10
th
February,
1994. However, after taking into account the
performance of the company which fell short of the
targets, the BIFR on 23.1.1996 treated the sanctioned
package as failure, and thereafter in its meeting held
on 4.12.2003 BIFR confrmed its prima-facie opinion
about winding up of IDPL in terms of Section 20(1)
of the Sick Industrial Companies (Special Provisions)
Act, 1985.
However, given the possibility of revival of the
company, Department of Chemicals & Petrochemicals
(Now Department of Pharmaceuticals) fled an appeal
against the opinion of BIFR in Appellate Authority for
Industrial & Financial Reconstruction (AAIFR) on
10.2.2004.
Consequently, an Expert Committee was appointed
in September, 2004, to study the Techno-
Financial Feasibility of rehabilitating IDPL. In this
connection, a Technical Audit of various plants of
IDPL was also assigned to National Institute of
Pharmaceutical Education and Research (NIPER).
NIPER in its report submitted to the Department
on 31.8.2005, recommended revival of all plants of
IDPL and its subsidiaries in phases for production
of existing and new products. IDBI, the then
Monitoring Agency on behalf of BIFR, supported
the recommendations for revival of IDPL subject
to certain conditions.
Accordingly, in a meeting held under the Chairmanship
of the then Minister (C&F&S), it was decided to
revive all the fve units of IDPL in a phased manner.
Honble AAIFR at its hearing on 13.9.2005 set aside
the impugned order of BIFR dated 4.12.2003 and
remanded the matter back to BIFR for taking further
action for rehabilitation of IDPL.
A Draft Rehabilitation Scheme for revival of Indian
Drugs & Pharmaceuticals Limited (IDPL) was
considered by the Board for Reconstruction of Public
Sector Enterprises (BRPSE) at its meeting held
on 9.3.2007 and recommended for approval. The
scheme was placed before the Cabinet for approval.
Cabinet considered the proposal at its meeting held
on 17.5.2007 and referred it to Group of Ministers
(GoM) for consideration at the frst instance. GoM
was constituted on 1.6.2007. The frst meeting of
the GoM was held on 11.10.2007. Based on the
recommendation of GoM and Draft scheme prepared
earlier, a Pre-Feasibility Report was prepared by
an Expert Agency, Ernst & Young. Now the revival
scheme of the company is under the consideration of
Central Government.
Despite being a sick company, during the countrys
calamity of outbreak of Plague in 1994, IDPL was
the only company which played the sheet anchor
role in supplying Tetracycline for the entire Nation.
Similarly, company had made uninterrupted supply of
Chloroquine to combat Malaria epidemic in different
parts of the country. In 2005 to combat national
emergency (Leptospirosis) arising due to foods in
Maharashtra, IDPL had supplied required Doxycycline
Caps within no time.
Packing / Inspection Hall, Chennai Plant, IDPL
38
Production and Sales Progress:
Details of Production & Sales fgures of IDPL from
2009-10 onwards are as under:
(Rs. in crore)
2009-10 2010-11* 2011-12*
2012-13*(up to
November 2012)
Production 108.20 55.24 49.75 33.43
Sales Turnover 96.59 60 52.47 34.42
0
20
40
60
80
100
120
* Provisional
VI) BENGAL IMMUNITY LIMITED (BIL)
BIL was a sick company in the private sector in
the name and style of Bengal Immunity Company
Limited. The management of the company was
taken over by the Central Government with effect
from the 18
th
May, 1978. It was nationalized w.e.f. 1
st

October, 1984 and a new public sector company in
the name and style of Bengal Immunity Limited was
incorporated on the 1
st
October, 1984.
The company has two manufacturing units, one
each at Baranagar at Kolkata (West Bengal) and at
Dehradun (Uttrakhand).
The Board for Industrial and Financial Reconstruction
(BIFR) formally declared the company sick on 9th
March, 1993. BIFR heard the case from time to
time. In the hearing held on 13
th
September, 2002,
BIFR formed its prima-facie opinion to wind up the
company. The opinion was confrmed by BIFR in
the hearing held on 25
th
February, 2003. With the
approval of the Cabinet, VSS was introduced in
the company. The company has since relieved all
employees under VSS as on 30
th
September, 2003.
The company is closed. The Offcial Liquidator
has already been appointed by the Kolkata High
Court. However, on a Writ Petition fled by the BIL
Employees Union, the appointment of Liquidator
in respect of BIL has been stayed by High Court of
Kolkata by its order dated 08.08.2005. High court
of Kolkata also directed that AAIFR shall hear and
dispose of the application of BIL Employees Unions.
AAIFR in its order dated 9.11.2005 directed that
possibility of revival through some other alternative
Pharmaceuticals company or some frm producing
some other goods using the available assets
should be considered. Thereafter a Committee
was constituted in this Department to look into the
issue of revival of BIL looking to the order passed
by AAIFR.
The Committee, constituted to explore the possibility
of revival of Bengal Immunity Limited (BIL),
recommended revival of BIL through public private
partnership mode. Bids were then called on revival
proposals and in continuation of orders of AAIFR
dated 03.03.2008 and 5 short listed companies were IDPL- Quality Control Lab. Chennai Plant
Presently, under different Class of Therapeutic
Medicines, around 82 generic/branded drugs covering
tablets, capsules, injection, vitamins, ORS pouches
etc. are being manufactured in various plants of IDPL.
The implementation of schedule-M at Rishikesh and
Gurgaon Plants has been partly completed and
the remaining work is in progress. The Company
is engaged in in-house production and its in-house
turnover has been growing. During year 2011-12,
IDPL manufactured medicines worth Rs. 49.75 crore
in-house at its 4 Plants, and IDPL Rishikesh produced
more than Rs. 18 crores, its highest ever.
The Company is also actively participating in
supporting the Jan Aushadhi Programme of Govt. of
India under which generic medicines are supplied for
sale through Jan Aushadhi outlets.
39
asked to give their proposals. Meanwhile, SBI Caps
have also been appointed for preparation of Bid/
RFP document for subsequent bidding by the 5 short
listed companies. SBI Caps has since submitted its
report which is under examination.
However, Honble High Court of Calcutta upheld the
decision of Liquidation on 02.08.2012. The Govt.
of India and the Company have opined to fle an
appeal against the verdict of the Honble High Court
of Kolkata and the draft appeal is under process for
approval.
VII) SMITH STANISTREET
PHARMACEUTICALS LIMITED (SSPL)
It was a sick company in the private sector in the
name and style of Smith Stanistreet Company Limited
set up in 1821 and its management was taken over
by the Government of India with effect from 4
th
May,
1972. The company was nationalized on 1
st
October,
1977, and a new public sector company in the name
and style of Smith Stanistreet Pharmaceuticals
Limited (SSPL) was incorporated on 19
th
July, 1978.
The company has its registered offce at 18, Convent
Road, Kolkata (West Bengal).
The company was formally declared sick by the
Board for Industrial and Financial Reconstruction
(BIFR) on 21
st
December, 1992. The BIFR approved
a revival package for the company on 31
st
August,
1994. The revival package was for a period of
ten years beginning from 1994-95. The same was
declared as having failed during the hearing on
October, 17, 2000.
The BIFR heard the case on 3
rd
December, 2001
and confrmed its prima facie opinion that it was just,
equitable and in public interest that the company
should be wound up. With the approval of the
Cabinet, VSS was introduced in the company. The
company has since relieved all the employees under
VSS as on 30th September, 2003. The company is
closed.
The Honble High Court, Kolkata vide its Order dated
4.01.2006 directed that the Company be wound
up and the Offcial Liquidator shall forthwith take
possession of the assets of the Company. Accordingly,
the Offcial Liquidator took possession of the assets
and documents including books of accounts of the
Company with effect from 01.02.2006. Ultimately,
the company has been liquidated and the assets
have been auctioned to M/s. Pataka Industries Ltd.
vide Honble Calcutta High Court dated 09.01.2010.
5.2 JOINT SECTOR UNDERTAKINGS
I) MAHARASHTRA ANTIBIOTICS &
PHARMACEUTICALS LTD (MAPL)
This is a Joint Sector Undertaking promoted by
Hindustan Antibiotics Limited (HAL) and State
Industrial & Investment Corporation of Maharashtra
(SIICOM) based at Nagpur (Maharashtra). HAL holds
52% of the equity shares, 38% is with SIICOM and
10% with IDBI. The company was incorporated in
November, 1979, and the commercial production
started in May, 1981.
After initial operations, the company could not be
run proftably and had to incur continuous losses.
Accordingly, BIFR formally declared MAPL as sick
on 14.1.1997. BIFR has since heard the case from
time to time. In the hearing held on 04.07.2000, BIFR
formed opinion for winding up of the company under
Section 20(1) of the SICA, 1985. Appeals fled in
AAIFR by M/s Environmental Engineers Inc. and a
group of employees were also dismissed. At present,
the company is closed and is before the High Court
of Mumbai, Nagpur Bench for appointing a Liquidator.
However, Writ Petitions have been fled by M/s
Environmental Engineers Inc. in the Nagpur Bench
of the Mumbai High Court against the liquidation
proceedings of MAPL. No further order has been
issued by the Bench in this connection.
Meanwhile, as winding up requirements and
additionally in accordance with the direction of
the Nagpur Bench of the High Court of Mumbai,
Government introduced VSS in MAPL. Accordingly
all employees were released under VSS.
II) MANIPUR STATE DRUGS &
PHARMACEUTICALS LIMITED (MSDPL)
This is a joint sector undertaking promoted by
Hindustan Antibiotics Limited (HAL) in collaboration
40
with Manipur Industrial Development Corporation
(MANIDO). HAL holds 51% of the equity shares and
49% is with MANIDO. The company was incorporated
on the 18th July, 1989. The manufacturing unit and
the registered offce are at Imphal (Manipur).
After initial operations, there were losses on account
of law & order and connected reasons. The Company
has since been closed as per recommendations of the
State Govt. of Manipur. Consequently, there has been
separation of employees with retrenchment benefts
under the Industrial Disputes Act / Worksmens
Compensation Act. At present, the company is
closed.
III) ORISSA DRUGS & CHEMICALS LTD.
(ODCL)
This is a joint sector undertaking promoted by Indian
Drugs & Pharmaceuticals Limited (IDPL) and the
Industrial Promotion and Investment Corporation
of Odisha (IPICOL). IDPL holds 51% of the equity
shares and 49% is with IPICOL. The company was
incorporated in 1979 and commissioned fully for
production from September, 1983. The company
has its manufacturing unit and its registered Offce
in Mancheshwar Industrial Area, Bhubaneshwar in
the State of Odisha. The company is engaged in the
manufacture of Pharmaceutical formulations in the
form of Tablets, Capsules, Powders, ORS, Injectables
etc.
After initial proftable operations, ODCL was formally
declared sick by the Board of Industrial and Financial
Reconstruction (BIFR) on 26
th
October, 1992. On
the basis of the report of the Operating Agency,
appointed by the BIFR and the support extended by
the promoters, the BIFR approved a revival package
for ODCL on 18
th
August, 1994. However the package
could not be implemented due to lack of support from
the State Government. BIFR heard the case from
time to time.
BIFR in its order dated 8
th
April, 2003 has fnally
passed orders for winding up of the company under
the provisions of Sick Industrial Companies (Special
Provisions) Act, 1985. The appeal fled by ODCL
employees against the winding up order of BIFR has
been dismissed by the AAIFR vide its order dated
23.6.2005. High Court of Orissa had appointed a
provisional Liquidator. This has since been stayed by
a larger Bench of the Odisha High Court.
After intervention of IDPL in the marketing activities
of ODCL from March 2007 the production and
sales have signifcantly gone up and the last years
turnover of Rs. 11.6 crores was highest ever achieved
by ODCL. This year Company is likely to surpass
last years production achieved. The unit has stated
generating proft since 2010-11. Last years proft was
Rs. 85 lacs. ODCL is taking all steps to complete
Schedule-M work.
5.3 WHOLLY OWNED SUBSIDIARIES
A. IDPL (TAMIL NADU) LIMITED, CHENNAI.
IDPL (Tamil Nadu) Ltd, Chennai incorporated in
September 1965, is a wholly owned subsidiary and
a sick unit of IDPL. In terms of the revival package
approved by BIFR in 1994 in the case of IDPL, the
Surgical and Formulation Unit of IDPL at Chennai
was converted into a wholly owned subsidiary in
the name and style of IDPL (Tamil Nadu) Limited,
Chennai with effect from the 1st April, 1994. IDPL
holds the entire equity capital of this unit. At present,
it is engaged in the manufacture of pharmaceutical
formulations. The production for the year 2011-12
was Rs. 1047.25 Lakhs and for the year 2012-13
(until Nov. 12 provisionally) amounted to Rs. 806.93
Lakhs. The implementation of Schedule-M has
been partly completed and the balance work is in
progress.
B. BIHAR DRUGS & ORGANIC CHEMICALS
LTD (BDOCL), MUZAFFARPUR
Bihar Drugs & Organic Chemicals Ltd (BDOCL),
Muzaffarpur was earlier a Organic Chemicals and
Drug Manufacturing unit of IDPL at Muzaffarpur
(Bihar). It was incorporated in November 1979. In
terms of the revival package approved by the Board
for Industrial & Financial Reconstruction (BIFR),
the Organic Chemicals and Drug Manufacturing
unit of IDPL at Muzaffarpur (Bihar), was converted
into a wholly owned subsidiary in the name and
style of Bihar Drugs & Organic Chemicals Limited,
Muzaffarpur with effect from the 1st April, 1994.
41
IDPL holds the entire equity capital of this Unit.
The past long-term liabilities amounting to Rs 36
crore as on 31.3.1994 were taken over by IDPL.
At present there is no production activity in the unit
and is closed since November 1996.
5.4 STATUS OF ANNUAL ACCOUNTS
Details of Annual Accounts fnalized till date are as
under:-
Karnataka Antibiotics & Pharmaceuticals
Limited
2011-12
Rajasthan Drugs & Pharmaceuticals
Limited
2010-11
Hindustan Antibiotics Limited 2010-11
Indian Drugs & Pharmaceuticals Limited 2009-10
Bengal Chemicals & Pharmaceuticals
Limited
2008-09
Bengal Immunity Limited 2005-06
Smith Stani-Street Pharmaceuticals
Limited
2004-05
5.5 GENERIC DRUGS CAMPAIGN THE
JAN AUSHADHI CAMPAIGN
Access to quality medicines at affordable prices is
a key challenge for the Government. The prices of
branded medicines are generally higher than generic
medicines due to various reasons as having patent
protection and having limited regulation through the
Drug Prices Control Order, 1995 etc.
For fulflling this goal, a Campaign in the name
of Jan Aushadhi Campaign has been launched.
The purpose of this campaign is to make available
medicines at affordable prices for all, especially the
poor and the disadvantaged. Under this campaign,
less priced quality unbranded generic medicines
will be made available through Jan Aushadhi Stores
which inherently are less priced but are of same and
equivalent quality, effcacy and safety as compared to
branded generic medicines.
Under this Scheme, the State Government has to
provide space in Government Hospital premises for the
running of the Jan Aushadhi Stores (JAS). Government
hospitals, NGOs, Charitable Organizations and public
societies like Red Cross Society, Rogi Kalyan Samitis
typically constituted for the purpose can be operating
agencies for the JAS. The operating agency for JAS
is nominated on the basis of the recommendations
of the State government. Operational expenditure is
met from trade margins admissible for the medicines.
The State Government has to ensure prescription of
unbranded generic medicines by the Government
doctors.
The Bureau of Pharma Public Sector Undertakings
of India (BPPI), comprising of all the Central Pharma
PSUs (CPSUs), namely, IDPL, RDPL, KAPL, HAL
and BCPL, was set up on 1st December 2008
with the objective to have a focused & empowered
structure to implement the Jan Aushadhi Campaign
initiated by the Department of Pharmaceuticals.
Initially it was as an independent, unincorporated
body but subsequently, it has been registered as a
Society under the Societies Registration Act, 1860
by the Govt. of NCT of Delhi on 21st April, 2010.
BPPI is monitoring the opening of Jan Aushadhi
Stores. It is also involved in promotion of the
unbranded generic drugs and the Generic Drug
Campaign.
The frst Jan Aushadhi Generic Drug Store was
opened in Civil Hospital, Amritsar on 25th November,
2008 and with the active support and cooperation
of the State Government of Punjab, the stores were
opened not only in all districts of Punjab but also
being opened at block level too. The campaign has
now been spread besides in Punjab, also in the States
of Haryana, Uttrakhand, Rajasthan, Andhra Pradesh,
Odisha, West Bengal, Jammu & Kashmir, Himachal
Pradesh, Jharkhand & UT of Delhi and Chandigarh
by having opened 147 Jan Aushadhi Generic Drug
Stores so far (till 14.02.2013). Efforts are on to open
more number of stores.
The Jan Aushadhi Campaign will help:
(i) Improve access to healthcare in as much as cost
of treatment would come down substantially.
This would enable the Public Health System to
increase the coverage.
(ii) Secure a socio- economically viable mechanism
/ institutional arrangement for effcacious sales of
42
Pharma CPSU products, thereby improving their
viability.
(iii) Promote & encourage private industry to sell
their quality unbranded generic products through
these retail outlets.
(iv) Ensure successful implementation of the Jan
Aushadhi campaign would dispel the myth
that quality of medicines is linked to price and
demonstrate that quality medicines can be sold
at substantially lower prices.
(v) Educate doctors that unbranded generic
medicines provide a better option than branded
products since quality of generic medicines can
be equally effcacious and safe at much lower
prices.
(vi) Create Consumer awareness & involve private &
charitable bodies & NGOs by making them part
of the campaign.
(vii) Reduce promotional cost and profts for the
beneft of patients etc.
Chapter
6
NATIONAL INSTITUTE OF PHARMACEUTICAL
Education & REsEaRch (niPER)
45
CHAPTER 6
NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH
(NIPER), S.A.S. NAGAR, MOHALI
NIPER, SAS Nagar, Mohali was initially registered as
a society under the Societies Act. The faculty for the
institute was appointed in 1994. In 1998, Parliament
enacted National Institute of Pharmaceutical Education
& Research Act, 1998. NIPER was declared as an
Institute of National Importance under the Act of
Parliament on 26
th
June 1998. NIPER is a member of
Association of Indian Universities.
The main objectives of the Institute:
1. Nurture and promote quality and excellence in
pharmaceutical education & research.
2. Toning up the level of pharmaceutical education
and research by training the future teachers,
research scientists and managers for the industry
and profession.
3. Creation of National Centers to cater to the
needs of the pharmaceutical industry and other
research and teaching institutes.
4. Collaboration with Indian industry to help it meet
global challenges.
5. National/International collaborative research.
6. Study of sociological aspects of drug use and
abuse and rural pharmacy etc.
7. Running programmes in drug surveillance,
community pharmacy and pharmaceutical
management.
NIPER has nine Departments and one
Centre:
1. Medicinal Chemistry
2. Pharmaceutics
3. Natural Products
4. Pharmacology & Toxicology
5. Pharmaceutical Analysis
6. Biotechnology
7. Pharmaceutical Technology
8. Pharmacy Practice
9. Pharmaceutical Management
10. Pharmacoinformatics
Disciplines:
The frst batch of students was admitted in 1998.
NIPER offers Masters and Ph.D. degrees in
following 15 streams that caters to the various needs
of pharmaceutical industry:
2. Natural Products
3. Traditional Medicine
6. Regulatory Toxicology
7. Pharmaceutical Technology (Biotechnology)
8. Pharmaceutical Technology (Formulations)
9. Pharmaceutical Technology (Process Chemistry)
10. Pharmaceutics
11. Biotechnology
12. Pharmacy Practice
13. Clinical Research
14. Pharmacoinformatics
15. Pharmaceutical Management
Infrastructure:
NIPER conducts regular education programmes for
academia and industry in various disciplines and
helps the Indian Pharmaceutical Industry in solving
their R&D related requirements. NIPER has upgraded
facilities for achieving the highest level of effciency in
imparting education and events.
There are state-of-art classrooms with installation of
TV panels and laptop systems. NIPER laboratories
are fully equipped with modern equipments that are
equivalent to other state-of-the-art laboratories in the
world. All the available facilities are of international
level and standards. A Technology Development
Centre has also been set up. In addition, there has been
signifcant improvement in research infrastructure as
several high value sophisticated instruments have
been added which has helped in increased thrust in
R&D activities.
Central Research Facilities:
Following central facilities provide support to the
research groups within the Institute as well as from
outside:
46
1. Central Instrument Laboratory
2. Computer Centre
3. Library and Information Centre
4. Central Animal facility
5. National Toxicology Centre (GLP compliant)
6. Technology Development Centre
7. National Bioavailability Centre (WHO accredited)
8. Impurity Profling & Stability Testing Laboratory
9. Pharmacological & Toxicological (GLP compliant)
Screening Facilities
Seats for admission to P.G. Courses, Ph.D in
NIPER, S.A.S. Nagar:
Since 2010, NIPER, S.A.S. Nagar, has increased
seats for admission to postgraduate courses and
Ph.D. programme:
Courses Students
admitted in year
2011
Students
admitted in year
2012
Ph.D. 34 39
M.S. 239 271
M.B.A. 58 65
Total 331 375
In July 2012, 230 Masters students [including M.S.
(Pharm.), M. Pharm. and M.Tech. (Pharm.)], 56
M.B.A. (Pharm.) and 22 Ph.D. candidates graduated
from the Institute.
Academic excellence: A new course leading to
M. Pharm. in Clinical Research has been started in
2011 with an initial intake of 9 students. During 2012
(till date), the Institute has published 120 articles in
journals of repute. As on date, NIPER has fled 152
patents, out of which 41 patents have been granted.
Since the inception of academic programme, 1,570
students have passed out (Masters-1,127, MBA-303
& Ph.D.-142). Presently, 901 students are studying in
NIPER, S.A.S. Nagar.
International collaborations: The Institute entered
into several International collaborations and a
number of visitors from abroad and within the country
visited the Institute, thus highlighting the ever-rising
status of the Institute. NIPER started conducting
training programs at the newly established Small and
Medium Pharmaceuticals Industry Centre (SMPIC)
for Small and Medium Pharmaceuticals industry on
the aspects of Good Manufacturing Practices (GMP)
and Good Laboratory Practices (GLP), Instrumental
analysis and manufacturing of APIs and Formulations.
The centre will also provide a focal point to industry
academia interaction.
Recent Developments at NIPER, S.A.S. Nagar
(General)
1. The Institute has played mother role to all the new
NIPERs started in different parts of the country
by helping them in variety of ways including
centralized admissions.
2. A Technology Development Centre has been
set up in the NIPER, S.A.S. Nagar.
3. The WHO accredited National Bioavailability
Centre has been established with support of
Deptt. of Science & Technology, Govt. of India,
which is one of the two centers of the world to
conduct the bioavailability studies for oral fxed-
dose combination of anti-tubercular drugs.
4. The Institute has also set up the Good Laboratory
Practices (GLP) compliant National Toxicology
Centre, National Centre of Pharmacoinformatics,
National Centre for Safety Pharmacology and
Centre for Nanotechnology with the support of
Department of Science & Technology (DST)
under Pharmaceutical Research & Development
Support Fund (PRDSF programme).
5. NIPER, S.A.S. Nagar, has now started
training programmes for Small and Medium
Pharmaceutical industry on the aspects of Good
Manufacturing Practices (GMP) and Good
Laboratory Practices (GLP), Instrumental analysis
and manufacturing of APIs and Formulations. An
important aspect of the training programs is the
demonstration in the Technology Development
Center (TDC), Central Instrument Laboratory
(CIL), and Central Animal Facility (CAF), etc.
Separate hands-on training modules are available
for High Performance Liquid Chromatography
(HPLC), Gas Chromatography (GC), and Atomic
Absorption Spectroscopy (AAS).
47
6. NIPER has more than 1500 publications, most
of them in reputed, peer-reviewed, international
journals. In 2012, NIPER has fled 15 patents and
4 patents have been granted till date.
7. The Plan budget proposal for Rs. 24.00 cr for
the year 2012-13 has been submitted to Deptt.
of Chemicals & Petrochemicals, Ministry of
Chemicals & Fertilizers, Govt. of India.
8. Non-Plan budget proposal of Rs. 34.91 crore has
been submitted out of which Rs. 21.14 crore has
been released by the Ministry for meeting the
expenses for the third quarter for the year 2012-
13.
9. New projects worth Rs. 1.25 crore were sanctioned
by various funding agencies to NIPER.
(Research)
1. Neglected diseases
Two of the most active dihydroartemisinin
derivatives synthesized in the Institute, which
were proven to be strongly more active (blood
schizontocidal activity) than artemisinin against
P. berghei in mice, are being studied for their
toxicity.
Derivatives of 8-aminoquinoline have been
synthesized which exhibit activity in the range of
15-20 ng/mL against drug-sensitive and resistant
strains of malaria parasite. Dose optimization of
the most potent analogues in in vivo evaluation is
under progress.
Synergistic activity of 3, 3 diindolylmethane and
miltefosine was observed at low doses of 3, 3
diindolylmethane. Antagonistic activity at higher
doses. The combination groups were found to
have higher activity than single doses as well as
control groups.
Around 78 semisynthetic derivatives based on
berberine, curcumin, carboline and tryptanthrin
templates have been synthesized and are
currently being evaluated for in vitroantileishmanial
activity.
Using DOS (diversity-oriented synthesis)
approach, various small molecules have been
designed to target the FtSZ (bacterial cell division
protein) and protein synthesis in Mycobacteria.
162 such compounds have been synthesized
and evaluated for anti-TB activity at AstraZeneca,
Bangalore. Eight compounds have shown
promising anti-TB activity (MIC = 16 g/mL).
2. Other diseases
Biological evaluation of the anti isomers formed
after aldol reactions of 5-methyl-3-(substituted
phenyl)-4-oxo-2-thioxoimidazolidines in PC-3
and LNCaP prostate cancer cells demonstrated
inhibition of cell growth. The highly potent
compounds demonstrated cytotoxicity better than
doxorubicin and futamide on PC-3 and LNCaP
cells, respectively.
Screening of 18 compounds from four medicinal
plants, viz. Ajugabracteosa, Dysophyllastellata,
Inulacuspidata and Rumexnepalensis for in vitro
COX-1, COX-2 and anti-infammatory activity in
vivo showed fve compounds to be highly active
and provided stellatin as a lead molecule.
Semi-synthetic modifcation of stellatin resulted
in 18 compounds of which three exhibited better
in vivo anti-infammatory activity than positive
control indomethacin.
Neuroprotective effect of GW1929, a PPAR-g
agonist in cerebral ischemia/reperfusion
injury induced brain damage and associated
neurobehavioral defcits, has been shown.
Melatonin and nicotinamide alone as well as
in combination were shown to ameliorate the
functional defcits along with improvement in pain
parameters in diabetic neuropathy.
Investigation of insulin treatment under high
glucose condition leading to the generation of
reactive oxygen species has been shown to
alter multiple histone H3 modifcations in L6
myoblasts.
Genotoxicity testing using different end points
(CA, MN, COMET, NRF2, p53, NF-kB, H
2
AX etc.)
has been developed to screen New Chemical
Entities (NCEs) as well as for the existing drugs
in the market.
48
Direct role of the neurotoxin MPTP in the
aggregation of a-synuclein, the protein implicated
in Parkinsons disease, has been demonstrated.
Some synthetic peptides, derived from full-length
apolipoproteins, have been shown to exhibit
unique binding specifcity towards particular
oxidized phospholipid species without binding
to normal, non-oxidized phospholipids. This
indicates their potential to be developed as drug
candidates in cardiovascular and other chronic
infammatory diseases.
3. Drug development and formulation
LDPE packs have been demonstrated to exhibit
higher sorption of preservatives, as compared
to polypropylene packs. An excipient has been
identifed that retarded the loss of parabens in
LDPE containers.
Novel role of antimicrobial preservatives, viz.
benzalkonium chloride, benzyl alcohol and
m-cresol, as inhibitors of protein aggregation,
has been reported.
Biomimetic polymeric particulate scaffolds
for tissue engineering have been developed.
These have been for osteoblasts for bone tissue
engineering.
Oral bioavailability of poorly water soluble/ poorly
permeable drugs (e.g. anticancer drugs like
tamoxifen, paclitaxel and doxorubicin; antifungal
drugs like amphotericin B and cyclosporine A;
antioxidants, etc.) and acid-labile drugs using
different types of nano formulations has been
carried out.
4. Other areas
3 - [5 - (4 - Fluorophenyl) - 5 (S) - hydroxypentanoyl]
- 4 (S) - 4 - phenyl - 1, 3 - oxazolidin - 2 - one, a
crucial intermediate for ezetimibe synthesis, was
prepared by lipase-mediated transesterifcation
and ester hydrolysis of the corresponding
precursors
Biocatalytic synthesis of silver and selenium
nanoparticles has been carried out for evaluation
of antimicrobial and anticancer activities,
respectively. Both areas have shown positive
results.
Overexpression of recombinant proteins in
bacterial systems has been achieved without
formation of inclusion bodies, resulting in higher
yields of functional target proteins.
A database of Adverse Drug Reactions (ADRs)
spotted in different settings over a long period of
time has been developed.
(Events and Activities)
1. The following awardshave been granted to the
Institute:
a. OPPI Scientist Award in pharmacology and
toxicology
b. Ranbaxy Science Scholar Award for
Pharmaceutical Sciences.
c. In addition, students have received awards at
various national and international symposia,
in recognition of the work carried out by
them.
2. The following events were conducted by the
Institute:
a. Seminar on Current Good Manufacturing
Practices (CGMP) (April 2-3, 2012)
b. Good Laboratory Practice (GLP) Training
Programme GLP in India: Present and
Future (April 13-15, 2012)
c. Seminar on Environment, Hazard and Waste
Management in Pharmaceutical Industries
(Sept. 29, 2012)
d. Intensive Course on Quality Assessment
of Drugs and Pharmaceutical for Export
ITEC-2012 (Oct. 8-19, 2012)
e. 3
rd
Biennial International Conference held on
New Development in Drug Discovery from
natural products and traditional medicines
(DDNPTM-2012) (Nov. 22-24, 2012)
f. Sixth Convocation (Oct. 13, 2012)
49
Photographs, NIPER, S.A.S. Nagar
Student receiving gold medal from the Chief Guest,
Padma Vibhushan, Dr. M.S. Gill, during the sixth
Convocation (Oct. 13, 2012)
Inauguration of Academic Session 2012-2013 by
Prof. M. K. Surappa, Director, IIT Roper
Inauguration of 3
rd
Biennial Conference on DDNPTM
2012 (Nov. 22-24, 2012)
Some of the degree recipients of the sixth
Convocation (Oct. 13, 2012)
Dr. S.S. Sharma receiving the OPPI Scientist Award
(Sept. 15, 2012)
Participants in the workshop on Advanced Analytical
Techniques, organized under ITEC/SCAAP
programme (Oct. 8-19, 2012)
50
Establishment of New NIPERs:
In terms of the amended National Institute of
Pharmaceutical Education and Research (NIPER)
Act, 1998, the Government of India has set up six
new NIPERs at Hajipur, Hyderabad, Ahmedabad,
Rae Bareli, Guwahati and Kolkata. These New
NIPERs will cater to the growing demand of the
pharmaceutical industry for highly trained man power
for continuous growth of the pharmaceuticals sector
with increased focus on R&D, particularly after the
amendment of Indian Patent Act. At present, new
NIPERs are functioning with the assistance of the
Mentor Institutes.
Sl. No. New NIPERs Mentor Institute
1. NIPER, Ahmedabad B.V. Patel Pharmaceutical Education and Research Development (PERD)
Centre, Ahmedabad.
2. NIPER, Hajipur Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna.
3. NIPER, Hyderabad Indian Institute of Chemical Technology (IICT), Hyderabad.
4. NIPER, Guwahati Guwahati Medical College and Hospital, Guwahati.
5. NIPER, Kolkata Indian Institute of Chemical Biology (IICB), Kolkata.
6. NIPER, Rae Bareli Central Drug Research Institute (CDRI), Lucknow.
Starting of Classes at New NIPERs:
Pursuant to the approval of the Cabinet to the setting
up of six new NIPERs, classes were started from the
academic Session 2007-08 with the help of Mentor
Institutes at Ahmedabad, Hyderabad, Kolkata and
Hajipur. The classes were started at NIPER, Guwahati
and Rae Bareli in 2008-09.
The students are selected through Common
Admission Test conducted by NIPER, SAS Nagar,
Mohali in association with these new NIPERs.
An Apex Committee under the chairmanship of
Secretary (Pharma) has been formed to oversee the
smooth functioning of new NIPERs till the Board of
Governors of each new NIPER is formed. Likewise,
State level Coordination Committee under the
Chairmanship of an offcer of the level of Principal
Secretary of the concerned State Government
has been formed for each NIPER to oversee the
functioning of the new NIPERs.
MS (Pharm) Course: Stream wise Details:
Sl.
No.
Name of Institute Existing Disciplines
1. Ahmedabad Natural Products, Pharmaceutics, Biotechnology, Pharmaceutical Analysis, Medicinal
Chemistry, Pharmacology and Toxicology, Medical Device.
2. Guwahati Pharmacology & Toxicology, Pharmacy Practice, Biotechnology.
3. Hajipur Biotechnology, Pharmacy Practice, Pharmacoinformatics.
4. Hyderabad Medicinal Chemistry, Pharmaceutical Analysis, Pharmacology & Toxicology,
Pharmaceutics.
5. Kolkata Medicinal Chemistry, Natural Products, Phamacoinformatics.
6. Rae Bareli Medicinal Chemistry, Pharmaceutics, Pharmacology & Toxicology.
51
NIPER AHMEDABAD
ACADEMIC ACTIVITIES
ADMISSION OF STUDENTS TO M.S PHARM
IN 2012-2013
The institute had Masters level programme in six
different disciplines till the ffth academic year leading
to M.S Pharm in Pharmaceutics, Natural Products,
Biotechnology, Pharmaceutical Analysis, Medicinal
Chemistry and Pharmacology streams.
NIPER Ahmedabad stepped into sixth academic year
from July 2012, introducing Medical Device as a new
stream, and in the sixth academic year, 53 students
were admitted to seven streams.
Discipline No. of Students admitted
(Batch 2011-13) (Batch 2012-14)
Natural Products 09 09
Pharmaceutics 12 13
Biotechnology 10 10
Pharmaceutical Analysis 06 05
Medicinal Chemistry 05 05
Pharmacology and toxicology 05 06
Medical Device - 05
Total 47 53
Teaching schedule for the Academic Year
2012-13
1
st
Semester
Teaching started with the orientation week on the
4
th
week of July 2012. Regular teaching schedule
followed the week after.
Weekly, four seminars were scheduled for the First
semester students.
The Mid-term exams were scheduled from 15
th
to 29
th

October 2012 and the Final Exams are scheduled in
December 2012.
3
rd
Semester
Third Semester started form the third week of June
2012. The students submitted their Project proposals
in the third week of July 2012 followed by the Project
Proposal Defense. The Project Progress Evaluation
is scheduled in January 2013.
NIPER-Ph. D. Program
NIPER-Ph. D. program was started at NIPER-
Ahmedabad during the academic year 2011-2012
with six Ph. D. fellows, three each in Natural products
stream and Biotechnology. The students have fnished
their course work and the synopsis presentation is
scheduled in December 2012.
In the academic year 2012-2013, nine Ph. D. fellows,
three each in Pharmaceutics, Natural products stream
and Biotechnology, have been enrolled on the basis
of common NIPER-Ph. D. entrance test conducted
in June 2012. The fellows have been assigned their
Ph.D. mentors and are pursuing their course work.
CONFERENCE/WORKSHOPS ORGANIZED
1. Mammalian Cell Culture: Hands-On Training
Programme, Organized at B. V. Patel PERD
Centre, from June 18 June 22, 2012
2. National Seminar on Opportunities and
Challenges in Academic Research (with
special reference to Life science, Drug and
Pharmaceutical research), Organized by B. V.
Patel PERD Centre and NIPER-Ahmedabad
in association with Department of Science and
Technology (DST), Govt. of India, from March 2
4, 2012.
PROJECTS
DOP funded project titled Development
and Clinical Evaluation of Novel fxed dose
combination of Rifampicin and Isoniazid to
52
improve Bioavailability of Rifampicin for the
treatment of Tuberculosis in collaboration with
AIIMS- New Delhi.
DBT funded project titled Synthesis
and Development of Antitubercular 1,4-
Naphthoquinone Congeners as Mycobacterium
tuberculosis Methionine Aminopeptidases
Inhibitors.
Inspire Fellowship from Department of
Science and Technology to Dr. Manju Misra.
In-situ gelling mucoadhesive system for brain
delivery of p-Glycoprotein (P-gp) substrates via
nasal route: Effect of a novel lipidic agent on drug
release and P-gp inhibition
RGYI, Department of Biotechnology to
Dr. Manju Misra, Dr. Abhijeet Joshi and
Dr. P. Venkatesh. Design of Oral delivery
system for macromolecules using gastrointestinal
patch system: Role of fatty acid as penetration
enhancer.
HONOURS/AWARDS
1. Tejas Vyas, Ranjeet Dash, Sheetal
Anandjiwala, Manish Nivsarkar. Formulation
and pharmacokinetic evaluation of hard gelatin
capsule encapsulating lyophilized Vasa Swaras
for improved stability and oral bioavailability of
vasicine. Fitoterapia 2011; 82: 446-453. Selected
as one of the papers for the Certifcate of Merit
Award Dr. P.D. Sethi Annual Award 2011
for Best Research Papers on Application
of TLC/HPTLC in Pharma, Herbal and other
Chemical Analysis 2011; September 2012.
2. Dr. Anita Mahapatra received Prof. A.R. Rao
Memorial Best Young Researcher Award for
Participants during Practical sessions of the Workshop
Floral Welcome of Chief Guest, Dr. G. J.
Samathanam by Prof. C. J. Shishoo.
Dr. Neeta Shrivastava delivering a lecture during the
seminar
53
the presentation at International Conference
on Recent Advances in Cancer Research
Therapeutics to Chemoprevention, during 8-9
th

February, 2012 by Central University of Gujarat,
Gandhinagar.
PLACEMENT ACTIVITIES
To provide placement to student at reputed
Pharma companies, a placement Cell (including
the faculty members as well as the students of
NIPER-A) has been created which is responsible
for publishing a placement brochure and sending
it to various Pharma companies.
Various companies have been visiting our
organization for Campus Interviews.
Our students have been placed in about 16
Pharma companies. About 80 % of the students
have been placed from the third that recently
passed out in June 2012.
EXTRACURRICULAR ACTIVITIES
Hindi Pakhwada (1
st
to 14
th
September 2012) Celebration of Independence Day, Speech on
Independence day by Dr. Manish Nivsarkar, Director,
PERD Centre
Navratri Celebration, Students playing Garba
NIPER, HYDERABAD
National Institute of Pharmaceutical Education and
Research (NIPER) is an autonomous body established
under the aegis of Department of Pharmaceuticals
(DOP), Ministry of Chemicals & Fertilizers as a
Centre of Excellence for higher education, research
and development in pharmaceutical sciences. In
pursuance of the decision of the Government of India,
NIPER Hyderabad started functioning as one of the
six new NIPERs in September 2007, in the premises
of IDPL R & D centre, Balanagar, Hyderabad. In terms
of the MOU between the DOP and CSIR (Council for
Scientifc and Industrial Research), Indian Institute
of Chemical Technology, Hyderabad, a reputed R
& D institute under CSIR, was bestowed with the
responsibility of Mentorship of NIPER-H. The institute
has been functioning with the mission of developing
human resource with excellence through conducting
2 year Post Graduate course M.S (Pharm) and MBA
(Pharm) for the students enrolled based on the Joint
Entrance Examination for all the NIPERs every
54
year. NIPER-H is conducting the courses in fve (5)
disciplines i.e. Medicinal Chemistry, Pharmaceutical
Analysis, Pharmacology & Toxicology, Pharmaceutics
and Pharma Management based on semester system.
The students have to undertake the course work
during 1
st
& 2
nd
semesters and to carry out dissertation
work in reputed industry/R&D institutes like IICT, NIN,
ILS and various Pharma Industries during 3
rd
& 4
th

semesters to get exposure to the best R&D practices.
Some of the dissertation works have been published as
peer reviewed papers and a good number of students
have been placed through campus placement. Ph.D
programme has also been initiated in Pharmaceutical
Sciences in the year 2011.
The main objectives of the Institute:
Enhancing creativity, motivation & drive and
inculcating professionalism
Bringing synergy between academic, R&D,
technology and industry through training and
exposure for such environment.
Bridging collaborations between pharmacy,
biotechnology, information technologies and
preparing for meeting global challenges.
Preparing professionals to suit to the need of
pharmaceutical industry
Developing and practicing e-learning for
the professionals and training for teachers,
researchers, regulators in the respective felds
Creating a world class institute of teaching and
research in the feld of Pharmaceutical Sciences
Expand research activities in new avenues and
emerging segments
Explore national and international collaboration
in pharmaceutical sciences
NIPER, Hyderabad is offering MS (Pharm)
degrees in the following disciplines:
4. Pharmaceutics
Enrolment of Students in 2011-12
The total number of students who have been enrolled to pursue M. S (Pharm) in NIPER Hyderabad during academic
year 2011-12
Department No. of students Admitted
(2011-12) 1
st
semester
No. of Senior students (2010-11)
3
rd
semester
Total
Medicinal Chemistry 29 30 59
Pharmaceutical Analysis 15 14 29
Pharmacology and
Toxicology
15 15 30
Pharmaceutics 16 16 32
Total 75 75 150
NIPER, Hyderabad is offering Ph.D
programme in following disciplines:
3. Pharmaceutics
Enrolment of Students in 2011-12
The total number of students who have been admitted
to pursue Ph.D in NIPER Hyderabad during academic
year 2011-12 was:
Department No. of students
admitted
Medicinal Chemistry 3
Pharmacology and Toxicology 3
Pharmaceutics 3
Total 9
55
YEAR WISE PLACEMENT DETAILS:
Placement Status for the Academic Year
2011-12 (2010-12) Batch
Total No. of students (2010-12
batch)
: 75
Total No. of students registered
at placement cell
: 54
Total No. of students placed : 47 (Phd/PA-15;
Job-32)
2010-11 (2009-11) Batch
batch)
: 57
at placement cell
: 51
Job-29)
2009-10 (2008-10) Batch
batch)
: 45
at placement cell
: 38
Job-23)
2008-09 (2007-09) Batch
Total No. of students (2007-
09 batch)
: 41
Total No. of students placed : 22 (PhD/PA-11;
Job-11)
*PA: Project Assistant Fellowship
The results of earlier batches of NIPER Hyderabad
(2007-11) and their placement in reputed
pharmaceutical organizations refect the sincere efforts
of Placement Committee, faculty and indispensable
support of mentor institute, IICT Hyderabad. In 2010-
12 batch, during 2011-12 academic year about 75%
(47 out of 54 registered); in 2009-2011 batch, above
65% of the students (32 out of 51 registered); in 2008-
10 batch 60% of the students (24 placed out of 40
registered); in 2007-09 batch 60% of the students (11
out of 19) are placed.
Higher Studies:
Apart from industrial placements, NIPER - H also
encourages the students to go for higher studies.
Some students have also been selected by the
prestigious institutes like IIM, IITs, and reputed
National Institutes.
Infrastructure and Facilities:
The Institute has good faculty. The institute is having
spacious, ventilated and well-furnished class rooms
and laboratory rooms; an excellent auditorium for
seminars; a large library within the campus. Furnished
hostel accommodation is provided to the students. The
ratio of Faculty to Student is 1:10. In addition, lectures
by eminent guest faculty on specialized subjects in the
concerned discipline, and various invited lectures by
experts from the academia, research establishments
and the industry are arranged for the beneft of
students. A number of conferences/workshops have
been organized to provide best exposure to the
advances of knowledge in pharmaceutical sciences to
NIPER students and faculty. Participation of students
in the seminars organized by professional bodies is
encouraged for interaction with persons in the feld of
their specialization.
NIPER-Hyderabad has acquired state-of-art facilities
and well equipped with good number of instruments
worth Rs.62,40,301/-.
Library and Information Facility:
NIPER Hyderabad library serves as a source of
information centre for pharmaceutical industry and
academic institutions. NIPER library has a rare
collection of old chemical and biological abstracts
since the year 1907 to 1983. NIPER-H library has
9476 titles of books, total no of copies is 18,499, 14
national scientifc journals, 12 pharmacy journals,
magazines, good number of news papers&
employment news. NIPER-H library provides the
facilities such as books and journal borrowing,
literature search, photo copying, news clipping
service etc. The online database Reaxys facility is
also available at NIPER-H.
56
Computer Lab Facility:
Computer centre at NIPER-Hyderabad serves the
needs of faculty, staff and students in updating the
literature and communication. In this institute, we are
maintaining LAN \ WAN infrastructure consisting of
110 desktops and 6 Servers ( Web, Mail, Proxy, FTP
etc.) with Windows and Linux enterprise environments.
In addition to windows 7, Vista and Windows XP
operating system, this centre has general software like
MS Offce 2007, Antivirus and other free software.
For day to day computer practicals and litera-
ture retrieval from internet, 50 desktops are in
use. For Molecular modelling / Drug discovery
activities, NIPER-Hyderabad procured license
for:
Molecular Operating Environment (MOE),
SCHRODINGER
BIO Solve Lead IT
Gaussian 09w
VLife MDS 3.5 Suite
For high performance computing, two work stations
are available and are used for free modelling software
like AUTODOCK, NAMD etc. This centre is equipped
with 4Mbps (1:1) leased line internet connectivity with
six servers set up in a rack which allows the users
to have access to the email, internet and etc. These
servers were installed with windows Server 2003 and
Linux (Red hat) operating system. We are maintaining
NIPER Hyderabad website (www.niperhyd.ac.in) and
mail server (Send mail, Open webmail) on our own.
Other computer related accessories including high
speed data transfer and network laser printer (colour
and black & white: 25nos) and scanners are also
available.
Latest achievements:
1) The Institute has published about 45 articles in
reputed national and international journals and
presented about 6 posters at different conferences
and symposiums. Since the inception of academic
programmes, 218 Master students have been
graduated. Some of the students are working as
research project assistants to gain an insight in to
their future research career.
2) Collaborations between NIPER and other
Institutions (IICT, NIN, ILS, etc) and industries
(USP-Hyd, Incogen therapeutics, Novartis,
Mylan, Daiichi, etc)
3) Apart from international delegations, a good
number of foreign visitors have visited the
Institute during this period for developing mutual
collaborations and for scientifc deliberations.
4) Creation of Molecular Modeling Lab,
Pharmacological Screening Lab, Bioanalytical
instrumentation Lab, Biochemistry Lab, Isolated
Tissue Experimentation Lab, Cell Culture Lab
and Animal House facility
5) One of the faculty Dr. M.V.N. Kumar Talluri,
Lecturer, Department of Pharmaceutical Analysis,
Elected as an Associate & Received Associate
Ship Award from the Institute of Chemist for the
high quality research contributions in the area of
Drugs and Pharmaceutical Analysis.
6) One of the faculty, Dr. Kolupula Srinivas,
Assistant Professor, Department of Medicinal
Chemistry achieved the prestigious Organization
of Pharmaceutical Producers of IndiaYoung
Scientist Award-2011 for his outstanding research
contribution in Pharmaceutical Sciences. Dr.
Srinivas carried out the research work for new
chemical entities of anticancer agents in drug
discovery.
7) The Grantin-aid General and Grants for
Creation of Capital Assets budget proposal for
Rs.9.71 crores for the year 2011-12 submitted to
Department of Pharmaceuticals, Govt.of India out
of which Rs.8.10 Crores actual was released.
8) The Grantin-aid General and Grants for Creation
of Capital Assets budget proposal for Rs.26.66
crores for the year 2012-13 has been submitted
to Department of Pharmaceuticals, Govt. of
India.
Areas of Research Activities:
1. Drug impurity profling, Stability studies,
Analysis and standardization of herbal drugs,
Drug metabolism studies, Bioanalytical method
development
57
2. Diabetic complications, Pain, Rheumatoid
arthritis (RA), Hepatic encephalopathy, Alcoholic
Hepatitis, Screening of new chemical entities as
Anti-Cancer drugs.
3. Improving the bioavailability of poorly soluble
drugs
4. Oral disintegrating extended release formulations
for geriatrics and paediatrics
5. Nanostructured lipid carriers for topical delivery
6. Plasma protein binding studies
7. Invitro metabolism and distribution studies of
enantiomers
8. Anticancer agents
9. Infectious diseases
10. Anti-Infammatory agents
11. Synthesis of New Chemical Entities (NCES)
12. Peptidomimetics
13. Computer Aided Drug Design
14. Molecular Recognition
Seminars / Events Conducted in NIPER Hyderabad during the Academic Year 2011-12
Date Title of the Talk Delegate
3
rd
& 4
th

Sep. 2011
International symposium 2
nd
PharmsSci@India :: AAPS 2011
High throughput Pharmaceutical manufacturing: Key
attributes for success
Dr. Bhaskar K. Arumugam,
CEO, Granules India Limited
MUPS : Impact and Compact Prof Paul Heng Wan Sia, NUS
Recent Advances in Medicinal Chemistry:
Development of Cancer Therapeutics
Dr. Ahmed Kamal,
NIPER-H & IICT, Hyderabad
Nanostructured synthetic hydrogels as scaffolds for
cell and gene delivery
Dr. EePui Lai, Rachel, NUS
Quality by Design : Concept, Design and Control Dr. Nalini Sastri, NIPER-H
New Drug Targets in Cancer Dr. V. Swaroop Kumar,
CEO, Incogen Therapeutics Pvt Ltd.
Developing fused 1,3,5-triazines into bioactive
agents with potential therapeutic value
Prof. Wai Keung CHUI
Carnosic acid attenuates renal injury in an
experimental model of rat cisplatin- induced
nephrotoxicity
Dr. S. Ramakrishna,
NIPER-H & IICT, Hyderabad
Pharmacists Improving Outcomes in the
Management of Infectious Diseases
Dr. Christine Teng, NUS
An Introduction to Process of Drug Discovery and
Development Today
Dr. A. KrishnamRaju, NIPER-H
7
th
Sep.
2011
Clinical trials-Intro, Prospects, Procedures and a
Real time Example
Dr. MohiIqbal Mohammed Abdul
12
th
Oct.
2011
Career Development in the Global Biotechnology
Industry through The Professional Science Masters
(PSM)
Prof. Graham B. Jones,
Barnett Institute of Chemical & Biological
Analysis at Northeastern
University in Boston
21
st
Oct.
2011
Lightening Dr. Vidyadhar Peesapati,
Knowledge Transfer Fellow,
School of Electrical and Electronic
Engineering, University of Manchester, U.K
58
12
th
Nov.
2011
National Conference Scope & Relevance of Ancient Indian
Sciences
Scope & Relevance of Ancient Indian Sciences Prof. K.V. KrishnaMurty Chairman,
I-SERVE
Ancient Indian Chemistry Smt. Dr. A. Gayatri Devi, I-SERVE
Fundamental Particles Dr. S. Sivarambabu, I-SERVE
Ancient Indian Agriculture Dr. K. Srinivasula Reddy, I-SERVE
Ancient Indian Mathematics Sri. M. Seetha Rama Rao, I-SERVE
Scope - Composite Ayurveda Dr. M.A. Virinchi, I-SERVE
20
th
Nov.
2011
50
th
National Pharmacy Week Celebrations
22
nd
Nov.
2011
Interaction of Magnesium with Nucleic Acid : From
RNA bases to the Ribosome
Dr. Sanyasi Sitha,
School of Chemical & Metallurgical
Engineering , University of the
Witwatersrand, Johannesburg, S.A
2
nd
Dec.
2011
Therapeutic Targets Based on Cell Signaling -
Focus on Cancer
Dr. V. Lakshmipathi,
Retd. Professor,
Kakatiya University
20
th

January
2012
The Drug Discovery Process Dr. Sunanda R Dastidar
Director Biological
Daiichi Sankyo Life Science Research
Centre (DMPK)
3
rd
February
2012
Biology, Chemistry and Medicine Dr. CH. Mohan Rao, FNA, FASc; Director,
CCMB
7
th
February
2012
Creating Markets Across the Globe covering the
Globalization, Global drivers technology, market
barriers, culture open markets etc
Dr. E. Murali Darshan, IIFT
9
th
February
2012
Workshop Bioinformatics@BioAsia 2011
Protein Crystallography : implications in drug
discovery and modern biology
Anthony Addlagatta, Senior Scientist, IICT,
Hyderabad
Genomes to Hit Molecules in Silico : A Country Path
Today, A Highway Tomorrow
Prof. B. Jayaram, IIT, Delhi
Construction of 3-D model of the Plasmodium
falciparum 20S core proteasome exploring the
biological and chemical space in the catalytic
subunits compared with yeast 20S proteasome
inhibitor complexes for rational drug design
Dr. K. Guruprasad, CCMB, Hyderabad
Emerging scenario in structure determinations and
predictions
Dr. Ravindranath S. Rathore, University of
Hyderabad
Visiting molecular docking algorithms and the
challenges in predictive abilities
Dr. Madhavi Sastry
D.E. Shaw India Software, Hyderabad.
59
11
th

February
2012
Impurity Profling in Pharmaceuticals Dr. M.V. Surya Narayana, Vice President,
Mylan
24
th

February
2012
Drug Discovery Dr. Mandip Singh Sachdeva
Editor in Chief
CRC Critical Reviews in Therapeutic Drug
Carrier Systems, Tallahassee
1
st
March
2012
&
21
st
, 28
th

February
2012
Applications of XRD, Crystallography & Structure
Determination of Small & Biomacromolecules
Dr. Y.V.N Swamy, IICT, Hyderabad
19
th
March
2012
Lipids as Potential Anti Cancer Drug Prof U.N. Das, MD FAMS FICP
Editor in Chief
Lipids in Health & Diseseas, USA
29
th
March
2012
New Trend in Chiral Seperations Dr. Ch. Lakshmi Narayana
Vice President
Daicel Chiral Technologies, India
30
th
March
2012
Emergence of Chiral Drugs Dr. V. Malla Reddy
General Manager - R&D
Divis Laboratories Limited
3
rd
April
2012
Potential Utility of Material Studio Software in
Pharmaceutical Field
Dr. Nihant Sinha
Scientist, Materials Modeling & Simulations
Accelrys, India
10
th
April
2012
Challenges & Opportunities in Pharma Industry Dr. J.B. Gupta
Vice President
GVK Biosciences
10
th
April
2012
Maternal Undernutrition and Pharmacokinetics in
Adult Offspring
Dr. Ganesh Cherala
Assistant Professor
Oregon State University, USA
19
th
April
2012
CANCER Awareness Dr. Sadashivudu
Dept. of Pharmacology
NIMS, Hyderabad
60
NIPER, KOLKATA
Establishment of NIPER-Kolkata:
The National Institute of Pharmaceutical Education
and Research-Kolkata (NIPER-Kolkata) was
established by the Government of India under the
NIPER Act 1998 as amended in 2007. The Institute is
presently housed at the Indian Institute of Chemical
Biology (IICB) a premier Institute of the Council of
Scientifc & Industrial Research (CSIR), India, which
is the Mentor Institute of NIPER-Kolkata.
NIPER-Kolkata was inaugurated on November 05,
2007. Since its inception, the Institute has been
Photographs, NIPER Hyderabad
Workshop on Bioinformatics@ Bio Asia 2012
OPPI Young Scientist Award 2011
Dr. Kolupula Srinivas, Assistant Professor
NIPER-Hyderabad
Blood Donation Camp, 2012
IDMA Young Pharmaceutical Analyst Award
Dr. M.V.N Kumar Talluri
Lecturer, Pharmaceutical Analysis
conducting Masters level programmes in three
different disciplines, Medicinal Chemistry, Natural
Products and Pharmacoinformatics, leading to M.S.
(Pharm.) degree.
Admission of students in 2012-2013
Counseling for admission of students took place
in NIPER-Mohali in the month of July, 2012. The
orientation programme of the students took place
on 1
st
August, 2012 and the frst year frst semester
classes commenced from 3
rd
August, 2012.
61
Discipline No. of students
Medicinal Chemistry 17
Natural Products 15
Pharmacoinformatics 10
Academic Programme
The frst batch of twenty nine Masters Students
graduated in June, 2009 and they received
their degrees in the frst annual convocation of
National Institute of Pharmaceutical Education
and Research (NIPER), Kolkata held on 11
th

June, 2010.
The second batch of thirty two Masters Students
graduated in June, 2010 and the third batch of
forty students graduated in June, 2011 and they
received their degrees in the second convocation
of NIPER-Kolkata held on 18
th
May, 2012. Sixty
students received their M.S. (Pharm.) degree
scrolls from Sri. Dilsher Singh Kalha, IAS,
Secretary, Department of Pharmaceuticals,
Ministry of Chemicals and Fertilizers, Govt.
of India & Chairman, Steering Committee of
NIPER-Kolkata. Twelve students were awarded
the degrees in absentia. Prof. Goverdhan Mehta,
National Research Professor & Lilly-Jubilant
Chair, School of Chemistry, Hyderabad, was the
Guest-in-Chief.
The fourth batch of 49 students graduated in
June, 2012.
The ffth batch of 47 students has completed their
2
nd
semester in June, 2012 and will be completing
the third semester in January, 2013. At present
they are engaged in their respective project work
under the supervision of Faculties/ Scientists of
Universities, Research institutes and Industries.
Their fnal examination is scheduled to be held in
the month of June, 2013.
The sixth batch of 39 students will be completing
their 1
st
semester examination in January
2013.The 2
nd
semester examination for them is
scheduled to be held in May- June, 2013.
A total of 371 books have been purchased by
NIPER-Kolkata. The Institute subscribes for
SciFinder.
Address by the Guest-in- Chief, 2
nd
Convocation at
NIPER, Kolkata
Second batch (2008-2010) recipients of degrees
Address by the Chairman, 2
nd
Convocation at
NIPER, Kolkata
Third batch (2009-2011) recipients of degrees
62
Placement activities:
Most of the students of the frst three batches
have been absorbed in the Industries, Colleges
and Research institutes. Placement was achieved
for these students according to their options for
employment in companies as well as in centres
for teaching and higher studies.
The campus placement for the fourth batch
of students has been not up to expectation.
However, a number of the students have secured
openings in colleges, research institutes and
industries.
The placement activities for the ffth batch of
students have been initiated and the placement
brochure has already been brought out.
Events & activities:
a) A symposium on carbohydrates at the interface
of chemistry and biology was jointly organized
by NIPER-Kolkata and IICB, the mentor institute,
during November 23-25, 2011. Apart from the
NIPER-Kolkata students, 300 delegates from all
over the country participated in the symposium.
b) Each second year student is allowed to attend
one scientifc conference.
c) A professional development course in English
(Workshop) was conducted by British Council,
Kolkata during 9
th
October, 2012 to 29
th
November,
2012 for the second year students of NIPER-
Kolkata.
The faculty:
The faculty involved in teaching the M.S. (Pharm.)
courses consists of visiting Teachers from Calcutta
University, Jadavpur University, West Bengal State
University at Barasat and West Bengal University of
Technology and Scientists from Bose Institute, Central
Research Institute of Ayurveda, Indian Association for
the Cultivation of Science, Indian Institute of Chemical
Biology, Institute of Post Graduate Medical Education
& Research, and Saha Institute of Nuclear Physics
and industries like TCG Life Sciences.
Staff and Officers:
NIPER-Kolkata does not have any permanent staff
and offcers. Retired persons have been appointed on
contract basis for running the academic programme,
administration, examination activities, and placement
of students, students hostel and other activities. The
following are the offcials:
Director, IICB &
Chairman, Advisory
Committee, NIPER-
Kolkata
: Prof. Siddhartha Roy
Project Director : Dr. Asish Kr. Banerjee
Honorary Advisor : Dr. Pradip Kr. Sengupta
Registrar : Dr. J. Rajan Vedasiromoni
Offcer on Special
Duty
: Dr. S.R. Sarkar
Student Counsellor : Dr. Probal Chattopadhyay
Course
Coordinators
: Dr. Anup Bhattacharjya
: Dr. Chabbinath Mondal
: Dr. Sibabrata Mukhopadhyay
Placement Cell
Coordinator
: Dr. Sukhendu Bikas Mandal
Purchase, fnance and other related activities are
looked after by Indian Institute of Chemical Biology,
the Mentor Institute.
Grants Received:
Financial
Year
Grant received from Ministry till
date
2012-2013 Rs.175 lakhs.
Hostel accommodation and facilities: The NIPER-
Kolkata students (total 86) are accommodated in the
CSIR Scientists Apartment, 428 Prince Anwar Shah
Road, Kolkata -700045. The hostels are self-suffcient
with canteens, common rooms, facilities and desktop
computers with wireless Internet service enabling
access to all International and National Journals.
Library, NIPER, Kolkata
63
Games & Sports activities
Facilities have been provided in the Hostel campus
for out-door games like Cricket, Badminton and
Volleyball and indoor games like carom and chess.
The annual sports and games of NIPER-Kolkata are
held in January/February every year.
NIPER, Raebareli
ACADEMIC ACTIVITIES
The National Institute of Pharmaceutical Education
and Research (NIPER), Raebareli created on
November 14, 2008 under the mentorship of CSIR-
Central Drug Research Institute, NIPER, Raebareli.
The institute started two P.G. Courses in the area of
Medicinal Chemistry and Pharmaceutics. From the
current academic year 2012-2013, a new stream of
M.S. (Pharm.) Pharmacology and Toxicology has been
introduced. The 4
th
batch students have completed
their I and II Semester here in Raebareli and are now
doing lab work under the able supervision of different
scientists of CDRI for the III and IV semester. The
present status is given below.
Courses No. of
students
in 4
th
Batch
(2011-13)
No. of
Students
in 5
th
Batch
(2012-14)
M.S. (Pharm.)
Medicinal Chemistry
16 16
M.S. (Pharm.)
Pharmaceutics
15 16
M.S. (Pharm.)
Pharmacology &
Toxicology
- 7
Total 31 39
EVENTS AND ACTIVITIES
4
th
NIPER (RBL) - CDRI SYMPOSIUM
ON MEDICINAL CHEMISTRY AND
PHARMACEUTICAL SCIENCES (FEBRUARY
23 -25, 2012)
As in previous years, 4
th
NIPER (RBL)-CDRI
Symposium on Medicinal Chemistry and
Pharmaceutical Sciences was organized during
February 23 -25, 2012 at CSIR-CDRI, Lucknow to
enable the students in updating their knowledge and
awareness about recent scientifc developments.
About 95 posters were presented and over 25
lectures on various research topics were delivered
by eminent speakers from pharma industry and
academia during two days of scientifc deliberations.
The poster session was spread over two days
where the students displayed their project based
presentations.
PHARMACY DAY
Rx Pharmacy Day, 2012 was organized at NIPER,
Raebareli on 22
nd
September, 2012. Scientifc session
included very informative lecture by Dr. D.K. Dikshit,
Ex-Chief Scientist, CSIR-CDRI, Lucknow and Ex-
project Director, NIPER, Raebareli on Drug Research
- A Historical Perspective, The second lecture was
delivered by Dr. Ashok Kumar, President, IPCA Lab.,
Mumbai on the topic Innovations, while the third
talk was on the topic PK-PD in drug discovery&
development, delivered by Prof. J.K. Paliwal, Deptt.
of Pharmaceutics, NIPER, Mohali.
ANNUAL DAY
The 4
th
Annual Day celebration of NIPER, Raebareli
was held on 9
th
November, 2012 under the
chairmanship of Dr. C.M. Gupta FNA, FASc, FNASc,
Ex-Director, CSIR-Central Drug Research Institute
who delivered the very innovative lecture titled
Biopharmaceuticals & Biosimilars: Present Position
& Emerging Trends The function was attended by
eminent scientists, technologists and academia of
Uttar Pradesh. Students were also given awards for
their participation in various extracurricular activities
during the year.
Students, NIPER, Kolkata
64
PUBLICATIONS
The students were inspired for scientifc publication
and presentation to bring NIPER, Raebareli on
scientifc research platform which led to publications
in reputed journals with inputs from project work and
presentation of papers in conferences. A total of 39
publications in research Journal and conferences
were carried out.
4
th
NIPER, Raebareli- CDRI Symposium.
Dr. Ashok Kumar, President, IPCA Laboratories,
delivering lecture on the occasion of Rx Pharmacy
Day 2012 celebrations
NIPER, Raebareli Laboratory Winners of Annual Sports-2012 of NIPER, Raebareli
(L to R) Dr. Achint Jain, Faculty, NIPER, Raebareli, Dr.
P.K. Shukla, Project Director, NIPER, Raebareli; Dr. C.M.
Gupta, Ex-Director, CSIR-CDRI and Dr. S.K. Puri, Chief
Scientist, CSIR-CDRI and Dr. B.Kundu, Dean, NIPER,
Raebareli releasing the Annual Magazine 2011-12 of
NIPER, Raebareli.
65
NIPER-HAJIPUR
NIPER Hajipur was established under the NIPER
Act,1998 as amended in 2007 under the mentorship
of Rajendra Memorial Research Institute of Medical
Sciences (an ICMR institution) Patna. Since
its inception, NIPER Hajipur developing into a
professional centre of higher learning and research in
pharmaceutical sciences.
Departments
From the beginning NIPER Hajipur has been entrusted
with the responsibility of teaching and research in the
following three disciplines:
Biotechnology
Pharmacy Practice
Pharmacoinformatics
Intake of the students:
Numbers of M Pharm / MS Pharm students admitted
and passed during 2009 to 2012 are as follows
Year Admitted Passed Left NIPER
2009-11 34 32 2
2010-12 42 40 2
2011-13 43 continuing 2
2012-14 21 continuing -
Number of students admitted in PhD programme
Year PhD
(Biotechnology)
PhD
(Pharmacoinformatics)
2011 3 2
2012 3 2
Examination:
Examinations are being conducted as per the declared
academic calendar. Students of the session 2010-
12 have already left after successfully completing
the course and most of them are either employed
(academia + industries+ administration) or pursuing
higher studies in different institutes/universities in
India or abroad. Two of these students have been
selected for PhD at NIPER Hajipur.
Ph. D Programme:
As per the decision of Department of Pharmaceuticals,
GOI, New Delhi, the Ph. D programme was introduced
NIPER-Hajipur from the session 2011 onward. So far
10 students have enrolled for the PhD. They have
been assigned to experts and the required course
works for those programmes have been initiated and
is in progress.
Infra-structure
Being in its infancy, infra structure is being
developed a little slowly due to some unavoidable
factors (particularly land). Currently NIPER, Hajipur
has well appointed trained teachers. Class rooms
accommodating a maximum of sixty students, a fully
air-condition seminar cum examination hall having a
capacity of 200 persons, a fully air-conditioned and
networked computer lab, a lab for Biotechnology,
an air conditioned well stocked library with internet
and facilities for indoor as well as outdoor games.
The well equipped laboratories at mentor institute
(RMRIMS) are always accessible to NIPER
students, procurement of some more instruments
for NIPER is also under active consideration. For
high end computing, tools like Schordinger Suite,
SPSS, Micromedixetc are already installed. Institute
is working towards getting some more sofwares to
further strengthen Pharmacoinformatics division.
Adjunct Faculty:
Prof. Bhaskar Saha, National Centre of Cell Science,
Pune, has been inducted as Adjunct Professor in
Biotechnology in NIPER Hajipur.
Guest faculty and special lectures:
From RMRIMS faculties namely, Dr. V.N.R. Das, Dr.
K. Pandey, Dr. C.S. Lal, Dr. G. Sahoo, Dr. V. Ali, Dr.
R.N. Pandey, Dr. Shubhankar, Dr. S. Bimal, Dr. Shyam
Narayan, and others regularly take classes. A number
of eminent academic personalities from different
places like Prof. R.N Mishra, Prof G.P. Singh, Dr. Alok
Kumar of BHU, Prof. Bishwajit Mukherjee of Jadavpur
University Kotkatta, Dr. AmitGhosh of NICED, Dr.
Shakti Patnayak of BIT-Mesra, Prof. S.P. Gupta,
66
Meerut Institute of Engineering and Technology, Dr.
Anthony Addlagatta from IICT Hyderabad, Prof. P.V.
Bhartham, NIPER Mohali, Dr. Oommen John, New
Delhi, Dr. M. Kartikeyan, NCL Pune, Dr. S.C. Roy,
CNLU Patna, etc. are actively involved in teaching
students of different streams. Moreover, a number
of prominent scientists from India and abroad visited
NIPER, Hajipur and delivered lectures on the various
topic of modern Pharmaceutical research. Some of
the prominent one were Dr. Shubhadeep Sinha MD of
Vimta Lab. Hyderabad , Dr. Satishkumar of Manich,
Germany, Prof. R.N Mishra of BHU, Varanasi, Prof.
Amit Ghosh, NICED, Kolkata, Dr. Ashish Ganguly
of IMTECH, Chandhigarh and Dr. Chandan Roy
Chaudhary of Bengaluru, Dr. Arvind Kumar of CCMB
Hyderabad.
Events and Activities:
Foundation Day
NIPER, hajipur celebrated its 5
th
Foundation Day
on 26
th
November 2012. A number of scientifc
and cultural events were organized. Prof.
Anil K. Bhowmick, Director, Indian Institute of
Technology, Patna delivered the 5
th
Foundation Day
Orientation lecture on Role of Nanotechnology
in Pharmaceutical Research. This function was
presided by Prof. JanakPandey, Vice Chancellor of
Central University of Bihar. Prof. Jeremy C. Mottram
from University of Glasgow, Scotland, UK presented
a special lecture on Is drug-induced cell death
in Leishmania regulated or incidental? Among
the other luminaries and distinguished guests Prof.
Simon Croft, London School of Hygiene & Tropical
Medicine, London, UK, Prof. P. Bhartam, Prof. and
Head of Pharmacoinformatics, all senior scientists
and eminent physicians from RMRIMS-Patna, have
also attended the ceremony.
Sports Day
NIPER, Hajipur has also arranged the Annual Sports
Meet-2012 from 5
th
to 8
th
November in which students,
teachers, offce staffs participated in various sports
events like cricket, volley ball, kabadi, gully cricket,
badminton, chess, carom, arm wrestling etc. The
prize giving ceremony for the sports meet has also
been a part of the foundation day program.
Hindi Pakhwara
Hindi Pakhwara was celebrated from 14
th
to 28
th

September 2012, during which several competitions
like Nibandh, Vaad-Vivaad, etc were held and prizes
were distributed among the winners.
Foundation Day celebration, NIPER, Hajipur
Oration Medal to Prof. Anil K. Bhowmick presented
by Dr.Pradeep Das, NIPER, Hajipur
67
Foundation Day celebration, NIPER, Hajipur
Sports at NIPER, Hajipur Cultural events on farewell, NIPER, Hajipur
Cultural events on Foundation Day, NIPER, Hajipur
NIPER GUWAHATI
NIPER-Guwahati is the ffth institute to be included
in the list of premium institutes under the Department
of Pharmaceuticals, Ministry of Chemicals and
Fertilizers, Government of India. NIPER-Guwahati
started functioning from the month of September,
2008. The institute was inaugurated by the former
Honble Union Minister for Fertilizers and Chemicals
and Steel, Shri Ram Vilas Paswan on September
16,2008 in the presence of several distinguished
persons, like the Honble Chief Minister of Assam
Shri Tarun Gogoi, then the Honble Union Minister
of State for Chemicals Shri Bijoy Krishna Handique,
Honble Minister of Health & Family Welfare of Assam
Dr. Himanta Biswa Sarma, Honble Union Secretary
for Pharmaceuticals Shri Ashok Kumar and the then
Principal of GMCH, Dr. M.M. Deka among others.
ACADEMIC EXCELLENCE:
NIPER, Guwahati offers P.G. Courses in three
disciplines viz. Pharmacology and Toxicology,
Biotechnology and Pharmacy Practice. It is a matter
of great satisfaction and pride that NIPER, Guwahati
stepped into ffth academic year. The 5
th
batch was
started on 1
st
of August 2012 with 19 students in
M.S. Pharmacology & Toxicology, 09 students in
M.S. Biotechnology and 09 students in M. Pharm
Pharmacy Practice. The 4
th
batch students have
completed their 2
nd
semester and currently doing
project works under the supervision of different
faculties for the 3
rd
and 4
th
semester. A total of four
Ph.D. students were enrolled for their Doctoral
Research at NIPER-Guwahati in the year 2012. The
present status is given below.
68
EVENTS AND ACTIVITIES
Foundation Day
Like every year NIPER-Guwahati has celebrated its 4
th

foundation day on 16
th
September, 2012. Numerous
dignitaries and delegates from various educational
institutes attended the function. On this occasion,
Director, Project Director, Chief Academic Coordinator
of NIPER-Guwahati and HOD of Psychiatry Deptt.,
GMCH have delivered the lectures and addressed
the staff members, students of NIPER and all other
participants. Students were also given awards for
their participation in various extracurricular activities
during the calender year.
Pharmacy Day
NIPER Guwahati has participated in Pharmacy
day celebration held on 25
th
November 2012 which
was collaboratively organized by GIPS, Guwahati
and NIPER- Guwahati at Sankardeva Kalakhetra,
Guwahati, Assam with the support of all the faculty
and staff members. The programmes included a
scientifc session and oral presentation of NIPER
Guwahati students.
Publications
The students were inspired for scientifc publication
and presentation to explore NIPER-Guwahati on
scientifc research platform in National as well as
International level. They made publications in reputed
journals with inputs from project work and presentation
of papers both posters as well as oral in conferences/
symposium in National and International level. A total
of 06 publications in research Journal were carried
out in this year.
Placement
In addition to providing quality education and research
as its priority, NIPER-Guwahati having placement cell
for the placement of its students. NIPER-Guwahati
has contacted different reputed Biotech and
Renowned Pharma industries and CRO Companies
like Parexel, Clinigene, GVK BioSciences, Quintiles,
Roche Scientifc, Strides, Matrix Laboratory, Advinus
Therapeutics, Johnson & Johnson and Hetero etc.
to have better opportunities in National as well as
International platform.
Recent Academic Advancement:
NIPER-Guwahati has got a great opportunity to
host Institutional Level Biotech hub (IB Thub),
Under the Department of Biotechnology, Ministry
of Science and Technology, Govt. of India. It was
inaugurated on 29
th
September 2012. During the
tenure, One SRF (Senior Research Fellow) was
recruited as man-power and basic equipments
required for biotechnology research were
procured under DBT project.
IB Thub, National Institute of Pharmaceutical
Education & Research, Guwahati in collaboration
with Gauhati Medical College & Hospital, Guwahati,
Assam organized a National Workshop on
Biotechnology under sponsorship of DBT,
Govt. of India on 29
th
September 2012.
Indian Pharmacological Society, Assam branch in
collaboration with College of Veterinary Science,
Khanapara, Gauhati Medical College & Hospital
and NIPER-Guwahati organized Eastern
Zonal Indian Pharmacological Society
(EZIPS) Conference- Assam with a theme on
Emerging Horizons in Therapeutics on 3
rd

and 4
th
November 2012.
Appointment of one faculty in the Department
of Biotechnology, NIPER-Guwahati under
Memo No: NIPER/GHY/2008/27/673-77, Dated
Guwahati the 12.10.2012.
Courses No. of students in 1
st

year (2012 -13)
No. of Students in 2
nd

year (2012-13)
M.S. (Pharmacology & Toxicology) 19 20
M.S. (Biotechnology) 09 09
M. Pharm. (Pharmacy Practice) 09 09
Ph.D. (Pharmacology & Toxicology) 04 04
69
Foundation day celebrations, NIPER Guwahati Faculty along with students of batch -2012
Inauguration of IBT HUB at NIPERG by Director
of NIPER cum Principal GMC, Guwahati
IBT Laboratory, NIPER Guwahati
Library, NIPER Guwahati Freshers day celebration, NIPER Guwahati
Chapter
7
NEW INITIATIVES
73
CHAPTER 7
NEW INITATIVES
7.1 DRUG DISCOVERY AND PHARMA
INNOVATION HUB 2020
To develop a roadmap to enhance the national
potential for Drug Discovery and Innovation, a
number of action points and future commitments
have been enshrined in the 12
th
Five Year Plan. The
Department engaged M/s Ernst & Young to prepare
a Detailed Project Report (DPR) in this regard. M/s
Ernst & Young has submitted a Draft Report. The
draft Report would be fnalized after consultation
with the stakeholders viz. industries and scientifc
departments of the Government of India.
7.2 COLLABORATIVE TB RESEARCH
PROJECT PROPOSAL OF NIPER,
AHMEDABAD AND AIIMS
The Department has sanctioned the project for
collaborative TB Research at NIPER Ahmedabad.
The project aims at Development and Clinical
evaluation of novel fxed dose combination of
Rifampicin and isoniazid designed to improve stability
and bioavailability of Rifampicin for the treatment of
tuberculosis. The project is in collaboration with All
India Institute of Medical Sciences (AIIMS), New
Delhi. The project is likely to be completed in 2013.
7.3 NATIONAL CENTRE FOR RESEARCH &
DEVELOPMENT IN DRUGS AT NIPER,
HYDERABAD
It is proposed to set up a National Centre for R&D in
bulk drugs at Hyderabad NIPER. The Centre would
aim at development of technologies and process
for cost competiveness, environmental impact
management, risk management and development
of safety in manufacturing operations, knowledge
transfer platform between industry and academia.
The research avenues for bulk drugs are: Drugs
process innovation, Drug discovery and development,
Analytical chemistry, Process engineering, cleaner
technology, Polymorphism, Nanotechnology etc. The
proposal has been accorded in principle approval
by the Planning Commission subject to certain
conditions.
Chapter
IMPLEMENTATION OF RAJBHASHA
8
77
CHAPTER 8
IMPLEMENTATION OF RAJBHASHA
Hindi Prayog Protsahan Pakhwara
Hindi Prayog Protsahan Pakhwara was observed
in the Department during 14
th
to 28
th
September,
2012 with the objective to encourage the offcers
and members of the staff of the Department to
progressively increase the use of Hindi in their offcial
work and also to help the Department to create an
atmosphere conducive to use of Hindi.
Use of Hindi in official work
Every possible effort was made for implementation
of the various provisions of the Offcial Language
Policy of the Union of India including those of Offcial
Languages Act, 1963 as well as Offcial Languages
(Use for Offcial Purposes of the Union) Rules, 1976
and orders issued thereunder. All the documents
mentioned in Sub Section (3) of Section 3 of the
Offcial Languages Act, 1963 were issued bilingually
i.e. in Hindi as well as in English. Letters received in
Hindi and representations etc. signed in Hindi were
replied to in Hindi as per provisions of the Rule 5 and
Rule 7(2) of the Offcial Languages (Use for Offcial
Purposes of the Union) Rules, 1976 (as amended
in 1987).
Official Language Implementation Committee
Department is having Offcial Language Implementation
Committee working under the chairmanship of
Joint Secretary (Pharma) to periodically review the
progressive use of Hindi in the offcial work and
suggest suitable measures to increase the use of
Hindi in the offcial work. Its meetings were held on
regular intervals and implementation status of the
various targets set in the Annual Programme for
transaction of the offcial work of the Union in Hindi
for the year 2012-13 issued by the Department of
Offcial Language, Ministry of Home Affairs was
reviewed. Standard and routine letters being used
by the various divisions/sections of the Department
in their day to day correspondence were translated
in Hindi to facilitate them to increase the use of Hindi
language in the offcial work.
Secretary (Pharma) while distributing the prizes to
the prize winners in the Hindi Prayog Protsahan
Pahkwara Prize Distribution Function
In addition to the message issued by the Secretary
(pharma) requesting, inter-alia, all the staff members
to make a commitment to use of Hindi, various Hindi
competitions were held during the Pakhwara and
winners were awarded cash prizes. As a part of the
Pakhwara, three Hindi workshops on different topics
were also organized to train the personnel of the
Department and also remove their hesitation to work
in Hindi.
Review of the status of use of Hindi in the
offices under the Department
Periodical review of the use of Hindi in the offces
under the Deptt. wasmade through the quarterly
reports on progressive use of Hindi received from
them. In compliance with the targets set in the Annual
Programme for use of Hindi for the year 2012-13,
Offcial Language offcials of the Department visited
three offces under the Deptt. viz. NIPER, Hyderabad,
NIPER Kolkata and BCPL, Kolkata with the objective
to review the implementation status of the OL Policy
of the Union of India and also to guide and help them
implement the various provisions of the Policy including
OL Act & Rules and motivate them to increase the use
of Hindi in their offcial work.
Secretary (Pharma) while addressing the Hindi Prayog
Protsahan Pahkwara Prize Distribution Function
Chapter
9
GENERAL ADMINISTRATION
9.1 Organisation Set Up of the Department
9.2 record Management
9.3 Grievance Cell
81
CHAPTER 9
GENERAL ADMINISTRATION
9.1 ORGANISATION SET UP OF THE
DEPARTMENT
The main activities of the Department are policy
making, sectoral planning promotion and Development
of Pharmaceutical industries. The administrative and
managerial control of the public sector undertakings
engaged in the manufacture of various, pharmaceutical
items and some other organization is a major function
of the Department.
2. The Department is headed by Secretary to
the Government of India who is assisted by two Joint
Secretaries one Economic Adviser and one Deputy
Director General.
3. There is an attached offce namely National
Pharmaceutical Pricing Authority which looks
after Price fxation/revision of pharmaceuticals and
other related matters. It also monitors the prices of
decontrolled drugs and formulation and oversees the
implementation of the provisions of the Drug (Price
Control) Order. In addition, there are 5 public sector
undertaking and 8 other organizations under the
administrative control of the Department. The names
of these are given in Annexure III.
EMPLOYMENT OF SCHEDULED CASTES /
SCHEDULED TRIBES/ PHYSICALLY HANDICAPPED
IN THE MAIN SCERETARIAT OF THE DEPARTMENT
OF PHARMACEUTICALS
The status of employment of Scheduled Castes
/ Scheduled / Tribes / Physically handicapped
in the main Secretariat of the Department of
Pharmaceuticals, as on 15.01.2013 is as under:-
4. Offcers in Group A include offcers belonging
to Central Secretariat Service besides offcers on
deputation from All India Services, Central Services
and other Departments/ Undertakings. Appointment
to posts in Group B and C is mostly done on the basis
of nominations made by the Department of Personnel
& Training.
5. The Department also monitors the progress
of flling up of the posts reserved for the members
of Scheduled Castes, Scheduled Tribes and
other Backward Classes in the Public Sector
Undertaking under the administration control of the
Department.
Group Total No. Of
Posts
Scheduled
Castes
Scheduled
Tribes
Other Backward
Castes
Physically
Handicapped
A 19 1 3 2 2
B 34 4 - 4 -
C 5 1 - 1 -
D 14 6 - - -
Total 72 12 3 7 2
LIST OF PERSONNEL IN THE DEPARTMENT OF PHARMACEUTICALS
Sl. No. Name Designation
1. Shri Dilsher Singh Kalha Secretary
2. Sh. Shambhu Kallolikar Joint Secretary
3. Sh. Pradeep Yadav Joint Secretary
4. Shri Kailash Pati Economic Adviser
5. Shri Binay Kumar Singh Director
6. Shri S.C. Sharma Director
7. Ms. Monika Verma Director
82
Sl. No. Name Designation
8. Shri Ravinder Mathur Director (Cost)
9. Shri Rakesh Kumar Maggo Deputy Secretary
10. Shri M. L. Sidana Deputy Secretary
11. Shri S.D. Maurya Joint Director (Cost)
12. Shri A.K. Karn Under Secretary
13. Shri Roshan Lal Under Secretary
14. Shri A.K. Sah Under Secretary
15. Shri Seeta Ram Meena Under Secretary
16. Shri Anil Jain Under Secretary
17. Shri Raj Kumar Under Secretary
18. Shri V.K. Tyagi Deputy industrial Advisor
19. Shri Brij Lal Sharma Assistant Director (OL)
20. Shri Shah Faiz Ahmed Section Offcer
21. Shri Sanjay Gupta Section Offcer
22. Shri P.K. Singh Section Offcer
23. Smt Seema Agrawal Section Offcer
24. Shri T.K. Munshi Section Offcer
25. Shri N.N. Ahuja Section Offcer
26. Shri Yogeshwar Sharma Section Offcer
27. Shri Mrutyunjay Tripathy Section Offcer
ORGANISATIONAL CHART OF DEPARTMENT OF PHARMACEUTICALS

108

ORGANISATIONAL CHART OF DEPARTMENT OF PHARMACEUTICALS
* One of the posts of Joint Secretary is vacant, all the works in the Department at present is being looked after by ShriShambhuKallolikar, who
joined the Department w.e.f. 5.2.2013.
Shri Dilsher Singh Kalha,
Secretary
Shri Pradeep Yadav
JS
Shri M.L. Sidana,
DS (PSU, PTUAS,
Parliament)
Shri A.K. Karn,US (PI-IV,
PSU)
Shri S.R. Meena, US
(Admin.,IT, Media,
Parliament, Estt.)
Ms. Monika Verma, Director
(O&M, Coord., OL, RTI)
Shri R.K. Maggo
DS (IT, Media, Admn.,DPEA/
DPCO, Court Cases, NPPA)
Shri Roshan Lal, US (NPPA,
PI-I)
Shri S.D. Maurya, J.D. (Cost)
NPPA
Shri Anil Jain,
US
(DPEA)
Shri Shambhu Kallolikar
JS
Shri S.C. Sharma,
Director
(NIPER, R&D,Envm. Cell)
Shri A.K. Sah, US
(NIPER,Environmental
Cell,R&D)
Shri V.K. Tyagi,
DIA
Shri Binay Kumar Singh,
Director
(PI-II,III Estt.,Vig.)
Shri V.K. Tyagi,
DIA
Shri Raj Kumar, US
(PI-II, III, Vig,,)
Shri A.K. Mathur, DDG
Shri Kailash Pati,
Economic Adviser
Shri Ravindra Mathur,
Director (Cost)
Shri Raj Kumar, US
(NORMS)
Shri S.K. Kundia
(AS & FA)
Shri V.K. Mehta, Director
(Finance)
Mr. R.K. Kureel, US
(Finance)
83
9.2 RECORD MANAGEMENT
The Parliament had enacted The Public Records Act
1993 to regulate the management, administration
and Preservation of Public Records of the Central
Government, Union Territory Administrations,
Public Sector Undertakings, statutory bodies and
corporations etc. The Central Government has also
made the rules to carry out the provisions of the Act.
In terms of the provisions and terms contained in
Section 5(1) of the Act, the Under Secretary Incharge
of General Administration has been nominated as
Records Offcer in the Department. The requisite
reports and returns are being sent to National Archives
of India (NAI) regularly.
9.3 GRIEVANCE CELL
The Grievance Cell is monitoring grievances related
to all Pharmaceuticals viz. their availability, quality,
pricing, policy matters etc. One of the main objectives
for opening of this cell was to make available
medicines to common man at affordable prices.
Publicity about the setting up of this Grievances Cell
was given through the National daily newspapers of
Hindi, English and Regional Languages. The on line
Grievance Redressel Mechanism, Public Grievances
Redressal and Monitoring System (PGRAMS) has
been brought into operation w.e.f. 1st August, 2005.
Recently an online Centralized Public Grievance
Redressal and Monitoring System (CPGRAMS) has
also been introduced by Department of Administrative
Reforms and Public Grievances (DARPG).
For giving wide publicity to the Grievance Cell,
information has been uploaded on the websites
of Department of Pharmaceuticals and also on the
websites of the Institutions/Organizations falling under
their purview. Links are given with the home pages of
Department of Chemicals and Petrochemicals and
Department of Pharmaceuticals to access CPGRAMS
with the websites of the Institutions/Organizations
under Department of Chemicals & Petrochemicals
and Department of Pharmaceuticals. Grievance Cell
plays a vital role in the redressal of grievances of
common man.
Chapter
10
PERFORMANCE EVALUATION AND MANAGEMENT SYSTEM
10.1 Our Vision
10.2 Our Mission
10.3 Our Objective
10.4 Functions
87
The Department of Pharmaceuticals has prepared its
Result Framework Document (RFD) for the year 2012-
2013 as required under the Performance Monitoring
and Evaluation System (PMES) for Government
Departments. Results Framework Document for
the year 2011-2012 and 2012-2013 are placed on
its website http://pharmaceuticals.gov.in. As per the
score approved by the High Powered Committee, the
Department has been given 45.11 for its performance
in the year 2011-12.
Vision, Mission, Objectives and Functions have been
fxed in concurrence with the Cabinet Secretariat.
10.1 Our Vision:
India: The largest global provider of quality medicines
10.2 Our Mission:
Ensure availability of drugs at reasonable
prices as per provisions of the Drug Prices
Control Order 1995
Develop Human Resources for
Pharmaceutical Industry and Drug Research
and Development
Public-Private Partnership for development
of pharmaceuticals Industry
Pharma Brand India through International
Cooperation
10.3 Our Objectives:
The objectives are based on the functions allocated
to the Department as per The Allocation of Business
Rules, 1961 vide Notifcation of Cabinet Secretariat
dated 1
st
July 2008:
1. Ensure availability of drugs at reasonable prices
Order 1995
2. Ensure proper functioning of the Central Pharma
Undertakings in control of the Department.
3. Project Based Support and Revival Schemes for
CPSUs
4. Ensure proper management of M Pharma and
PhD programs in NIPERs
5. Develop Human Resources, Infrastructure for
Pharma R&D and Industry including Public-
Private-Partnerships (PPP)
6. Formulate Scheme/ Project for promoting Pharma
Brand India
7. Formulate Scheme/ Project for promoting
8. Formulation of Annual Plan, Budget and
Monitoring of Budget Expenditure
9. Start preparation of Strategy Paper for the
Department
10.4 Functions:
The Functions of the Department of Pharmaceuticals
arise from the following work allocated to it as per The
Allocation of Business Rules, 1961 vide Notifcation
of Cabinet Secretariat dated 1
st
July 2008:
1) Drugs and Pharmaceuticals, excluding those
specifcally allotted to other departments.
2) Promotion and co-ordination of basic, applied
and other research in areas related to the
Pharmaceuticals sector.
3) Development of infrastructure, manpower
and skills for the Pharmaceuticals sector and
management of related information.
4) Education and training including high end
research and grant of fellowships in India and
abroad, exchange of information and technical
guidance on all matters relating to pharmaceutical
sector.
5) Promotion of public private partnership in
pharmaceutical related areas.
6) International cooperation in pharmaceutical
research, including work related to international
conferences in related areas in India and
abroad.
CHAPTER 10
PERFORMANCE EVALUATION AND MANAGEMENT SYSTEM
88
7) Inter-sectoral coordination including coordination
between organizations and institutes under the
Central and State Governments in areas related
to the subjects entrusted to the Department.
8) Technical support for dealing with national
hazards in pharmaceutical sector.
9) All matters relating to National Pharmaceuticals
Pricing Authority including related functions of
price control/monitoring.
10) All matters relating to National Institutes for
Pharmaceutical Education and Research.
11) Planning, development and control of; and
assistance to, all industries dealt with by the
Department.
12) Bengal Chemicals and Pharmaceuticals Limited.
13) Hindustan Antibiotics Limited.
14) Indian Drugs and Pharmaceuticals Limited.
15) Karnataka Antibiotics and Pharmaceuticals
Limited.
16) Rajasthan Drugs and Pharmaceuticals Limited
Chapter
11
CITIZEN CENTRIC GOVERNANCE
11.1 Our Vision
11.2 Our Mission
11.3 Our Clients
11.4 Our Commitment
11.5 Our Services
11.6 Our Activities
11.7 rTI-2005
11.8 CPGrAMS
91
CHAPTER 11
CITIZEN CENTRIC GOVERNANCE
11.1 Our Vision
vision has been fxed in concurrence with the Cabinet
Secretariat, which isas follows:
India: The largest global provider of quality medicines
11.2 Our Mission
Ensure availability of drugs at reasonable prices
Order 1995
Develop Human Resources for Pharmaceutical
Industry and Drug Research and Development
Public-Private Partnership for development of
pharmaceuticals Industry
Formulate Scheme/ Project for promoting Pharma
Brand India through International Cooperation
11.3 Our Clients
Consumers and users of the products and by-
products of the Pharma Industry
Entrepreneurs of pharmaceuticals sectors
Industry Associations
Central government ministries/departments/
organizations
11.4 Our Commitment
We are committed to provide impartial,
sympathetic and prompt services to the public
in matters relating to the pharmaceuticals
industries.
Our commitment is to take prompt steps to
provide quick redressal of the grievances of our
personnel and public at large.
Our commitment is to formulate policies and
initiate consulations with all Industry Associations/
stakeholders and to amend them whenever so
required.
11.5 Our Services
We formulate and implement policies relating
to drugs and pharmaceuticals, dyestuff and dye
intermediates.
11.6 Our Activities
The key activities of the Department focus on:
1. Ensure availability of drugs at reasonable prices
Order 1995
2. Ensure proper functioning of the Central Pharma
Undertakings in control of the Department.
3. Project Based Support and Revival Schemes for
CPSUs
4. Ensure proper management of M Pharma and
PhD programs in NIPERs
5. Develop Human Resources, Infrastructure for
Pharma R&D and Industry including Public-
Private-Partnerships (PPP)
6. Formulate Scheme/ Project for promoting Pharma
Brand India
7. Formulate Scheme/ Project for promoting
8. Formulation of Annual Plan, Budget and
Monitoring of Budget Expenditure
The Citizen Charter of the Department has been
placed on the website of the Department.
11.7 Right to Information Act 2005
As per the provisions of the RTI Act 2005, All the
relevant information relating to Department of
Pharmaceuticals has been available on the web
site in a manner, which is easily accessible and
comprehensible to the public.
Central Public Information Offcers have been
nominated in the department to provide information
to the public.
92
11.8 CPGRAMS (Centralized Public
Grievances and Monitoring System)
A portal of CPGRAMS has been uploaded on the
website of the Department. Public Grievances
received on CPGRAMS are monitor and disposed
regularly. Shri M.L. Sidana, Deputy Secretary, is the
Public Grievances Offcer of the Department
Chapter
12
INFORMATION AND TECHNOLOGY
12.1 Local Area Network (LAN)
12.2 IT Infrastructure
12.3 Website
12.4 Video Conferencing
12.5 File Tracking System
12.6 Voice Mail Facility
12.7 E. Governance
95
Information and Technology
With the increased use of the internet, the need for better
awareness and information fow has also increased.
Also the usage of Information and Communication
Technologies (ICT) has instigated the desire of
various users and stakeholders of the department to
be more familiar with the rules, protocols and policies
which govern their proper functioning. Understanding
these concerns, the Department of Pharmaceuticals
has taken sincere initiatives towards adoption of best
practices and organized useful information not only to
improve administrative operations but also to enhance
the overall effciency of the department
12.1 Local Area Network (LAN):
A local Area Network (LAN) is functioning in the
Department inter-connecting all the Windows based
computers of offcers, personal staff and sections. All
computers are equipped with the facility of Internet and
easy accessibility of applications from the server.
An IT based Computer Centre, set up by National
Informatics Centre (NIC) is operational in the
Department and is equipped with latest Servers, Client
machines for providing Internet and E-mail facilities
for local and global connectivity. LAN of Department
is being upgraded as per IPv6 guidelines.
12.2 IT Infrastructure:
Department of Pharmaceuticals in close association
with NIC has focused on building up the IT infrastructure
within the Ministry with the following objectives:
Improve workfow, work management and
monitoring.
Assist in analyzing, decision making and
scheduling through Management Information
Systems (MIS).
Storage of data, analysis and handling of
databases.
Provide Graphical User Interface (GUI) based
environment.
LAN for sharing the resources among users.
Simplify dissemination of information to public
and make it interactive.
Train all personnel in making most of this
technology.
12.3 Website:
As Website is an electronic medium to provide
information and enhance government citizen
interaction, a Web Site in English and in Hindi
has been launched by the Department (http://
pharmaceuticals.gov.in) and is hosted at NIC to
ensure maximum reach of information and services
to the citizens. It provides details of organizational
set up of the department, its functions, subordinate
offces, policies, publications, statistical data/
information on functional parameters. It is also
a medium for interacting with citizens for taking
decisions for making policies like NPPP 2012.
Another website for Jan Aushadhi Scheme of the
Department is also launched (http://janaushadhi.gov.
in). It provides details of the scheme, list of generic
medicines (unbranded) which are being dispensed
through the Jan Aushadhi Stores (JAS) being setup
in various districts of India. It facilitates the visitors to
know the locations of the JAS already opened. It also
provides comparative prices of Generic Medicines
sold at Jan Aushadhi Stores and Branded Products.
12.4 Video Conferencing:
Video Conferencing facility is operational for Joint
Secretary and above level Offcers. PSUs of the
department and Educational Institutes (NIPERs) have
also initiated installation of the Video Conferencing
facility. With the facility already implemented at a few of
the PSUs and NIPERs, Department is able to interact
with them frequently to monitor their performance and
communicate the decisions.
12.5 File Tracking System:
Department has implemented a web based File
Tracking system (FTS) to keep record of its receipts
being received at various locations in the department
and to maintain a consistent watch over the movement
of various important Files and Receipts at different
levels in the process of decision-making. The system
is used as a tool to curb down pendency at all levels
in the Department. It is upgraded to new version for
enhanced functionality.
CHAPTER 12
INFORMATION AND TECHNOLOGY
96
12.6 Voice Mail Facility:
Voice Mail facility is successfully implemented in
the Dept. through the landline telephone system
at all levels to ensure high availability, enhance
accountability and effciency of the offcials of the
department at work.
12.7 E. Governance:
Taking advantage of latest ICT enabled tools,
Department of Pharmaceuticals with the support of
NIC has taken sincere initiatives towards adoption
of best practices. Various applications have been
developed and implemented by NIC to strengthen,
monitor and decision making and high availability of
right information at right time.
Activity Monitoring System- A web based MIS has
been developed and implemented to monitor time
bound important activities and tasks assigned to
offcials/sections of Department.
Intra portal for Department of Pharma:- An intranet
portal Intrapharma with electronic Notice Board
is available to offcials of the Department for
ready reference of various circulars, offce orders,
letters etc. It is also a gateway of application
like digital library for Parliament Questions and
presentation material etc.
Centralized Public Grievance Redress Monitoring
System (CPGRAMS) : CPGRAMS is implemented
in the Department and all the attached offce to
address Public grievances received online with
minimum delay.
E-publishing of Tenders E-publishing of tenders
is implemented by uploading tenders on Central
Public Procurement Portal. It has improved the
accessibility of tenders.
Other e-Governance applications like RTI
Request & Appeal Management Information
System, Composite Payroll System (Comp
DDO), Result Framework Management System,
ACC Vacancy Monitoring System are functional
in the Department to facilitate various sections.
To enhance e-Governance further various applications
in various domains such as G2C, G2B, G2G & G2E
have been envisaged to be developed & implemented
with assistance of NIC.
Chapter
13
ANNEXURE
Annexure I
Annexure II
Annexure III
Annexure - IV
Annexure - V
99
ANNEXURE I
PRODUCTION OF SELECTED BULK DRUGS MONITORED BY NPPA BASED ON THE PRODUCTION RETURN
RECEIVED FROM THE COMPANIES FOR THE YEAR 2009-10, 2010-11, 2011-12 AND 2012-13 (PROVISIONAL)
(Ref: Chapter 4)
Sl.
No.
Name of the Therapeutic Group and
Bulk Drugs
Unit 2009-10 2010-11 2011-12 2012-13
upto Sept
(Prov.)
I ANAESTHETICS
1 Lignocaine / Xylocaine / Lidocaine MT 85.760 106.750 57.300 28.250
2 Procaine MT N.A. N.A. N.A. N.A.
II ANALGESICS & ANTIPYRETICE
3 Analgin / Metamizole (s) MT 186.708 243.757 157.559 88.132
4 Aspirins (s) MT 1018.737 1151.436 1364.745 461.150
5 Ibuprofen (s) MT 4687.000 4822.000 4654.000 789.000
6 Oxyphenylbutazone MT N.A N.A N.A N.A
7 Paracetamol MT 11209.612 13669.802 7146.000 3566.000
8 Pethidine MT N.A N.A N.A N.A
9 Phenylbutazone MT 42.242 33.255 0.000 N.A
10 Piroxicam MT N.A N.A N.A N.A
III ANTI-ASTHAMATICS
11 Aminophylline (s) MT 5.445 8.035 3.375 0.000
12 Ephedrine (s) MT 413.716 472.803 411.512 107.782
13 Salbutamol (s) MT 7.115 9.543 7.562 3.133
14 Terbutaline MT 0.576 0.602 0.531 0.096
15 Theophylline (s) MT 80.980 N.A N.A N.A
IV ANTI-BIOTICS
16 Amoxycilline MT 1545.670 1219.608 1150.323 565.128
17 Ampicilline MT 90.260 64.410 113.820 49.860
18 Cephalexin MT 1088.787 1259.667 1042.118 386.475
19 Chloramphenicol Palmitate MT 42.943 34.509 29.939 8.590
20 Chloramphenicol Powder MT 24.554 31.113 33.631 8.863
21 Cloxacillin (s) MT 29.920 3.000 20.340 10.260
22 Doxycycline (s) MT 1.929 6.248 3.356 0.000
23 Erythromycin (s) MT 480.457 492.853 555.283 303.165
24 Framycetin (s) MT N.A N.A N.A N.A
25 Gentamycin (s) MT N.A N.A N.A N.A
26 Griseofulvin (s) MT N.A N.A N.A N.A
27 Oxytetracycline (s) MT N.A N.A N.A N.A
100
Sl.
No.
Bulk Drugs
Unit 2009-10 2010-11 2011-12 2012-13
upto Sept
(Prov.)
28 Penicillin (s)
a. Penicillin G 1st Crystal MMU 1789.000 2000.000 876.086 0.000
b. Penicillin G Procaine MMU N.A. N.A. N.A. N.A.
c. Penicillin G Sodium MMU N.A. N.A. N.A. N.A.
d. Penicillin G Benzathine MMU 4.170 0.000 N.A N.A
29 Rifampicin (s) MT 369.735 407.714 213.765 165.119
30 Streptomycin (s) MT N.A. N.A. N.A. N.A.
31 Tetracycline (s) MT N.A. N.A. N.A. N.A.
V ANTI-DIABETICS
32 Chlorpropamide (s) MT 4.100 8.525 2.720 10.077
33 Glibenclamide MT 2.421 1.686 1.336 0.888
34 Insulin (s) KG N.A. N.A. N.A. N.A.
35 Tolbutamide MT 44.800 52.135 70.058 33.402
VI ANTI-DYSENTRY DRUGS
36 DiloxanideFuroate MT 48.750 38.647 71.622 34.079
37 IodoChloroHydroxyQuinoline (s) MT 185.427 220.242 77.197 23.140
38 Metronidazole (s) MT 374.122 326.094 224.855 66.376
39 Tinidazole MT 76.501 73.500 79.000 8.500
VII ANTI-FILARIALS
40 Diethyl Carbamazine (DEC Citrate) MT 24.800 9.015 22.995 5.825
VIII ANTI-HELMENTICS
41 Mebandazole MT N.A N.A N.A N.A
42 Piperazine and Salts MT N.A N.A N.A N.A
43 PyrantelPamoate (s) MT N.A N.A N.A N.A
44 Tetramisole / Levamisole MT N.A N.A N.A N.A
IX ANTI-HISTAMINS
45 Diphenhydramine MT 52.415 51.946 65.310 6.181
46 Pheniramine Maleate (s) MT 35.429 53.430 52.946 27.024
X ANTI-LEPROTICS
47 Clofuzamine MT N.A N.A N.A N.A
48 Dapsone MT N.A N.A N.A N.A
101
Sl.
No.
Bulk Drugs
Unit 2009-10 2010-11 2011-12 2012-13
upto Sept
(Prov.)
XI ANTI-MALARIALS
49 Amodiaquin (s) MT 17.400 0.587 2.448 2.045
50 Chloroquine (s) MT 168.194 119.888 54.115 22.308
XII ANTI-T.B. DRUGS
51 Ethambutol MT 931.401 935.192 924.854 469.330
52 INH MT N.A N.A N.A N.A
53 Pas & its Salts MT 37.687 51.578 97.500 22.911
54 Pyrazinamide MT 299.186 339.248 303.959 222.981
55 Thiacetazone MT N.A N.A N.A N.A
XIII CARDIOVASCULAR DRUGS
56 Digoxin MT N.A N.A N.A N.A
57 Methyl Dopa (s) MT N.A N.A N.A N.A
58 Propranolol MT N.A N.A N.A N.A
59 XanthinolNicotinate MT N.A N.A N.A N.A
XIV CNS STIMULANTS
60 Caffeine MT N.A N.A N.A N.A
61 Nikethamide MT N.A N.A N.A N.A
XV CORTICOSTEROIDS
62 Betamethasone (s) MT 5.101 4.886 2.997 0.261
63 Dexamethasone (s) MT N.A N.A N.A N.A
64 Hydrocortisone MT N.A N.A N.A N.A
65 Prednisolone (s) MT N.A N.A N.A N.A
XVI DIURETICS
66 Acetazolamide MT N.A N.A N.A N.A
67 Frusemide (s) MT N.A 2.433 7.666 0.527
68 Hydrochlorothiazide MT 44.564 65.723 75.256 19.956
69 Spironolactone MT 3.550 2.246 3.794 2.034
XVII GASTRO INTESTINAL
70 Ranitidine (s) MT 1254.709 1686.114 1559.384 704.171
102
Sl.
No.
Bulk Drugs
Unit 2009-10 2010-11 2011-12 2012-13
upto Sept
(Prov.)
XVIII OTHER ANTI-BACTERIALS
71 Nalidixic Acid (s) MT 182.299 174.411 81.030 13.343
72 Trimethoprim (s) MT 275.699 299.557 271.202 152.536
XIX SULPHA DRUGS
73 Sulphacetamide MT N.A N.A N.A N.A
74 Sulphadiazine (s) MT N.A N.A N.A N.A
75 Sulphadimidine (s) MT N.A N.A N.A N.A
76 Sulphaguanidine MT N.A N.A N.A N.A
77 Sulphamethoxazole (s) MT N.A N.A N.A N.A
78 Sulphamoxole (s) MT N.A N.A N.A N.A
79 Sulphaphenazole MT N.A N.A N.A N.A
80 Sulphasomidine MT N.A N.A N.A N.A
XX TRANQUILIZERS & SEDATIVES
81 Diazepam MT 6.155 6.956 8.041 4.070
82 Imipramine MT N.A. N.A. N.A. N.A.
83 Nitrazepam MT 0.259 0.076 0.206 0.018
84 Phenobarbitone MT 31.194 22.092 0.000 0.000
85 Trifuperazine MT N.A. N.A. N.A. N.A.
XXI VITAMINS
86 Folic Acid MT 81.120 39.340 39.990 0.000
87 Nicotinamide MT N.A. N.A. N.A. N.A.
88 Niacotinic Acid MT N.A. N.A. N.A. N.A.
89 Vitamin A (s) MT 38.268 36.203 13.429 0.000
90 Vitamin B1 / Thiamine(s) MT N.A N.A N.A N.A
91 Vitamin B12 MT N.A N.A N.A N.A
92 Vitamin B2 (s) MT N.A N.A N.A N.A
93 Vitamin B6 MT N.A N.A N.A N.A
94 Vitamin C/Ascorbic Acid(s) MT N.A N.A N.A N.A
95 Vitamin D3 MT N.A N.A N.A N.A
96 Vitamin E (s) MT 354.000 392.960 103.520 0.000
103
ANNEXURE II
(Ref: Chapter 4)
PRICES OF SCHEDULED BULK DRUG/DERIVATIVES FIXED /REVISED BY NPPA
SINCE ITS INCEPTION
Sl.
No.
NAME OF THE DRUG Existing Revised %
1 PCMX 762(E) 305.00 12.06.2009 309.00 09.04.2012 1.31
2 Vitamin C Plain 761(E) 613.00 20.01.2010 409.00 09.04.2012 (33.28)
3 Vitamin C Coated 761(E) 600.00 20.01.2010 419.00 09.04.2012 (30.17)
4 Vitamin C - Sodium
Ascorbate
761(E) 645.00 20.01.2010 469.00 09.04.2012 (27.29)
5 Ibuprofen 2741(E) 498.00 20.09.2011 527.00 16.11.2012 5.82
6 Rifampicin 2742(E) 4,111.00 20.09.2011 4,485.00 16.11.2012 9.10
7 Iodochlorohydroxyquinoline
(ICHQ)
2743(E) 1,158.00 20.09.2011 1,526.00 16.11.2012 31.78
8 Metronidazole 2744(E) 514.00 01.07.2011 588.00 16.11.2012 14.40
9 Metronidazole Benzoate 2744(E) 450.00 01.07.2011 525.00 16.11.2012 16.67
10 Glipizide 2745(E) 26,114.00 24.04.2009 15,946.00 16.11.2012 (38.94)
First Time 17 cases* Since Inception of NPPA
No Change 10 cases Bulk Drug - 342
Increases 158 cases Derivative - 190
Decreases 347 cases Total 532
532 cases
* Notifcation of Oxcarbazapine is withdrawn
105
ANNEXURE-III
List of Public Sector Undertaking and other Organisation under the administration Control of the Department of
Pharmaceuticals
ATTACHED OFFICE
NATIONAL PHARMACEUTICAL PRICING AUTHORITY
1. Karnataka Antibiotics & Pharmaceuticals Limited (KAPL), Bangalore.
2. Rajasthan Drugs & Pharmaceuticals Limited (RDPL), Jaipur.
3. Hindustan Antibiotics Limited (HAL), Pimpri, Pune, Maharashtra
4. Bengal Chemicals & Pharmaceuticals Limited (BCPL), Kolkata, West Bengal
5. Indian Drugs & Pharmaceuticals Limited (Idpl), Dundahera, Gurgaon, Haryana
6. Bengal Immunity Limited (BIL), Kolkata, West Bengal Since Closed
7. Smith Stanistreet Pharmaceuticals Limited (SSPL), Kolkata, West Bengal Since Closed
OTHER ORGANISATIONS
1. National Institute of Pharmaceuticals Education and Research (NIPER) at Mohali, SAS Nagar (Punjab)
2. National Institute of Pharmaceuticals Education and Research at Hyderabad (Andhra Pradesh).
3. National Institute of Pharmaceuticals Education and Research at Kolkata (West Bengal)
4. National Institute of Pharmaceuticals Education and Research atRai Bareli (Uttar Pradesh).
5. National Institute of Pharmaceuticals Education and Research at Hajipur (Bihar)
6. National Institute of Pharmaceuticals Education and Research at Ahmedabad (Gujarat)
7. National Institute of Pharmaceuticals Education and Research at Guwahati (Assam)
(Ref: Chapter - 9)
107
ANNEXURE III(A).
Address and Name of Head of various Organizations & PSUs under the Department of Pharmaceuticals
Sl.
No.
Address and Organizations Name Designation
1. Indian Drugs & Pharmaceuticals Limited (IDPL), Gurgaon Shri Praveen Kumar
Chairperson &
Managing Director
2. Hindustan Antibiotics Limited (HAL), Pune - 411010 Shri K.V. Varkey Managing Director
3.
Karnataka Antibiotics & Pharmaceuticals Limited (KAPL),
Bangalore - 560 010
(Vacant) Managing Director
4.
Bengal Chemicals & Pharmaceuticals Limited (BCPL),
Kolkata - 700 013
Shri S. Kundu Managing Director
5.
Rajasthan Drugs & Pharmaceuticals Limited (RDPL), Road
No. 12 V.K.I Area Jaipur - 302 013
Shri M.K. Nagendra Managing Director
6. Bengal Immunity Limited (BIL), Kolkata (since closed) Sh. S. Kundu Managing Director
7.
Smith Stanistreet Pharmaceuticals Limited (SSPL), Kolkata
(Since Closed), under liquidation)
(Ref. Chapter 9)
109
ANNEXURE III(B)
(Ref. Chapter 9)
List of Responsibility Centers and Subordinate Organisations for the Year 2012-13
Sl.
No.
Responsibility Centers
and Subordinate
Organizations
Description
Landline
Number
Email Address
1. Dr. K. KBhutani,
Offciating Director
1722214692 director@niper.ac.in National Institute of
Pharmaceuticals Education &
Research (NIPERS) Sector- 67,
SAS Nagar, Punjab 160062
2. Dr. Neeta Shrivastava,
Project Director
07927450449 perd@perdcentre.com NIPER Ahmedabad, B.V. Patel
Pharmaceutical, Education
and Research Development
(PERD) Center Thaltej-
Gandinagar Highway, Thaltej,
Ahmedabad - 380054
3. Dr. Ahmed Kamal,
Project Director
04023073751 niperhyd@yahoo.com NIPER Hydrabad IDPL
Township, Balangar,
Hyderabad - 500007
4. Dr. Pradeep Das, Project
Director
0612263437 drpradeep.das@gmail.
com
NIPER Hajipur Rajendra
Memorial Research Institute of
Medical Sciences (RMRIMS)
Agam Kuan, Patna - 800 007
5. Dr. Asish Kumar
Banerjee, Project
Director
3324735197 asishbanerjeeiich@
gmail.com
NIPER Kolkata Indian Institute
of Chemical Biology 4, Raja
S.C. Mullick Road, Jadavpur,
Kolkata - 700032
6. Dr. B.K. Bezbaruah 03612132751 niperghy@gmail.com NIPER Guwahati, Guwahati
Medical College and Hospital
(Guwahati) - 781032
7. Dr. P.K. Shukla 05222620713 Pk_shukla@cdri.res.in NIPER Rai Bareli, Central Drug
Research Institute Chatter
Manzil P.O Box 173,
Lucknow - 226001
8. Mr. C.P. Singh,
Chairman, National
Pharmaceuticals Pricing
Authority
01123389866 nppa@nic.in NPPA, YMCA Cultural Centre
Building, 3
rd
Floor, 1, Jai Singh
Road, New Delhi - 110001
111
ANNEXURE IV
Organisational Chart of NPPA (Ref. Chapter 4)
D
i
r
e
c
t
o
r
M
I
S

D
i
v
i
s
i
o
n
1
.
G
e
n
e
r
a
t
i
o
n

a
n
d
v
a
l
i
d
a
t
i
o
n

o
f
M
o
n
t
h
l
y

R
e
p
o
r
t
b
a
s
e
d

o
n

I
M
S

D
a
t
a
.
2
.
C
o
o
r
d
i
n
a
t
i
o
n

w
o
r
k
r
e
l
a
t
e
d

t
o

A
u
t
h
o
r
i
t
y
M
e
e
t
i
n
g
s

-

A
g
e
n
d
a
/
M
i
n
u
t
e
s
3
.
P
r
i
c
e

L
i
s
t

c
o
l
l
e
c
t
i
o
n
&

e
x
a
m
i
n
a
t
i
o
n
4
.
P
r
o
d
u
c
t
i
o
n

&

I
m
p
o
r
t
D
a
t
a

o
f

B
u
l
k

D
r
u
g
s
&

F
o
r
m
u
l
a
t
i
o
n
s
5
.
A
n
n
u
a
l

e
x
e
r
c
i
s
e

i
n
r
e
s
p
e
c
t

o
f

m
a
r
k
e
t
s
t
r
u
c
t
u
r
e
/
n
u
m
b
e
r

o
f
N
L
E
M

m
a
n
u
f
a
c
t
u
r
-
e
r
s

f
o
r

e
a
c
h

N
L
E
M
f
o
r
m
u
l
a
t
i
o
n
s
6
.
S
t
o
r
a
g
e
&
P
r
e
s
e
r
v
a
n
c
e

o
f
D
a
t
a

a
n
d

p
r
o
v
i
d
i
n
g
i
n
p
u
t
s

t
o

t
h
e

c
o
n
-
c
e
r
n
e
d

D
i
v
s
i
o
n
s

o
f
N
P
P
A
7
.
U
p
d
a
t
i
o
n

o
f

N
P
P
A
'
s
w
e
b
s
i
t
e
.
8
.
R
e
l
a
t
e
d

P
a
r
l
i
a
m
e
n
t
Q
u
e
s
t
i
o
n
s
/
m
a
t
t
e
r
s
.
D
i
r
e
c
t
o
r
P
r
i
c
i
n
g

D
i
v
i
s
i
o
n
1
.
F
i
x
a
t
i
o
n
/
R
e
v
i
s
i
o
n

o
f

p
r
i
c
e
s
o
f

N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s
b
a
s
e
d

o
n

i
n
p
u
t
s

r
e
c
d
.

f
r
o
m
M
I
S

D
i
v
n
,

M
&
E

D
i
v
n

a
n
d
A
p
p
l
i
c
a
t
i
o
n
s
/
R
e
q
u
e
s
t
s

f
r
o
m
m
a
n
u
f
a
c
t
u
r
e
r
s
.
2
.
W
o
r
k
i
n
g

o
u
t

f
a
c
t
o
r
s
/

n
o
r
m
s
r
e
l
a
t
e
d

t
o

p
r
i
c
i
n
g

f
o
r
m
u
l
a
g
i
v
e
n

i
n

D
P
C
O
,

2
0
1
3

a
n
d
i
t
s

r
e
v
i
s
i
o
n

f
r
o
m

t
i
m
e

t
o

t
i
m
e
3
.
C
o
l
l
e
c
t
i
o
n

o
f

m
a
r
k
e
t

b
a
s
e
d
d
a
t
a

f
o
r

f
i
x
a
t
i
o
n

o
f

p
r
i
c
e
s

o
f
N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s

f
o
r
w
h
i
c
h

I
M
S

d
a
t
a

i
s

n
o
t

a
v
a
i
l
-
a
b
l
e
.
4
.
A
n
n
u
a
l

r
e
v
i
s
i
o
n

o
f

p
r
i
c
e
s

o
f
N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s

b
a
s
e
d
o
n

W
P
I

o
n

o
r

a
f
t
e
r

1
s
t

A
p
r
i
l
,
e
v
e
r
y

y
e
a
r
.
5
.
A
n
n
u
a
l

r
e
v
i
s
i
o
n

o
f

p
r
i
c
e
s
w
h
e
n
e
v
e
r

t
h
e
r
e

i
s

a

c
h
a
n
g
e
i
n

m
a
r
k
e
t

s
t
r
u
c
t
u
r
e

i
n

r
e
-
s
p
e
c
t

o
f

N
L
E
M

f
o
r
m
u
l
a
-
t
i
o
n
s
6
.

P
r
i
c
e

f
i
x
a
t
i
o
n
/

r
e
v
i
s
i
o
n

o
f
n
o
n
-
N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s
w
h
e
r
e
v
e
r

c
o
n
s
i
d
e
r
e
d

n
e
c
-
e
s
s
a
r
y
.
7
.
N
o
t
i
f
i
c
a
t
i
o
n

o
f

p
r
i
c
e
s

i
n

t
h
e
o
f
f
i
c
i
a
l

G
a
z
a
t
t
e

a
n
d

m
a
i
n
-
t
a
i
n
i
n
g

t
h
e

p
r
i
c
e

d
a
t
a

o
f
N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s
8
.
R
e
l
a
t
e
d

P
a
r
l
i
a
m
e
n
t

Q
u
e
s
-
t
i
o
n
s
/
m
a
t
t
e
r
s
.
D
i
r
e
c
t
o
r
M
o
n
.
&

E
n
f
.

D
i
v
i
s
i
o
n
1
.
E
n
f
o
r
c
i
n
g

a
n
d

i
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

t
h
e
p
r
i
c
e
s

o
f

N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s

f
i
x
e
d

b
y
N
P
P
A
.
2
.
M
o
n
i
t
o
r
i
n
g

o
f

t
h
e

p
r
i
c
e

m
o
v
e
m
e
n
t

o
f

n
o
n
-
N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s

b
a
s
e
d

o
n

m
o
n
t
h
l
y

r
e
-
p
o
r
t
s

o
f

I
M
S

a
n
d

a
c
t
i
o
n

t
h
e
r
e
o
f
,

i
f

f
o
u
n
d
m
o
r
e

t
h
a
n

1
0
%
.
3
.
P
r
o
c
e
s
s
i
n
g

o
f

S
D
C
s

r
e
p
o
r
t
s

r
e
c
e
i
v
e
d

i
n
r
e
s
p
e
c
t

o
f

n
o
n
-
i
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

t
h
e
p
r
i
c
e
s

o
f

N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s

a
n
d

o
t
h
e
r
D
P
C
O

r
e
l
a
t
e
d

m
a
t
t
e
r
s
.
4
.
S
a
m
p
l
i
n
g

o
f

N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s

f
r
o
m

d
i
f
-
f
e
r
e
n
t

p
l
a
c
e
s

a
n
d

a
n
a
l
y
s
i
s

o
n

a

r
e
g
u
l
a
r
b
a
s
i
s
.
5
.
C
o
m
p
l
a
i
n
t
s

r
e
c
e
i
v
e
d

f
r
o
m

i
n
d
i
v
i
d
u
a
l
s
,
N
G
O
s
,

i
n
s
t
i
t
u
t
e
s

r
e
l
a
t
e
d

t
o

p
r
i
c
i
n
g
/

m
a
r
-
k
e
t
i
n
g

a
t

p
r
i
c
e
s

h
i
g
h
e
r

t
h
a
n

t
h
e

p
r
i
c
e

f
i
x
e
d
b
y

N
P
P
A
o
r

p
r
i
c
e

i
n
c
r
e
a
s
e

m
o
r
e

t
h
a
n

1
0
%
.
6
.
S
e
n
d
i
n
g

r
e
p
o
r
t
s

t
o

O
v
e
r
c
h
a
r
g
i
n
g

D
i
v
i
s
i
o
n
f
o
r

r
e
c
o
v
e
r
y

o
f

o
v
e
r
c
h
a
r
g
e
d

a
m
o
u
n
t
.
7
.
S
e
n
d
i
n
g

r
e
p
o
r
t
s

t
o

P
r
i
c
i
n
g

D
i
v
i
s
i
o
n

t
o

f
i
x
t
h
e

p
r
i
c
e
s

i
n

r
e
s
p
e
c
t

o
f

N
L
E
M

f
o
r
m
u
l
a
-
t
i
o
n
s
,

i
f

p
r
i
c
e

i
s

n
o
t

f
i
x
e
d
.
8
.
I
n
t
e
r
a
c
t
i
o
n
/

c
o
r
r
e
s
p
o
n
d
e
n
c
e

w
i
t
h

S
t
a
t
e
D
r
u
g
s

C
o
n
t
r
o
l
l
e
r
s

i
n

t
h
e

m
a
t
t
e
r

r
e
l
a
t
e
d

t
o
e
n
f
o
r
c
e
m
e
n
t

o
f

D
P
C
O

p
r
o
v
i
s
i
o
n
s
.
9
.
S
h
o
r
t
a
g
e

a
n
d

a
v
a
i
l
a
b
i
l
i
t
y

o
f

N
L
E
M

a
n
d
n
o
n
-
N
L
E
M

f
o
r
m
u
l
a
t
i
o
n
s
1
0
.
P
o
l
i
c
y

m
a
t
t
e
r

r
e
l
a
t
e
d

t
o

n
e
w

D
P
C
O
.
1
1
.
V
I
P

R
e
f
e
r
e
n
c
e
s
1
2
.
R
e
l
a
t
e
d

P
a
r
l
i
a
m
e
n
t

Q
u
e
s
t
i
o
n
s
/
m
a
t
t
e
r
s
.
D
i
r
e
c
t
o
r
O
v
e
r
c
h
a
r
g
i
n
g

D
i
v
i
s
i
o
n
1
.
I
s
s
u
e

n
o
t
i
c
e

t
o

t
h
e

c
o
m
-
p
a
n
i
e
s

f
o
r

o
v
e
r
c
h
a
r
g
i
n
g
a
n
d

s
u
b
s
e
q
u
e
n
t

f
o
l
l
o
w
u
p
.
2
.
I
s
s
u
e

s
h
o
w

c
a
u
s
e

n
o
-
t
i
c
e
,

w
o
r
k
i
n
g

o
u
t

t
h
e
o
v
e
r
c
h
a
r
g
e
d

a
m
o
u
n
t
a
n
d

r
a
i
s
e

d
e
m
a
n
d

f
o
r
r
e
c
o
v
e
r
y

o
f

t
h
e

o
v
e
r
-
c
h
a
r
g
e
d

a
m
o
u
n
t
.
3
.
R
e
c
o
v
e
r
y

o
f

o
v
e
r
-
c
h
a
r
g
e
d

a
m
o
u
n
t

u
n
d
e
r
D
P
C
O
,

1
9
9
5
.
4
.
G
r
a
n
t

p
e
r
s
o
n
a
l

h
e
a
r
i
n
g
a
n
d

p
a
s
s

s
p
e
a
k
i
n
g
/

r
e
a
-
s
o
n
e
d

o
r
d
e
r

w
h
e
n
e
v
e
r
n
e
e
d
e
d
.
5
.
E
x
a
m
i
n
a
t
i
o
n

o
f

o
t
h
e
r

i
s
-
s
u
e
s

r
e
l
a
t
e
d

t
o

o
v
e
r
-
c
h
a
r
g
i
n
g

u
n
d
e
r

D
P
C
O
,
2
0
1
3

f
o
r

r
e
c
o
v
e
r
y

o
f

t
h
e
o
v
e
r
c
h
a
r
g
e
d

a
m
o
u
n
t
.
6
.
E
x
a
m
i
n
a
t
i
o
n

o
f

o
t
h
e
r

i
s
-
s
u
e
s

r
e
l
a
t
e
d

t
o

o
v
e
r
-
c
h
a
r
g
i
n
g

u
n
d
e
r

D
P
C
O
,
1
9
9
5

f
o
r

r
e
c
o
v
e
r
y

o
f

t
h
e
o
v
e
r
c
h
a
r
g
e
d

a
m
o
u
n
t
.
7
.
E
x
a
m
i
n
a
t
i
o
n

o
f

o
t
h
e
r

i
s
-
s
u
e
s

r
e
l
a
t
e
d

t
o

o
v
e
r
-
c
h
a
r
g
i
n
g

u
n
d
e
r

D
P
C
O
,
1
9
8
7

f
o
r

r
e
c
o
v
e
r
y

o
f

t
h
e
o
v
e
r
c
h
a
r
g
e
d

a
m
o
u
n
t
.
8
.
P
r
o
v
i
d
i
n
g

i
n
p
u
t

t
o

L
e
g
a
l
D
i
v
i
s
i
o
n

f
o
r

c
o
u
r
t

c
a
s
e
s
.
9
.
R
e
l
a
t
e
d

P
a
r
l
i
a
m
e
n
t
Q
u
e
s
t
i
o
n
s
/
m
a
t
t
e
r
s
.
D
i
r
e
c
t
o
r
L
e
g
a
l

D
i
v
i
s
i
o
n
1
.
C
o
u
r
t

c
a
s
e
s

u
n
d
e
r
D
P
C
O
,

1
9
8
7

a
n
d
1
9
9
5
2
.
C
o
u
r
t

c
a
s
e
s

u
n
d
e
r
D
P
C
O
,

2
0
1
3
3
.
A
d
v
i
c
e

t
o

o
t
h
e
r

D
i
-
v
i
s
i
o
n
s

o
f

N
P
P
A
r
e
l
a
t
e
d

t
o

i
n
t
e
r
p
r
e
-
t
a
t
i
o
n

a
n
d

a
p
p
l
i
c
a
-
t
i
o
n
s

o
f

v
a
r
i
o
u
s
p
r
o
v
i
s
i
o
n
s

o
f
D
P
C
O
.
4
.
L
e
g
a
l

m
a
t
t
e
r
s

r
e
-
l
a
t
e
d

t
o

e
s
t
a
b
l
i
s
h
-
m
e
n
t

m
a
t
t
e
r
s

/
N
P
P
A
'
s
a
c
c
o
m
o
d
a
t
i
o
n
5
.
N
P
P
A
'
s

w
o
r
k
i
n
g
g
u
i
d
e
l
i
n
e
s
/

p
r
o
c
e
-
d
u
r
e
s

e
t
c
.
6
.
L
a
u
n
c
h
i
n
g

p
r
o
s
-
e
c
u
t
i
o
n

a
g
a
i
n
s
t
t
h
e

d
e
f
a
u
l
t
i
n
g
c
o
m
p
a
n
i
e
s

f
o
r

v
i
o
-
l
a
t
i
o
n

o
f

t
h
e

p
r
o
v
i
-
s
i
o
n
s

o
f

D
P
C
O
.
7
.
R
e
l
a
t
e
d

P
a
r
l
i
a
-
m
e
n
t

Q
u
e
s
t
i
o
n
s
/
m
a
t
t
e
r
s
.
D
i
r
e
c
t
o
r
A
d
m
n
.

D
i
v
i
s
i
o
n
1
.
E
s
t
a
b
l
i
s
h
m
e
n
t
m
a
t
t
e
r
s
2
.
G
e
n
e
r
a
l

A
d
m
n
.
3
.
C
a
s
h
/
B
u
d
g
e
t
4
.
C
o
o
r
d
i
n
a
t
i
o
n
5
.
R

&

I

S
e
c
t
i
o
n
6
.
V
i
g
i
l
a
n
c
e
7
.
W
o
r
k

r
e
l
a
t
e
d

t
o
P
a
r
l
i
a
m
e
n
t

C
o
m
-
m
i
t
t
e
e
s
8
.
C
o
n
s
o
l
i
d
a
t
i
o
n
a
n
d

c
o
m
p
i
l
a
t
i
o
n
o
f

P
a
r
l
i
a
m
e
n
t
q
u
e
s
t
i
o
n
s
/

r
e
p
l
y
/
m
a
t
t
e
r
s
.
9
.
I
S
O

A
u
d
i
t
1
0
.
A
n
y

o
t
h
e
r

s
u
b
-
j
e
c
t
s

n
o
t

l
i
s
t
e
d
e
l
s
e
w
h
e
r
e
.
C
h
a
i
r
m
a
n
N
P
P
A
M
e
m
b
e
r

S
e
c
r
e
t
a
r
y
A
d
v
i
s
o
r
113
ANNEXURE V
RFD for the year 2011-12 (Ref. Chapter 10)
Section 1:
Vision, Mission, Objectives and Functions
Results-Framework Document (RFD) for Department of Pharmaceuticals-(2011-2012)
India: The Largest Global Provider of Quality Medicines at Reasonable Prices.
Mission
Ensure availability of quality drugs at reasonable prices as per the Pharma Policy.Development of Pharma Infrastructure
and Innovative Development in Pharma Sector including through PPP.Promote Pharma Brand IndiaEncourage
environmentally sustainable development of Pharmaceutical Industry
Objective
1 Ensure availability of drugs at reasonable prices as per the Pharma policy
2 .Facilitate growth of Central pharma PSUs with required support
3 Develop Pharma Infrastructure and Catalyze Drug Discovery and Innovation
4 Launch and Position Pharma India Brand
5 Develop Pharma Human Resources through M.Pharma and Ph.D programmes in NIPERS
6 Provide Infrastructure and staff for new NIPERs
7 Strengthening of NIPER Mohail
8 Jan Aushadi Campaign and implementation of Business Plan for setting up of 3000 Jan Aushadhi Stores (upto Subdivision
level in the country)
9 Incentivising Private Sector for development of new Drugs for diseases endemic to India
Functions
Drugs and Pharmaceuticals, excluding those specifically allotted to other departments 1
Promotion and co-ordination of basic, applied and other research 2
Development of infrastructure, manpower and skills 3
Education and training including high end research and grant of fellowships in India and abroad and technical guidance 4
Promotion of Public Private Partnership 5
International cooperation in pharmaceutical research, including work related to international conferences in India and abroad 6
Inter-sectoral coordination including coordination between organizations and institutes under the Central and State Governments 7
Vision
page : 2 of 18 Generated on : 14/02/2012
114
Section 1:
Vision, Mission, Objectives and Functions
Results-Framework Document (RFD) for Department of Pharmaceuticals-(2011-2012)
Technical support for dealing with national hazards in pharma sector. 8
All matters relating to National Pharmaceuticals Pricing Authority including related functions of price control/monitoring. 9
All matters relating to National Institutes for Pharmacy Education and Research. 10
Planning, development and control of; and assistance to, all industries dealt with by the Department 11
CPSUs: BCPL, HAL, IDPL, KAPL & RDPL 12
115
S
e
c
t
i
o
n

2
:
I
n
t
e
r

s
e

P
r
i
o
r
i
t
i
e
s

a
m
o
n
g

K
e
y

O
b
j
e
c
t
i
v
e
s
,

S
u
c
c
e
s
s

i
n
d
i
c
a
t
o
r
s

a
n
d

T
a
r
g
e
t
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
b
j
e
c
t
i
v
e
W
e
i
g
h
t
A
c
t
i
o
n
U
n
i
t

T
a
r
g
e
t

/

C
r
i
t
e
r
i
a

V
a
l
u
e
W
e
i
g
h
t

8
0
%
1
0
0
%

7
0
%

6
0
%
9
0
%
V
e
r
y

G
o
o
d

F
a
i
r

P
o
o
r
E
x
c
e
l
l
e
n
t

G
o
o
d
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
E
n
s
u
r
e

a
v
a
i
l
a
b
i
l
i
t
y

o
f

d
r
u
g
s

a
t

r
e
a
s
o
n
a
b
l
e
p
r
i
c
e
s

a
s

p
e
r

t
h
e

P
h
a
r
m
a

p
o
l
i
c
y
3
.
0
0
P
r
o
c
e
s
s
i
n
g

o
f

n
e
w

r
e
v
i
e
w
a
p
p
l
i
c
a
t
i
o
n
s

u
n
d
e
r

D
P
C
O
r
e
c
e
i
v
e
d

u
p
t
o

3
1
.
1
.
2
0
1
2

f
o
r
o
r
d
e
r
s

b
y

c
o
m
p
e
t
e
n
t
a
u
t
h
o
r
i
t
y
N
o
.
o
f

r
e
v
i
e
w
a
p
p
l
i
c
a
t
i
o
n
s
d
i
s
p
o
s
e
d

i
n

9
0

d
a
y
s
o
f

r
e
c
e
i
p
t

i
n

t
h
e
D
e
p
a
r
t
m
e
n
t
d
a
y
s

a
n
d
%
9
0
1
1
0
1
2
0
1
0
0
8
0
3
.
0
0
[
1
]
[
1
.
1
]
[
1
.
1
.
1
]
.
F
a
c
i
l
i
t
a
t
e

g
r
o
w
t
h

o
f

C
e
n
t
r
a
l

p
h
a
r
m
a

P
S
U
s
w
i
t
h

r
e
q
u
i
r
e
d

s
u
p
p
o
r
t
1
8
.
0
0
P
r
o
v
i
d
i
n
g

a
s
s
i
s
t
a
n
c
e

t
o
C
e
n
t
r
a
l

P
h
a
r
m
a

P
S
U
s

a
s
p
e
r

M
O
U

o
b
l
i
g
a
t
i
o
n
A
c
h
i
e
v
e
m
e
n
t

o
f
d
e
s
i
r
e
d

r
e
s
u
l
t
s

a
s
e
n
v
i
s
a
g
e
d

t
h
r
o
u
g
h
a
s
s
i
s
t
a
n
c
e
%
9
0
6
0
5
0
8
0
1
0
0
3
.
0
0
[
2
]
[
2
.
1
]
[
2
.
1
.
1
]
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
P
S
U
s

f
o
r

W
H
O

-

G
M
P
c
o
m
p
l
i
a
n
c
e

A
s
s
i
s
t
a
n
c
e
S
c
h
e
m
e
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
%
9
0
6
0
5
0
8
0
1
0
0
3
.
0
0
[
2
.
2
]
[
2
.
2
.
1
]
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
H
A
L

f
o
r

t
a
k
i
n
g
u
p
/
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f
E
r
y
t
h
r
o
m
i
c
i
n

P
r
o
j
e
c
t
,

M
u
l
t
i
P
r
o
d
u
c
t

S
t
e
r
i
l
e

f
a
c
i
l
i
t
i
e
s

f
o
r
B
e
t
a
l
a
c
t
u
m

A
n
t
i
b
i
o
t
i
c
s

a
n
d
L
a
r
g
e

V
o
l
u
m

P
a
r
e
n
t
e
r
a
l
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
%
9
0
6
0
5
0
8
0
1
0
0
2
.
0
0
[
2
.
3
]
[
2
.
3
.
1
]
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
B
C
P
L

f
o
r

I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f
P
r
o
j
e
c
t
s

u
n
d
e
r
t
a
k
e
n

i
n
R
e
v
i
v
a
l

S
c
h
e
m
e
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
%
9
0
6
0
5
0
8
0
1
0
0
2
.
0
0
[
2
.
4
]
[
2
.
4
.
1
]
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
R
D
P
L

f
o
r

t
h
e

p
r
o
j
e
c
t
s

f
o
r
W
H
O
-
G
M
P

C
o
m
p
l
i
a
n
c
e
(
C
a
p
i
t
a
l

S
u
p
p
o
r
t
)
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
%
9
0
6
0
5
0
8
0
1
0
0
2
.
0
0
[
2
.
5
]
[
2
.
5
.
1
]
R
e
v
i
v
a
l

o
f

I
D
P
L
T
o

t
a
k
e

f
i
n
a
l

v
i
e
w
D
a
t
e
3
1
/
0
8
/
2
0
1
1
3
1
/
1
0
/
2
0
1
1
3
0
/
1
1
/
2
0
1
1
3
0
/
0
9
/
2
0
1
1
3
0
/
0
6
/
2
0
1
1
2
.
0
0
[
2
.
6
]
[
2
.
6
.
1
]
A
p
p
r
o
v
a
l

f
r
o
m

t
h
e
C
a
b
i
n
e
t
/
C
C
E
A
D
a
t
e
3
1
/
0
1
/
2
0
1
2
2
8
/
0
2
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
1
5
/
0
2
/
2
0
1
2
3
1
/
1
2
/
2
0
1
1
2
.
0
0
[
2
.
6
.
2
]
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
%
9
0
6
0
5
0
8
0
1
0
0
2
.
0
0
[
2
.
6
.
3
]
p
a
g
e

:

4

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
116
S
e
c
t
i
o
n

2
:
I
n
t
e
r

s
e

P
r
i
o
r
i
t
i
e
s

a
m
o
n
g

K
e
y

O
b
j
e
c
t
i
v
e
s
,

S
u
c
c
e
s
s

i
n
d
i
c
a
t
o
r
s

a
n
d

T
a
r
g
e
t
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
b
j
e
c
t
i
v
e
W
e
i
g
h
t
A
c
t
i
o
n
U
n
i
t

T
a
r
g
e
t

/

C
r
i
t
e
r
i
a

V
a
l
u
e
W
e
i
g
h
t

8
0
%
1
0
0
%

7
0
%

6
0
%
9
0
%
V
e
r
y

G
o
o
d

F
a
i
r

P
o
o
r
E
x
c
e
l
l
e
n
t

G
o
o
d
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
D
e
v
e
l
o
p

P
h
a
r
m
a

I
n
f
r
a
s
t
r
u
c
t
u
r
e

a
n
d

C
a
t
a
l
y
z
e
D
r
u
g

D
i
s
c
o
v
e
r
y

a
n
d

I
n
n
o
v
a
t
i
o
n
1
5
.
0
0
D
e
v
e
l
o
p
m
e
n
t

o
f

n
e
w

d
r
u
g
s
f
o
r

T
B

&

K
a
l
a
z
a
r

b
y

N
I
P
E
R
A
p
p
r
o
v
a
l

o
f

s
c
h
e
m
e
f
o
r

d
e
v
e
l
o
p
m
e
n
t

o
f
n
e
w

d
r
u
g
s

b
y
N
I
P
E
R

i
n
c
l
u
d
i
n
g
P
P
P
/

J
o
i
n
t
C
o
l
l
a
b
o
r
a
t
i
o
n
D
a
t
e
1
5
/
0
2
/
2
0
1
2
1
5
/
0
3
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
2
8
/
0
2
/
2
0
1
2
3
1
/
0
1
/
2
0
1
2
4
.
0
0
[
3
]
[
3
.
1
]
[
3
.
1
.
1
]
F
i
n
a
l
i
z
a
t
i
o
n

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

f
o
r

W
o
r
l
d
C
l
a
s
s

P
h
a
r
m
a
I
n
f
r
a
s
t
r
u
c
t
u
r
e
,

F
i
n
a
l
i
z
a
t
i
o
n
o
f

S
c
h
e
m
e
/
P
r
o
j
e
c
t

f
o
r

R
&
D
a
n
d

F
i
n
a
l
i
z
a
t
i
o
n

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

f
o
r

I
n
d
u
s
t
r
y
s
u
p
p
o
r
t

f
o
r
W
H
O
/
I
n
t
e
r
n
a
t
i
o
n
a
l
S
t
a
n
d
a
r
d
s

M
a
n
u
f
a
c
t
u
r
i
n
g
s
o

a
s

t
o

c
a
t
a
l
y
z
e

t
h
e
G
r
o
w
t
h

o
f

P
h
a
r
m
a

I
n
d
u
s
t
r
y
A
p
p
r
o
v
a
l

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

b
y
P
l
a
n
n
i
n
g
C
o
m
m
i
s
s
i
o
n

f
o
r
s
u
p
p
o
r
t
i
n
g
I
n
t
e
r
n
a
t
i
o
n
a
l
S
t
a
n
d
a
r
d
M
a
n
u
f
a
c
t
u
r
i
n
g
-
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
T
e
c
h
n
o
l
o
g
y
U
p
g
r
a
d
a
t
i
o
n
A
s
s
i
s
t
a
n
c
e

S
c
h
e
m
e
(
P
T
U
A
S
)
D
a
t
e
1
5
/
0
2
/
2
0
1
2
1
5
/
0
3
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
2
8
/
0
2
/
2
0
1
2
3
1
/
0
1
/
2
0
1
2
3
.
0
0
[
3
.
2
]
[
3
.
2
.
1
]
R
e
c
e
i
p
t

o
f

p
r
o
j
e
c
t
r
e
p
o
r
t
s

f

r
o
m

t
h
e
c
o
n
s
u
l
a
n
t
s

f
o
r
d
e
v
e
l
o
p
i
n
g
i
n
f
r
a
s
t
r
u
c
t
u
r
e

f
o
r
P
h
a
r
m
a

R
&
D

(
G
L
P
C
o
m
p
l
i
a
n
t
l
a
b
s
/
A
n
i
m
a
l

H
o
u
s
e
)
D
a
t
e
1
5
/
0
2
/
2
0
1
2
2
1
/
0
3
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
1
5
/
0
3
/
2
0
1
2
1
5
/
0
1
/
2
0
1
2
4
.
0
0
[
3
.
2
.
2
]
A
p
p
r
o
v
a
l

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

b
y
t
h
e

P
l
a
n
n
i
n
g
C
o
m
m
i
s
s
i
o
n

f
o
r
D
e
v
e
l
o
p
m
e
n
t

o
f
I
n
f
r
a
s
t
r
u
c
t
u
r
e

a
s
p
e
r

d
e
t
a
i
l
e
d

p
r
o
j
e
c
t
r
e
p
o
r
t

t
o

b
e
s
u
b
m
i
t
t
e
d

b
y

t
h
e
g
l
o
b
a
l

l
e
v
e
l
c
o
n
s
u
l
t
a
n
t
D
a
t
e
1
5
/
0
2
/
2
0
1
2
1
5
/
0
3
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
2
8
/
0
2
/
2
0
1
2
3
1
/
0
1
/
2
0
1
2
4
.
0
0
[
3
.
2
.
3
]
p
a
g
e

:

5

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
117
S
e
c
t
i
o
n

2
:
I
n
t
e
r

s
e

P
r
i
o
r
i
t
i
e
s

a
m
o
n
g

K
e
y

O
b
j
e
c
t
i
v
e
s
,

S
u
c
c
e
s
s

i
n
d
i
c
a
t
o
r
s

a
n
d

T
a
r
g
e
t
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
b
j
e
c
t
i
v
e
W
e
i
g
h
t
A
c
t
i
o
n
U
n
i
t

T
a
r
g
e
t

/

C
r
i
t
e
r
i
a

V
a
l
u
e
W
e
i
g
h
t

8
0
%
1
0
0
%

7
0
%

6
0
%
9
0
%
V
e
r
y

G
o
o
d

F
a
i
r

P
o
o
r
E
x
c
e
l
l
e
n
t

G
o
o
d
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
L
a
u
n
c
h

a
n
d

P
o
s
i
t
i
o
n

P
h
a
r
m
a

I
n
d
i
a

B
r
a
n
d
7
.
0
0
L
a
u
n
c
h

a
n
d

P
o
s
i
t
i
o
n
P
h
a
r
m
a

I
n
d
i
a

b
r
a
n
d

i
n
t
a
r
g
e
t

c
o
u
n
t
r
i
e
s
L
a
u
n
c
h

a
n
d

P
o
s
i
t
i
o
n
P
h
a
r
m
a

I
n
d
i
a

B
r
a
n
d
i
n

t
a
r
g
e
t

c
o
u
n
t
r
i
e
s

i
n
a

p
h
a
s
e
d

m
a
n
n
e
r
a
f
t
e
r

r
e
c
e
i
v
i
n
g

i
n
p
r
i
n
c
i
p
l
e

a
p
p
r
o
v
a
l
f
r
o
m

P
l
a
n
n
i
n
g
C
o
m
m
i
s
s
i
o
n
D
a
t
e
0
7
/
0
3
/
2
0
1
2
2
1
/
0
3
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
1
5
/
0
3
/
2
0
1
2
2
8
/
0
2
/
2
0
1
2
2
.
0
0
[
4
]
[
4
.
1
]
[
4
.
1
.
1
]
F
o
l
l
o
w

u
p

a
c
t
i
o
n

o
f

S
e
c
o
n
d
I
n
d
i
a

P
h
a
r
m
a

S
u
m
m
i
t

h
e
l
d
i
n

N
o
v
e
m
b
e
r

2
0
1
0
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

2
F
i
n
a
l
i
z
e
d

p
r
o
p
o
s
a
l
s
f
o
r

f
o
l
l
o
w

u
p

a
c
t
i
o
n
o
f

p
h
a
r
m
a

s
u
m
m
i
t
2
0
1
0
:
:
1

A

S
e
m
i
n
a
r

o
n
r
e
g
u
l
a
t
o
r
y

i
s
s
u
e
s

o
n
m
e
d
i
c
a
l

d
e
v
i
c
e
s
.
.
.
2

A

T
a
s
k

f
o
r
c
e

f
o
r
r
e
p
o
r
t

o
n

d
r
u
g
d
i
s
c
o
v
e
r
y
,

w
i
t
h

f
o
c
u
s
o
n

r
e
g
u
l
a
t
o
r
y

i
s
s
u
e
s
o
f

c
l
i
n
i
c
a
l

t
r
i
a
l
s

i
n
I
n
d
i
a
D
a
t
e
3
1
/
1
2
/
2
0
1
1
2
8
/
0
2
/
2
0
1
1
3
1
/
0
3
/
2
0
1
2
3
1
/
0
1
/
2
0
1
2
3
0
/
1
1
/
2
0
1
1
5
.
0
0
[
4
.
2
]
[
4
.
2
.
1
]
D
e
v
e
l
o
p

P
h
a
r
m
a

H
u
m
a
n

R
e
s
o
u
r
c
e
s

t
h
r
o
u
g
h
M
.
P
h
a
r
m
a

a
n
d

P
h
.
D

p
r
o
g
r
a
m
m
e
s

i
n
N
I
P
E
R
S
1
4
.
0
0
I
n
t
a
k
e

o
f

s
t
u
d
e
n
t
s

f
o
r
M
a
s
t
e
r
s

a
n
d

P
h
.
D

d
e
g
r
e
e
s
b
y

N
I
P
E
R
,

M
o
h
a
l
i
:
P
h
D
-
4
6
,
M
S
-
2
5
0
,
M
B
A
-
6
1
;
%
9
0
7
0
6
0
8
0
1
0
0
2
.
0
0
[
5
]
[
5
.
1
]
[
5
.
1
.
1
]
I
n
t
a
k
e

o
f

s
t
u
d
e
n
t
s

f
o
r
M
a
s
t
e
r
s

d
e
g
r
e
s
s

b
y

N
e
w
N
I
P
E
R
s
A
h
m
e
d
a
b
a
d
-

6
,
G
u
w
a
h
a
t
i
-

4
0
,
H
a
j
i
p
u
r
-

4
6
,
.
H
y
d
e
r
a
b
a
d
-

7
5
,
K
o
l
k
a
t
a

-

5
0
,

R
a
i
B
a
r
e
l
i

-

3
5
%
9
0
7
0
6
0
8
0
1
0
0
1
2
.
0
0
[
5
.
2
]
[
5
.
2
.
1
]
P
r
o
v
i
d
e

I
n
f
r
a
s
t
r
u
c
t
u
r
e

a
n
d

s
t
a
f
f

f
o
r

n
e
w
N
I
P
E
R
s
6
.
0
0
P
r
e
p
a
r
a
t
i
o
n

a
n
d

A
p
p
r
o
v
a
l
o
f

C
a
b
i
n
e
t

N
o
t
e
s

f
o
r
e
s
t
a
b
l
i
s
h
m
e
n
t

o
f

N
e
w
N
I
P
E
R
s

b
y

t
h
e
A
p
p
r
o
v
a
l

o
f

t
h
e
C
a
b
i
n
e
t
D
a
t
e
1
4
/
0
5
/
2
0
1
1
0
1
/
0
6
/
2
0
1
2
1
5
/
0
7
/
2
0
1
2
3
0
/
0
4
/
2
0
1
1
2
1
/
0
4
/
2
0
1
1
2
.
0
0
[
6
]
[
6
.
1
]
[
6
.
1
.
1
]
p
a
g
e

:

6

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
118
S
e
c
t
i
o
n

2
:
I
n
t
e
r

s
e

P
r
i
o
r
i
t
i
e
s

a
m
o
n
g

K
e
y

O
b
j
e
c
t
i
v
e
s
,

S
u
c
c
e
s
s

i
n
d
i
c
a
t
o
r
s

a
n
d

T
a
r
g
e
t
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
b
j
e
c
t
i
v
e
W
e
i
g
h
t
A
c
t
i
o
n
U
n
i
t

T
a
r
g
e
t

/

C
r
i
t
e
r
i
a

V
a
l
u
e
W
e
i
g
h
t

8
0
%
1
0
0
%

7
0
%

6
0
%
9
0
%
V
e
r
y

G
o
o
d

F
a
i
r

P
o
o
r
E
x
c
e
l
l
e
n
t

G
o
o
d
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
E
f
f
i
c
i
e
n
t

F
u
n
c
t
i
o
n
i
n
g

o
f

t
h
e

R
F
D

S
y
s
t
e
m
3
.
0
0
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

D
r
a
f
t

f
o
r
A
p
p
r
o
v
a
l
O
n
-
t
i
m
e

s
u
b
m
i
s
s
i
o
n
D
a
t
e
0
8
/
0
3
/
2
0
1
1
1
0
/
0
3
/
2
0
1
1
1
1
/
0
3
/
2
0
1
1
0
9
/
0
3
/
2
0
1
1
0
7
/
0
3
/
2
0
1
1
2
.
0
*
*

M
a
n
d
a
t
o
r
y

O
b
j
e
c
t
i
v
e
(
s
)
C
a
b
i
n
e
t
C
o
n
s
t
i
t
u
t
i
o
n

o
f

B
o
G

o
f

N
e
w
N
I
P
E
R
s

a
n
d

i
s
s
u
e

o
f

o
r
d
e
r
o
f

c
o
n
s
t
i
t
u
t
i
o
n

o
f

B
O
G
I
s
s
u
e

o
f

O
r
d
e
r

o
f
c
o
n
s
t
i
t
u
t
i
o
n

o
f

B
O
G
D
a
t
e
1
5
/
1
0
/
2
0
1
1
0
7
/
1
1
/
2
0
1
1
1
5
/
1
2
/
2
0
1
1
3
1
/
1
0
/
2
0
1
1
1
5
/
0
9
/
2
0
1
1
2
.
0
0
[
6
.
2
]
[
6
.
2
.
1
]
A
p
p
o
i
n
t
m
e
n
t

o
f

D
i
r
e
c
t
o
r
s

o
f
N
e
w

N
I
P
E
R
s

b
y

f
i
l
l
i
n
g

u
p

o
f
p
o
s
t
s

o
f

D
i
r
e
c
t
o
r
s
.
I
s
s
u
e

o
f
A
d
v
e
r
t
i
s
e
m
e
n
t

i
n
N
e
w
s

P
a
p
e
r
s
,
s
e
l
e
c
t
i
o
n

o
f
D
i
r
e
c
t
o
r
s

a
n
d

i
s
s
u
e
o
f

a
p
p
o
i
n
t
m
e
n
t

l
e
t
t
e
r
D
a
t
e
1
5
/
1
2
/
2
0
1
1
2
1
/
0
1
/
2
0
1
2
0
7
/
0
2
/
2
0
1
2
3
1
/
1
2
/
2
0
1
1
1
5
/
1
1
/
2
0
1
1
2
.
0
0
[
6
.
3
]
[
6
.
3
.
1
]
S
t
r
e
n
g
t
h
e
n
i
n
g

o
f

N
I
P
E
R

M
o
h
a
i
l
2
.
0
0
C
o
n
s
t
i
t
u
t
i
o
n

o
f

B
o
G

o
f
N
I
P
E
R
s

a
n
d

i
s
s
u
e

o
f

o
r
d
e
r
o
f

c
o
n
s
t
i
t
u
t
i
o
n

o
f

B
O
G
I
s
s
u
e

o
f

O
r
d
e
r

o
f
c
o
n
s
t
i
t
u
t
i
o
n

o
f

B
O
G
.
D
a
t
e
1
5
/
0
5
/
2
0
1
1
0
7
/
0
7
/
2
0
1
1
1
5
/
0
7
/
2
0
1
1
1
5
/
0
6
/
2
0
1
1
3
0
/
0
4
/
2
0
1
1
2
.
0
0
[
7
]
[
7
.
1
]
[
7
.
1
.
1
]
J
a
n

A
u
s
h
a
d
i

C
a
m
p
a
i
g
n

a
n
d

i
m
p
l
e
m
e
n
t
a
t
i
o
n
o
f

B
u
s
i
n
e
s
s

P
l
a
n

f
o
r

s
e
t
t
i
n
g

u
p

o
f

3
0
0
0

J
a
n
A
u
s
h
a
d
h
i

S
t
o
r
e
s

(
u
p
t
o

S
u
b
d
i
v
i
s
i
o
n

l
e
v
e
l

i
n
t
h
e

c
o
u
n
t
r
y
)
1
2
.
0
0
f
r
a
m
i
n
g

o
f

p
r
o
p
o
s
a
l

a
n
d

i
n
p
r
i
n
c
i
p
a
l

a
p
p
r
o
v
a
l

o
f
P
l
a
n
n
i
n
g

C
o
m
m
i
s
s
i
o
n
A
c
h
i
e
v
e
m
e
n
t

o
f
d
e
s
i
r
e
d

r
e
s
u
l
t
D
a
t
e
3
1
/
1
0
/
2
0
1
1
3
1
/
0
1
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
3
0
/
1
1
/
2
0
1
1
3
1
/
0
8
/
2
0
1
1
3
.
0
0
[
8
]
[
8
.
1
]
[
8
.
1
.
1
]
I
n
t
e
r
a
c
t
i
o
n

w
i
t
h

S
t
a
t
e
G
o
v
e
r
n
m
e
n
t
s

a
n
d

s
e
t
t
i
n
g
u
p

o
f

J
a
n

A
u
s
h
a
d
i

S
t
o
r
e
s
S
e
t
t
i
n
g

u
p

o
f

1
0
0
s
t
o
r
e
s
%
8
0
5
0
4
0
6
0
1
0
0
7
.
0
0
[
8
.
2
]
[
8
.
2
.
1
]
P
r
e
p
a
r
e
d
n
e
s
s

o
f

C
P
S
U
s
e
t
c
.

f
o
r

t
h
e

s
u
p
p
l
y

c
h
a
i
n
m
a
n
a
g
e
m
e
n
t
T
i
m
e
l
y

s
u
p
p
l
y

o
f
M
e
d
i
c
i
n
e
s

o
f

J
a
n
A
u
s
h
a
d
h
i

S
t
o
r
e
s
%
8
0
5
0
4
0
6
0
1
0
0
2
.
0
0
[
8
.
3
]
[
8
.
3
.
1
]
I
n
c
e
n
t
i
v
i
s
i
n
g

P
r
i
v
a
t
e

S
e
c
t
o
r

f
o
r

d
e
v
e
l
o
p
m
e
n
t
o
f

n
e
w

D
r
u
g
s

f
o
r

d
i
s
e
a
s
e
s

e
n
d
e
m
i
c

t
o

I
n
d
i
a
8
.
0
0
S
e
t
t
i
n
g

u
p

o
f

v
e
n
t
u
r
e

f
u
n
d
A
p
p
r
o
v
a
l

o
f

s
c
h
e
m
e
/
p
r
o
p
o
s
a
l

b
y
P
l
a
n
n
i
n
g

C
o
m
m
i
s
i
o
n
D
a
t
e
2
8
/
0
2
/
2
0
1
2
2
1
/
0
3
/
2
0
1
2
3
1
/
0
3
/
2
0
1
2
1
5
/
0
3
/
2
0
1
2
3
1
/
0
1
/
2
0
1
2
8
.
0
0
[
9
]
[
9
.
1
]
[
9
.
1
.
1
]
p
a
g
e

:

7

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
119
S
e
c
t
i
o
n

2
:
I
n
t
e
r

s
e

P
r
i
o
r
i
t
i
e
s

a
m
o
n
g

K
e
y

O
b
j
e
c
t
i
v
e
s
,

S
u
c
c
e
s
s

i
n
d
i
c
a
t
o
r
s

a
n
d

T
a
r
g
e
t
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
b
j
e
c
t
i
v
e
W
e
i
g
h
t
A
c
t
i
o
n
U
n
i
t

T
a
r
g
e
t

/

C
r
i
t
e
r
i
a

V
a
l
u
e
W
e
i
g
h
t

8
0
%
1
0
0
%

7
0
%

6
0
%
9
0
%
V
e
r
y

G
o
o
d

F
a
i
r

P
o
o
r
E
x
c
e
l
l
e
n
t

G
o
o
d
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

R
e
s
u
l
t
s
O
n
-

t
i
m
e

s
u
b
m
i
s
s
i
o
n
D
a
t
e
0
3
/
0
5
/
2
0
1
2
0
5
/
0
5
/
2
0
1
2
0
6
/
0
5
/
2
0
1
2
0
4
/
0
5
/
2
0
1
2
0
1
/
0
5
/
2
0
1
2
1
.
0
I
m
p
r
o
v
i
n
g

I
n
t
e
r
n
a
l

E
f
f
i
c
i
e
n
c
y

/
R
e
s
p
o
n
s
i
v
e
n
e
s
s

/

S
e
r
v
i
c
e

d
e
l
i
v
e
r
y

o
f
M
i
n
i
s
t
r
y

/

D
e
p
a
r
t
m
e
n
t
1
0
.
0
0
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

S
e
v
o
t
t
a
m
R
e
s
u
b
m
i
s
s
i
o
n

o
f

r
e
v
i
s
e
d
d
r
a
f
t

o
f

C
i
t
i
z
e
n
s

/

C
l
i
e
n
t
s
C
h
a
r
t
e
r
D
a
t
e
2
0
/
1
2
/
2
0
1
1
2
8
/
1
2
/
2
0
1
1
3
1
/
1
2
/
2
0
1
1
2
5
/
1
2
/
2
0
1
1
1
5
/
1
2
/
2
0
1
1
2
.
0
*
I
n
d
e
p
e
n
d
e
n
t

A
u
d
i
t

o
f
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f
G
r
i
e
v
a
n
c
e

R
e
d
r
e
s
s
M
e
c
h
a
n
i
s
m
%
9
5
8
5
8
0
9
0
1
0
0
2
.
0
E
n
s
u
r
e

c
o
m
p
l
i
a
n
c
e

w
i
t
h

S
e
c
t
i
o
n
4
(
1
)

(
b
)

o
f

t
h
e

R
T
I

A
c
t
,

2
0
0
5
N
o
.

o
f

i
t
e
m
s

o
n

w
h
i
c
h
i
n
f
o
r
m
a
t
i
o
n

i
s

u
p
l
o
a
d
e
d

b
y
F
e
b
r
u
a
r
y

1
0
,

2
0
1
2
N
o
1
5
1
3
1
2
1
4
1
6
2
.
0
I
d
e
n
t
i
f
y

p
o
t
e
n
t
i
a
l

a
r
e
a
s

o
f
c
o
r
r
u
p
t
i
o
n

r
e
l
a
t
e
d

t
o
d
e
p
a
r
t
m
e
n
t
a
l

a
c
t
i
v
i
t
i
e
s

a
n
d
d
e
v
e
l
o
p

a
n

a
c
t
i
o
n

p
l
a
n

t
o
m
i
t
i
g
a
t
e

t
h
e
m
F
i
n
a
l
i
z
e

a
n

a
c
t
i
o
n

p
l
a
n

t
o
m
i
t
i
g
a
t
e

p
o
t
e
n
t
i
a
l

a
r
e
a
s

o
f
c
o
r
r
u
p
t
i
o
n
.
D
a
t
e
1
5
/
0
2
/
2
0
1
2
2
4
/
0
2
/
2
0
1
2
2
9
/
0
2
/
2
0
1
2
2
0
/
0
2
/
2
0
1
2
1
0
/
0
2
/
2
0
1
2
2
.
0
D
e
v
e
l
o
p

a
n

a
c
t
i
o
n

p
l
a
n

t
o
i
m
p
l
e
m
e
n
t

I
S
O

9
0
0
1

c
e
r
t
i
f
i
c
a
t
i
o
n
F
i
n
a
l
i
z
e

a
n

a
c
t
i
o
n

p
l
a
n

t
o
i
m
p
l
e
m
e
n
t

I
S
O

9
0
0
1
c
e
r
t
i
f
i
c
a
t
i
o
n
D
a
t
e
1
5
/
0
2
/
2
0
1
2
2
4
/
0
2
/
2
0
1
2
2
9
/
0
2
/
2
0
1
2
2
0
/
0
2
/
2
0
1
2
1
0
/
0
2
/
2
0
1
2
2
.
0
E
n
s
u
r
i
n
g

c
o
m
p
l
i
a
n
c
e

t
o

t
h
e

F
i
n
a
n
c
i
a
l
A
c
c
o
u
n
t
a
b
i
l
i
t
y

F
r
a
m
e
w
o
r
k
2
.
0
0
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

A
T
N
S

o
n
A
u
d
i
t

P
a
r
a
s

o
f

C
&
A
G
P
e
r
c
e
n
t
a
g
e

o
f

A
T
N
S
s
u
b
m
i
t
t
e
d

w
i
t
h
i
n

d
u
e

d
a
t
e

(
4
m
o
n
t
h
s
)

f
r
o
m

d
a
t
e

o
f
p
r
e
s
e
n
t
a
t
i
o
n

o
f

R
e
p
o
r
t

t
o
P
a
r
l
i
a
m
e
n
t

b
y

C
A
G

d
u
r
i
n
g
t
h
e

y
e
a
r
.
%
9
0
7
0
6
0
8
0
1
0
0
0
.
5
*
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

A
T
R
s

t
o
t
h
e

P
A
C

S
e
c
t
t
.

o
n

P
A
C

R
e
p
o
r
t
s
.
P
e
r
c
e
n
t
g
e

o
f

A
T
R
s
s
u
b
m
i
t
t
e
d

w
i
t
h
i
n

d
u
e

d
a
t
e

(
6
m
o
n
t
h
s
)

f
r
o
m

d
a
t
e

o
f
p
r
e
s
e
n
t
a
t
i
o
n

o
f

R
e
p
o
r
t

t
o
P
a
r
l
i
a
m
e
n
t

b
y

P
A
C

d
u
r
i
n
g
t
h
e

y
e
a
r
.
%
9
0
7
0
6
0
8
0
1
0
0
0
.
5
E
a
r
l
y

d
i
s
p
o
s
a
l

o
f

p
e
n
d
i
n
g

A
T
N
s
o
n

A
u
d
i
t

P
a
r
a
s

o
f

C
&
A
G

R
e
p
o
r
t
s
p
r
e
s
e
n
t
e
d

t
o

P
a
r
l
i
a
m
e
n
t

b
e
f
o
r
e
3
1
.
3
.
2
0
1
1
.
P
e
r
c
e
n
t
a
g
e

o
f

o
u
t
s
t
a
n
d
i
n
g
A
T
N
s

d
i
s
p
o
s
e
d

o
f
f

d
u
r
i
n
g
t
h
e

y
e
a
r
.
%
9
0
7
0
6
0
8
0
1
0
0
0
.
5
*

M
a
n
d
a
t
o
r
y

O
b
j
e
c
t
i
v
e
(
s
)
p
a
g
e

:

8

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
120
S
e
c
t
i
o
n

2
:
I
n
t
e
r

s
e

P
r
i
o
r
i
t
i
e
s

a
m
o
n
g

K
e
y

O
b
j
e
c
t
i
v
e
s
,

S
u
c
c
e
s
s

i
n
d
i
c
a
t
o
r
s

a
n
d

T
a
r
g
e
t
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
b
j
e
c
t
i
v
e
W
e
i
g
h
t
A
c
t
i
o
n
U
n
i
t

T
a
r
g
e
t

/

C
r
i
t
e
r
i
a

V
a
l
u
e
W
e
i
g
h
t

8
0
%
1
0
0
%

7
0
%

6
0
%
9
0
%
V
e
r
y

G
o
o
d

F
a
i
r

P
o
o
r
E
x
c
e
l
l
e
n
t

G
o
o
d
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
E
a
r
l
y

d
i
s
p
o
s
a
l

o
f

p
e
n
d
i
n
g

A
T
R
s
o
n

P
A
C

R
e
p
o
r
t
s

p
r
e
s
e
n
t
e
d

t
o
P
a
r
l
i
a
m
e
n
t

b
e
f
o
r
e

3
1
.
3
.
2
0
1
1
P
e
r
c
e
n
t
a
g
e

o
f

o
u
t
s
t
a
n
d
i
n
g
A
T
R
s

d
i
s
p
o
s
e
d

o
f
f

d
u
r
i
n
g
t
h
e

y
e
a
r
.
%
9
0
7
0
6
0
8
0
1
0
0
0
.
5
*

M
a
n
d
a
t
o
r
y

O
b
j
e
c
t
i
v
e
(
s
)
p
a
g
e

:

9

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
121
S
e
c
t
i
o
n

3
:
T
r
e
n
d

V
a
l
u
e
s

o
f

t
h
e

S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
T
a
r
g
e
t

V
a
l
u
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
O
b
j
e
c
t
i
v
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
A
c
t
i
o
n
S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
U
n
i
t
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
A
c
t
u
a
l

V
a
l
u
e
A
c
t
u
a
l

V
a
l
u
e
F
Y

1
3
/
1
4
3
0
0
9
0
d
a
y
s

a
n
d
%
N
o
.
o
f

r
e
v
i
e
w
a
p
p
l
i
c
a
t
i
o
n
s

d
i
s
p
o
s
e
d
i
n

9
0

d
a
y
s

o
f

r
e
c
e
i
p
t

i
n
t
h
e

D
e
p
a
r
t
m
e
n
t
E
n
s
u
r
e

a
v
a
i
l
a
b
i
l
i
t
y

o
f

d
r
u
g
s

a
t
r
e
a
s
o
n
a
b
l
e

p
r
i
c
e
s

a
s

p
e
r

t
h
e

P
h
a
r
m
a
p
o
l
i
c
y
P
r
o
c
e
s
s
i
n
g

o
f

n
e
w

r
e
v
i
e
w
a
p
p
l
i
c
a
t
i
o
n
s

u
n
d
e
r

D
P
C
O
r
e
c
e
i
v
e
d

u
p
t
o

3
1
.
1
.
2
0
1
2
f
o
r

o
r
d
e
r
s

b
y

c
o
m
p
e
t
e
n
t
a
u
t
h
o
r
i
t
y
9
0
9
0
3
0
0
[
1
]
[
1
.
1
]
[
1
.
1
.
1
]
1
0
0
9
0
%
A
c
h
i
e
v
e
m
e
n
t

o
f
d
e
s
i
r
e
d

r
e
s
u
l
t
s

a
s
e
n
v
i
s
a
g
e
d

t
h
r
o
u
g
h
a
s
s
i
s
t
a
n
c
e
.
F
a
c
i
l
i
t
a
t
e

g
r
o
w
t
h

o
f

C
e
n
t
r
a
l

p
h
a
r
m
a
P
S
U
s

w
i
t
h

r
e
q
u
i
r
e
d

s
u
p
p
o
r
t
P
r
o
v
i
d
i
n
g

a
s
s
i
s
t
a
n
c
e

t
o
C
e
n
t
r
a
l

P
h
a
r
m
a

P
S
U
s

a
s
p
e
r

M
O
U

o
b
l
i
g
a
t
i
o
n
1
0
0
1
0
0
8
9
[
2
]
[
2
.
1
]
[
2
.
1
.
1
]
1
6
5
9
0
%
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
P
S
U
s

f
o
r

W
H
O

-

G
M
P
c
o
m
p
l
i
a
n
c
e

A
s
s
i
s
t
a
n
c
e
S
c
h
e
m
e
1
0
0
1
0
0
1
0
0
[
2
.
2
]
[
2
.
2
.
1
]
9
5
9
0
%
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
H
A
L

f
o
r

t
a
k
i
n
g
u
p
/
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f
E
r
y
t
h
r
o
m
i
c
i
n

P
r
o
j
e
c
t
,
M
u
l
t
i

P
r
o
d
u
c
t

S
t
e
r
i
l
e
f
a
c
i
l
i
t
i
e
s

f
o
r

B
e
t
a
l
a
c
t
u
m
A
n
t
i
b
i
o
t
i
c
s

a
n
d

L
a
r
g
e
V
o
l
u
m

P
a
r
e
n
t
e
r
a
l
1
0
0
1
0
0
1
0
0
[
2
.
3
]
[
2
.
3
.
1
]
1
0
0
9
0
%
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
B
C
P
L

f
o
r

I
m
p
l
e
m
e
n
t
a
t
i
o
n
o
f

P
r
o
j
e
c
t
s

u
n
d
e
r
t
a
k
e
n

i
n
R
e
v
i
v
a
l

S
c
h
e
m
e
1
0
0
1
0
0
1
0
0
[
2
.
4
]
[
2
.
4
.
1
]

-
-
9
0
%
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e
P
r
o
j
e
c
t

b
a
s
e
d

s
u
p
p
o
r
t

t
o
R
D
P
L

f
o
r

t
h
e

p
r
o
j
e
c
t
s

f
o
r
W
H
O
-
G
M
P

C
o
m
p
l
i
a
n
c
e
(
C
a
p
i
t
a
l

S
u
p
p
o
r
t
)

-
-

-
-

-
-
[
2
.
5
]
[
2
.
5
.
1
]

-
-
3
1
/
0
8
/
2
0
1
1
D
a
t
e
T
o

t
a
k
e

f
i
n
a
l

v
i
e
w
R
e
v
i
v
a
l

o
f

I
D
P
L

-
-

-
-

-
-
[
2
.
6
]
[
2
.
6
.
1
]

-
-
3
1
/
0
1
/
2
0
1
2
D
a
t
e
A
p
p
r
o
v
a
l

f
r
o
m

t
h
e
C
a
b
i
n
e
t
/
C
C
E
A

-
-

-
-

-
-
[
2
.
6
.
2
]

-
-
9
0
%
T
i
m
e
l
y

f
u
n
d

r
e
l
e
a
s
e

-
-

-
-

-
-
[
2
.
6
.
3
]
p
a
g
e

:

1
0

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
122
S
e
c
t
i
o
n

3
:
T
r
e
n
d

V
a
l
u
e
s

o
f

t
h
e

S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
T
a
r
g
e
t

V
a
l
u
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
O
b
j
e
c
t
i
v
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
A
c
t
i
o
n
S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
U
n
i
t
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
A
c
t
u
a
l

V
a
l
u
e
A
c
t
u
a
l

V
a
l
u
e
F
Y

1
3
/
1
4

-
-
1
5
/
0
2
/
2
0
1
2
D
a
t
e
A
p
p
r
o
v
a
l

o
f

s
c
h
e
m
e
f
o
r

d
e
v
e
l
o
p
m
e
n
t

o
f
n
e
w

d
r
u
g
s

b
y

N
I
P
E
R
i
n
c
l
u
d
i
n
g

P
P
P
/

J
o
i
n
t
C
o
l
l
a
b
o
r
a
t
i
o
n
D
e
v
e
l
o
p

P
h
a
r
m
a

I
n
f
r
a
s
t
r
u
c
t
u
r
e

a
n
d
C
a
t
a
l
y
z
e

D
r
u
g

D
i
s
c
o
v
e
r
y

a
n
d
I
n
n
o
v
a
t
i
o
n
D
e
v
e
l
o
p
m
e
n
t

o
f

n
e
w
d
r
u
g
s

f
o
r

T
B

&

K
a
l
a
z
a
r
b
y

N
I
P
E
R

-
-

-
-

-
-
[
3
]
[
3
.
1
]
[
3
.
1
.
1
]

-
-
1
5
/
0
2
/
2
0
1
2
D
a
t
e
A
p
p
r
o
v
a
l

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

b
y
P
l
a
n
n
i
n
g

C
o
m
m
i
s
s
i
o
n
f
o
r

s
u
p
p
o
r
t
i
n
g
I
n
t
e
r
n
a
t
i
o
n
a
l

S
t
a
n
d
a
r
d
M
a
n
u
f
a
c
t
u
r
i
n
g
-
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
T
e
c
h
n
o
l
o
g
y
U
p
g
r
a
d
a
t
i
o
n
A
s
s
i
s
t
a
n
c
e

S
c
h
e
m
e
(
P
T
U
A
S
)
F
i
n
a
l
i
z
a
t
i
o
n

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

f
o
r
W
o
r
l
d

C
l
a
s
s

P
h
a
r
m
a
I
n
f
r
a
s
t
r
u
c
t
u
r
e
,
F
i
n
a
l
i
z
a
t
i
o
n

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

f
o
r

R
&
D
a
n
d

F
i
n
a
l
i
z
a
t
i
o
n

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

f
o
r
I
n
d
u
s
t
r
y

s
u
p
p
o
r
t

f
o
r
W
H
O
/
I
n
t
e
r
n
a
t
i
o
n
a
l
S
t
a
n
d
a
r
d
s

M
a
n
u
f
a
c
t
u
r
i
n
g
s
o

a
s

t
o

c
a
t
a
l
y
z
e

t
h
e
G
r
o
w
t
h

o
f

P
h
a
r
m
a
I
n
d
u
s
t
r
y

-
-

-
-

-
-
[
3
.
2
]
[
3
.
2
.
1
]

-
-
1
5
/
0
2
/
2
0
1
2
D
a
t
e
R
e
c
e
i
p
t

o
f

p
r
o
j
e
c
t
r
e
p
o
r
t
s

f

r
o
m

t
h
e
c
o
n
s
u
l
a
n
t
s

f
o
r
d
e
v
e
l
o
p
i
n
g
i
n
f
r
a
s
t
r
u
c
t
u
r
e

f
o
r
P
h
a
r
m
a

R
&
D

(
G
L
P
C
o
m
p
l
i
a
n
t

l
a
b
s
/
A
n
i
m
a
l
H
o
u
s
e
)

-
-

-
-

-
-
[
3
.
2
.
2
]

-
-
1
5
/
0
2
/
2
0
1
2
D
a
t
e
A
p
p
r
o
v
a
l

o
f
S
c
h
e
m
e
/
P
r
o
j
e
c
t

b
y

t
h
e
P
l
a
n
n
i
n
g

C
o
m
m
i
s
s
i
o
n
f
o
r

D
e
v
e
l
o
p
m
e
n
t

o
f
I
n
f
r
a
s
t
r
u
c
t
u
r
e

a
s

p
e
r
d
e
t
a
i
l
e
d

p
r
o
j
e
c
t

r
e
p
o
r
t
t
o

b
e

s
u
b
m
i
t
t
e
d

b
y

t
h
e
g
l
o
b
a
l

l
e
v
e
l

c
o
n
s
u
l
t
a
n
t

-
-

-
-

-
-
[
3
.
2
.
3
]

-
-
0
7
/
0
3
/
2
0
1
2
D
a
t
e
L
a
u
n
c
h

a
n
d

P
o
s
i
t
i
o
n
P
h
a
r
m
a
L
a
u
n
c
h

a
n
d

P
o
s
i
t
i
o
n

P
h
a
r
m
a

I
n
d
i
a
B
r
a
n
d
L
a
u
n
c
h

a
n
d

P
o
s
i
t
i
o
n
P
h
a
r
m
a

I
n
d
i
a

b
r
a
n
d

-
-

-
-

-
-
[
4
]
[
4
.
1
]
[
4
.
1
.
1
]
p
a
g
e

:

1
1

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
123
S
e
c
t
i
o
n

3
:
T
r
e
n
d

V
a
l
u
e
s

o
f

t
h
e

S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
T
a
r
g
e
t

V
a
l
u
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
O
b
j
e
c
t
i
v
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
A
c
t
i
o
n
S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
U
n
i
t
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
A
c
t
u
a
l

V
a
l
u
e
A
c
t
u
a
l

V
a
l
u
e
F
Y

1
3
/
1
4
I
n
d
i
a

B
r
a
n
d

i
n

t
a
r
g
e
t
c
o
u
n
t
r
i
e
s

i
n

a

p
h
a
s
e
d
m
a
n
n
e
r

a
f
t
e
r

r
e
c
e
i
v
i
n
g
i
n

p
r
i
n
c
i
p
l
e

a
p
p
r
o
v
a
l
f
r
o
m

P
l
a
n
n
i
n
g
C
o
m
m
i
s
s
i
o
n
i
n

t
a
r
g
e
t

c
o
u
n
t
r
i
e
s

-
-
3
1
/
1
2
/
2
0
1
1
D
a
t
e
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

2
F
i
n
a
l
i
z
e
d

p
r
o
p
o
s
a
l
s

f
o
r
f
o
l
l
o
w

u
p

a
c
t
i
o
n

o
f
p
h
a
r
m
a

s
u
m
m
i
t

2
0
1
0
:
:
1

A

S
e
m
i
n
a
r

o
n
r
e
g
u
l
a
t
o
r
y

i
s
s
u
e
s

o
n
m
e
d
i
c
a
l

d
e
v
i
c
e
s
.
.
.
2

A

T
a
s
k

f
o
r
c
e

f
o
r
r
e
p
o
r
t

o
n

d
r
u
g
d
i
s
c
o
v
e
r
y
,

w
i
t
h

f
o
c
u
s
o
n

r
e
g
u
l
a
t
o
r
y

i
s
s
u
e
s

o
f
c
l
i
n
i
c
a
l

t
r
i
a
l
s

i
n

I
n
d
i
a
F
o
l
l
o
w

u
p

a
c
t
i
o
n

o
f
S
e
c
o
n
d

I
n
d
i
a

P
h
a
r
m
a
S
u
m
m
i
t

h
e
l
d

i
n
N
o
v
e
m
b
e
r

2
0
1
0

-
-

-
-
1
6
/
1
1
/
2
0
1
0
[
4
.
2
]
[
4
.
2
.
1
]
1
0
0
9
0
%
P
h
D
-
4
6
,
M
S
-
2
5
0
,

M
B
A
-
6
1
;
D
e
v
e
l
o
p

P
h
a
r
m
a

H
u
m
a
n

R
e
s
o
u
r
c
e
s
t
h
r
o
u
g
h

M
.
P
h
a
r
m
a

a
n
d

P
h
.
D
p
r
o
g
r
a
m
m
e
s

i
n

N
I
P
E
R
S
I
n
t
a
k
e

o
f

s
t
u
d
e
n
t
s

f
o
r
M
a
s
t
e
r
s

a
n
d

P
h
.
D
d
e
g
r
e
e
s

b
y

N
I
P
E
R
,
M
o
h
a
l
i
:
1
0
0
1
0
0
1
0
0
[
5
]
[
5
.
1
]
[
5
.
1
.
1
]
9
6
9
0
%
A
h
m
e
d
a
b
a
d
-

6
,
G
u
w
a
h
a
t
i
-

4
0
,

H
a
j
i
p
u
r
-
4
6
,
.

H
y
d
e
r
a
b
a
d
-

7
5
,
K
o
l
k
a
t
a

-

5
0
,

R
a
i

B
a
r
e
l
i
-

3
5
I
n
t
a
k
e

o
f

s
t
u
d
e
n
t
s

f
o
r
M
a
s
t
e
r
s

d
e
g
r
e
s
s

b
y

N
e
w
N
I
P
E
R
s
9
8
1
0
0
9
6
[
5
.
2
]
[
5
.
2
.
1
]

-
-
1
4
/
0
5
/
2
0
1
1
D
a
t
e
A
p
p
r
o
v
a
l

o
f

t
h
e
C
a
b
i
n
e
t
P
r
o
v
i
d
e

I
n
f
r
a
s
t
r
u
c
t
u
r
e

a
n
d

s
t
a
f
f

f
o
r
n
e
w

N
I
P
E
R
s
P
r
e
p
a
r
a
t
i
o
n

a
n
d

A
p
p
r
o
v
a
l
o
f

C
a
b
i
n
e
t

N
o
t
e
s

f
o
r
e
s
t
a
b
l
i
s
h
m
e
n
t

o
f

N
e
w
N
I
P
E
R
s

b
y

t
h
e

C
a
b
i
n
e
t

-
-

-
-

-
-
[
6
]
[
6
.
1
]
[
6
.
1
.
1
]
p
a
g
e

:

1
2

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
124
S
e
c
t
i
o
n

3
:
T
r
e
n
d

V
a
l
u
e
s

o
f

t
h
e

S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
T
a
r
g
e
t

V
a
l
u
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
O
b
j
e
c
t
i
v
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
A
c
t
i
o
n
S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
U
n
i
t
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
A
c
t
u
a
l

V
a
l
u
e
A
c
t
u
a
l

V
a
l
u
e
F
Y

1
3
/
1
4
0
5
/
0
3
/
2
0
1
0
0
7
/
0
3
/
2
0
1
1
D
a
t
e
O
n
-
t
i
m
e

s
u
b
m
i
s
s
i
o
n
E
f
f
i
c
i
e
n
t

F
u
n
c
t
i
o
n
i
n
g

o
f

t
h
e

R
F
D
S
y
s
t
e
m
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

D
r
a
f
t

f
o
r
A
p
p
r
o
v
a
l

-
-

-
-
0
9
/
0
3
/
2
0
1
0
*
*

M
a
n
d
a
t
o
r
y

O
b
j
e
c
t
i
v
e
(
s
)

-
-
1
5
/
1
0
/
2
0
1
1
D
a
t
e
I
s
s
u
e

o
f

O
r
d
e
r

o
f
c
o
n
s
t
i
t
u
t
i
o
n

o
f

B
O
G
C
o
n
s
t
i
t
u
t
i
o
n

o
f

B
o
G

o
f
N
e
w

N
I
P
E
R
s

a
n
d

i
s
s
u
e
o
f

o
r
d
e
r

o
f

c
o
n
s
t
i
t
u
t
i
o
n

o
f
B
O
G

-
-

-
-

-
-
[
6
.
2
]
[
6
.
2
.
1
]

-
-
1
5
/
1
2
/
2
0
1
1
D
a
t
e
I
s
s
u
e

o
f

A
d
v
e
r
t
i
s
e
m
e
n
t
i
n

N
e
w
s

P
a
p
e
r
s
,
s
e
l
e
c
t
i
o
n

o
f

D
i
r
e
c
t
o
r
s
a
n
d

i
s
s
u
e

o
f
a
p
p
o
i
n
t
m
e
n
t

l
e
t
t
e
r
A
p
p
o
i
n
t
m
e
n
t

o
f

D
i
r
e
c
t
o
r
s
o
f

N
e
w

N
I
P
E
R
s

b
y

f
i
l
l
i
n
g
u
p

o
f

p
o
s
t
s

o
f

D
i
r
e
c
t
o
r
s
.

-
-

-
-

-
-
[
6
.
3
]
[
6
.
3
.
1
]

-
-
1
5
/
0
5
/
2
0
1
1
D
a
t
e
I
s
s
u
e

o
f

O
r
d
e
r

o
f
c
o
n
s
t
i
t
u
t
i
o
n

o
f

B
O
G
.
S
t
r
e
n
g
t
h
e
n
i
n
g

o
f

N
I
P
E
R

M
o
h
a
i
l
C
o
n
s
t
i
t
u
t
i
o
n

o
f

B
o
G

o
f
N
I
P
E
R
s

a
n
d

i
s
s
u
e

o
f
o
r
d
e
r

o
f

c
o
n
s
t
i
t
u
t
i
o
n

o
f
B
O
G

-
-

-
-

-
-
[
7
]
[
7
.
1
]
[
7
.
1
.
1
]

-
-
3
1
/
1
0
/
2
0
1
1
D
a
t
e
A
c
h
i
e
v
e
m
e
n
t

o
f
d
e
s
i
r
e
d

r
e
s
u
l
t
J
a
n

A
u
s
h
a
d
i

C
a
m
p
a
i
g
n

a
n
d
i
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

B
u
s
i
n
e
s
s

P
l
a
n

f
o
r
s
e
t
t
i
n
g

u
p

o
f

3
0
0
0

J
a
n

A
u
s
h
a
d
h
i
S
t
o
r
e
s

(
u
p
t
o

S
u
b
d
i
v
i
s
i
o
n

l
e
v
e
l

i
n

t
h
e
c
o
u
n
t
r
y
)
f
r
a
m
i
n
g

o
f

p
r
o
p
o
s
a
l

a
n
d
i
n

p
r
i
n
c
i
p
a
l

a
p
p
r
o
v
a
l

o
f
P
l
a
n
n
i
n
g

C
o
m
m
i
s
s
i
o
n

-
-

-
-

-
-
[
8
]
[
8
.
1
]
[
8
.
1
.
1
]
3
6
8
0
%
S
e
t
t
i
n
g

u
p

o
f

1
0
0
s
t
o
r
e
s
I
n
t
e
r
a
c
t
i
o
n

w
i
t
h

S
t
a
t
e
G
o
v
e
r
n
m
e
n
t
s

a
n
d

s
e
t
t
i
n
g
u
p

o
f

J
a
n

A
u
s
h
a
d
i

S
t
o
r
e
s
2
0
0
2
7
2
5
2
[
8
.
2
]
[
8
.
2
.
1
]
8
.
2
3
8
0
%
T
i
m
e
l
y

s
u
p
p
l
y

o
f
M
e
d
i
c
i
n
e
s

o
f

J
a
n
A
u
s
h
a
d
h
i

S
t
o
r
e
s
P
r
e
p
a
r
e
d
n
e
s
s

o
f

C
P
S
U
s
e
t
c
.

f
o
r

t
h
e

s
u
p
p
l
y

c
h
a
i
n
m
a
n
a
g
e
m
e
n
t
3
7
9
.
8
0
5
1
8
.
5
2
1
5
9
.
7
4
[
8
.
3
]
[
8
.
3
.
1
]

-
-
2
8
/
0
2
/
2
0
1
2
D
a
t
e
A
p
p
r
o
v
a
l

o
f

s
c
h
e
m
e
/
p
r
o
p
o
s
a
l

b
y

P
l
a
n
n
i
n
g
C
o
m
m
i
s
i
o
n
I
n
c
e
n
t
i
v
i
s
i
n
g

P
r
i
v
a
t
e

S
e
c
t
o
r

f
o
r
d
e
v
e
l
o
p
m
e
n
t

o
f

n
e
w

D
r
u
g
s

f
o
r
d
i
s
e
a
s
e
s

e
n
d
e
m
i
c

t
o

I
n
d
i
a
S
e
t
t
i
n
g

u
p

o
f

v
e
n
t
u
r
e
f
u
n
d

-
-

-
-

-
-
[
9
]
[
9
.
1
]
[
9
.
1
.
1
]
p
a
g
e

:

1
3

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
125
S
e
c
t
i
o
n

3
:
T
r
e
n
d

V
a
l
u
e
s

o
f

t
h
e

S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
T
a
r
g
e
t

V
a
l
u
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
O
b
j
e
c
t
i
v
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
A
c
t
i
o
n
S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
U
n
i
t
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
A
c
t
u
a
l

V
a
l
u
e
A
c
t
u
a
l

V
a
l
u
e
F
Y

1
3
/
1
4

-
-
0
3
/
0
5
/
2
0
1
2
D
a
t
e
O
n
-

t
i
m
e

s
u
b
m
i
s
s
i
o
n
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

R
e
s
u
l
t
s

-
-

-
-
0
2
/
0
5
/
2
0
1
1

-
-
2
0
/
1
2
/
2
0
1
1
D
a
t
e
R
e
s
u
b
m
i
s
s
i
o
n

o
f

r
e
v
i
s
e
d

d
r
a
f
t
o
f

C
i
t
i
z
e
n
s

/

C
l
i
e
n
t
s

C
h
a
r
t
e
r
I
m
p
r
o
v
i
n
g

I
n
t
e
r
n
a
l

E
f
f
i
c
i
e
n
c
y

/
R
e
s
p
o
n
s
i
v
e
n
e
s
s

/

S
e
r
v
i
c
e

d
e
l
i
v
e
r
y

o
f
M
i
n
i
s
t
r
y

/

D
e
p
a
r
t
m
e
n
t
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

S
e
v
o
t
t
a
m

-
-

-
-
-
-
*

-
-
9
5
%
I
n
d
e
p
e
n
d
e
n
t

A
u
d
i
t

o
f
I
m
p
l
e
m
e
n
t
a
t
i
o
n

o
f

G
r
i
e
v
a
n
c
e
R
e
d
r
e
s
s

M
e
c
h
a
n
i
s
m

-
-

-
-
-
-

-
-
1
5
N
o
N
o
.

o
f

i
t
e
m
s

o
n

w
h
i
c
h
i
n
f
o
r
m
a
t
i
o
n

i
s

u
p
l
o
a
d
e
d

b
y
F
e
b
r
u
a
r
y

1
0
,

2
0
1
2
E
n
s
u
r
e

c
o
m
p
l
i
a
n
c
e

w
i
t
h
S
e
c
t
i
o
n

4
(
1
)

(
b
)

o
f

t
h
e

R
T
I

A
c
t
,
2
0
0
5

-
-

-
-
-
-

-
-
1
5
/
0
2
/
2
0
1
2
D
a
t
e
F
i
n
a
l
i
z
e

a
n

a
c
t
i
o
n

p
l
a
n

t
o
m
i
t
i
g
a
t
e

p
o
t
e
n
t
i
a
l

a
r
e
a
s

o
f
c
o
r
r
u
p
t
i
o
n
.
I
d
e
n
t
i
f
y

p
o
t
e
n
t
i
a
l

a
r
e
a
s

o
f
c
o
r
r
u
p
t
i
o
n

r
e
l
a
t
e
d

t
o
d
e
p
a
r
t
m
e
n
t
a
l

a
c
t
i
v
i
t
i
e
s

a
n
d
d
e
v
e
l
o
p

a
n

a
c
t
i
o
n

p
l
a
n

t
o
m
i
t
i
g
a
t
e

t
h
e
m

-
-

-
-
-
-

-
-
1
5
/
0
2
/
2
0
1
2
D
a
t
e
F
i
n
a
l
i
z
e

a
n

a
c
t
i
o
n

p
l
a
n

t
o
i
m
p
l
e
m
e
n
t

I
S
O

9
0
0
1
c
e
r
t
i
f
i
c
a
t
i
o
n
D
e
v
e
l
o
p

a
n

a
c
t
i
o
n

p
l
a
n

t
o
i
m
p
l
e
m
e
n
t

I
S
O

9
0
0
1
c
e
r
t
i
f
i
c
a
t
i
o
n

-
-

-
-
-
-

-
-
9
0
%
P
e
r
c
e
n
t
a
g
e

o
f

A
T
N
S
s
u
b
m
i
t
t
e
d

w
i
t
h
i
n

d
u
e

d
a
t
e

(
4
m
o
n
t
h
s
)

f
r
o
m

d
a
t
e

o
f
p
r
e
s
e
n
t
a
t
i
o
n

o
f

R
e
p
o
r
t

t
o
P
a
r
l
i
a
m
e
n
t

b
y

C
A
G

d
u
r
i
n
g

t
h
e
y
e
a
r
.
E
n
s
u
r
i
n
g

c
o
m
p
l
i
a
n
c
e

t
o

t
h
e

F
i
n
a
n
c
i
a
l
A
c
c
o
u
n
t
a
b
i
l
i
t
y

F
r
a
m
e
w
o
r
k
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

A
T
N
S

o
n
A
u
d
i
t

P
a
r
a
s

o
f

C
&
A
G

-
-

-
-
-
-
*

-
-
9
0
%
P
e
r
c
e
n
t
g
e

o
f

A
T
R
s

s
u
b
m
i
t
t
e
d
w
i
t
h
i
n

d
u
e

d
a
t
e

(
6

m
o
n
t
h
s
)
f
r
o
m

d
a
t
e

o
f

p
r
e
s
e
n
t
a
t
i
o
n

o
f
R
e
p
o
r
t

t
o

P
a
r
l
i
a
m
e
n
t

b
y

P
A
C
d
u
r
i
n
g

t
h
e

y
e
a
r
.
T
i
m
e
l
y

s
u
b
m
i
s
s
i
o
n

o
f

A
T
R
s

t
o
t
h
e

P
A
C

S
e
c
t
t
.

o
n

P
A
C
R
e
p
o
r
t
s
.

-
-

-
-
-
-

-
-
9
0
%
P
e
r
c
e
n
t
a
g
e

o
f

o
u
t
s
t
a
n
d
i
n
g
A
T
N
s

d
i
s
p
o
s
e
d

o
f
f

d
u
r
i
n
g

t
h
e
y
e
a
r
.
E
a
r
l
y

d
i
s
p
o
s
a
l

o
f

p
e
n
d
i
n
g
A
T
N
s

o
n

A
u
d
i
t

P
a
r
a
s

o
f

C
&
A
G
R
e
p
o
r
t
s

p
r
e
s
e
n
t
e
d

t
o

-
-

-
-
-
-
*

M
a
n
d
a
t
o
r
y

O
b
j
e
c
t
i
v
e
(
s
)
p
a
g
e

:

1
4

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
126
S
e
c
t
i
o
n

3
:
T
r
e
n
d

V
a
l
u
e
s

o
f

t
h
e

S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
s
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
T
a
r
g
e
t

V
a
l
u
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
O
b
j
e
c
t
i
v
e
P
r
o
j
e
c
t
e
d
V
a
l
u
e

f
o
r
A
c
t
i
o
n
S
u
c
c
e
s
s

I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
U
n
i
t
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
A
c
t
u
a
l

V
a
l
u
e
A
c
t
u
a
l

V
a
l
u
e
F
Y

1
3
/
1
4
P
a
r
l
i
a
m
e
n
t

b
e
f
o
r
e

3
1
.
3
.
2
0
1
1
.

-
-
9
0
%
P
e
r
c
e
n
t
a
g
e

o
f

o
u
t
s
t
a
n
d
i
n
g
A
T
R
s

d
i
s
p
o
s
e
d

o
f
f

d
u
r
i
n
g

t
h
e
y
e
a
r
.
E
a
r
l
y

d
i
s
p
o
s
a
l

o
f

p
e
n
d
i
n
g
A
T
R
s

o
n

P
A
C

R
e
p
o
r
t
s
p
r
e
s
e
n
t
e
d

t
o

P
a
r
l
i
a
m
e
n
t

b
e
f
o
r
e
3
1
.
3
.
2
0
1
1

-
-

-
-
-
-
*

M
a
n
d
a
t
o
r
y

O
b
j
e
c
t
i
v
e
(
s
)
p
a
g
e

:

1
5

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2
127
Section 4:
Description and Definition of Success Indicators
and Proposed Measurement Methodology
Results-Framework Document (RFD) for Department of Pharmaceuticals -(2011-2012)

The success indicators have been defined on the basis of appropriate measurable parameters such as for Time
wherever applications for disposal are concerned or preparation of proposals for various schemes and projects and
concerning approvals from concerned central Ministries is concerned. It is defined in values in Rs crores wherever funds
expenditure is involved. Care has been taken so as each of the activities is measurable in respect of performance
monitoring and evaluation.
Results-Framework Document (RFD) for Department of Pharmaceuticals -(2011-2012)
Section 5:
Specific Performance Requirements
from other Departments

1. Receipt of timely approval from the Planning Commission and budgetary sanctions from the Ministry of Finance
relating to the proposed schemes of the Department. Accordingly Planning Commission and Finance Department are
expected to approve the proposed outlays and related budget for fulfillment of targets / project proposals.

2. Sl-2 of Objective: As regards the performance of CPSUs, the Department in its periodic monthly reviews can guide
the CPSUs towards achieving the targets. However actual target achievement would depend on the efforts of the MDs
concerned.

3. Subject to approval of the Competent Authority {Honourable M(C&F)}
128
S
e
c
t
i
o
n

6
:
O
u
t
c
o
m
e
/
I
m
p
a
c
t

o
f

D
e
p
a
r
t
m
e
n
t
/
M
i
n
i
s
t
r
y
R
e
s
u
l
t
s
-
F
r
a
m
e
w
o
r
k

D
o
c
u
m
e
n
t

(
R
F
D
)

f
o
r

D
e
p
a
r
t
m
e
n
t

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

-
(
2
0
1
1
-
2
0
1
2
)
O
u
t
c
o
m
e
/
I
m
p
a
c
t

o
f
D
e
p
a
r
t
m
e
n
t
/
M
i
n
i
s
t
r
y
J
o
i
n
t
l
y

r
e
s
p
o
n
s
i
b
l
e

f
o
r
i
n
f
l
u
e
n
c
i
n
g

t
h
i
s

o
u
t
c
o
m
e

/
i
m
p
a
c
t

w
i
t
h

t
h
e

f
o
l
l
o
w
i
n
g
d
e
p
a
r
t
m
e
n
t

(
s
)

/

m
i
n
i
s
t
r
y
(
i
e
s
)
S
u
c
c
e
s
s
I
n
d
i
c
a
t
o
r
F
Y

0
9
/
1
0
F
Y

1
1
/
1
2
F
Y

1
0
/
1
1
F
Y

1
2
/
1
3
F
Y

1
3
/
1
4
U
n
i
t
8
.
6
5

-
-
G
r
o
w
t
h

o
f

P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
P
r
o
d
u
c
t
i
o
n

i
n

t
h
e

C
o
u
n
t
r
y
H
i
g
h
e
r

g
r
o
w
t
h

o
f
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

I
n
d
u
s
t
r
y

i
n
t
h
e

C
o
u
n
t
r
y

-
-

-
-

-
-
1
%
V
e
c
t
o
r

b
o
r
n
e

d
i
s
e
a
s
e
s

a
n
d
P
a
r
a
s
i
t
i
c

D
i
s
e
a
s
e
s

f
o
r

w
h
i
c
h
D
r
u
g
s

a
r
e

n
o
t

a
v
a
i
l
a
b
l
e
G
r
e
a
t
e
r

a
v
a
i
l
a
b
i
l
i
t
y

o
f

D
r
u
g
s
f
o
r

e
n
d
e
m
i
c

d
i
s
e
a
s
e
s
,

V
e
c
t
o
r
b
o
r
n
e

a
n
d

p
a
r
a
s
i
t
i
c

d
i
s
e
a
s
e
s
f
o
r

w
h
i
c
h

i
n
d
i
g
e
n
o
u
s

a
n
d
e
f
f
e
c
t
i
v
e

d
r
u
g
s

a
r
e

n
o
t
a
v
a
i
l
a
b
l
e
M
i
n
i
s
t
r
y

o
f

H
e
a
l
t
h

a
n
d

F
a
m
i
l
y

W
e
l
f
a
r
e
2
N
o
s
Q
u
a
n
t
i
t
y

o
f

S
p
u
r
i
o
u
s

d
r
u
g
s
d
e
t
e
c
t
e
d

i
n

t
h
e

m
a
r
k
e
t

b
y

t
h
e
i
n
s
p
e
c
t
o
r
s
R
e
d
u
c
t
i
o
n

i
n

S
p
u
r
i
o
u
s

D
r
u
g
s
M
i
n
i
s
t
r
y

o
f

H
e
a
l
t
h

a
n
d

F
a
m
i
l
y

W
e
l
f
a
r
e
3
N
o
4
.
1

S
k
i
l
l
e
d

m
a
n
p
o
w
e
r

p
a
s
s
i
n
g
o
u
t

o
f

N
I
P
E
R
s

e
v
e
r
y

y
e
a
r

w
i
t
h
P
.
G

d
e
g
r
e
e
s

a
n
d

P
h
.
D

i
n
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

s
c
i
e
n
c
e
D
e
v
e
l
o
p
m
e
n
t

o
f

H
u
m
a
n
r
e
s
o
u
r
c
e
s

i
n

P
h
a
r
m
a

I
n
d
u
s
t
r
y
4
N
o
1
.
1
7
P
r
i
c
e

I
n
d
e
x

o
f
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

M
e
d
i
c
i
n
e
s

i
n
t
h
e

C
o
u
n
t
r
y

(
C
o
m
p
a
r
i
s
o
n

v
i
s

a
v
i
s

p
r
e
v
i
o
u
s

y
e
a
r

w
i
l
l

r
e
v
e
a
l

t
h
e
t
r
e
n
d
s
)
A
v
a
i
l
a
b
i
l
i
t
y

o
f
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s

a
t
r
e
a
s
o
n
a
b
l
e
/
L
o
w
e
r

p
r
i
c
e

i
n

t
h
e
c
o
u
n
t
r
y
2
.
3
8
5
%
p
a
g
e

:

1
8

o
f

1
8
G
e
n
e
r
a
t
e
d

o
n

:

1
4
/
0
2
/
2
0
1
2

A Report 201213

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

A Report 201213

Hochgeladen von

Copyright:

Verfügbare Formate

2012-13

Das könnte Ihnen auch gefallen